Antibody drug conjugate and preparation method thereof
By genetically engineering microorganisms to produce ester peptides and preparing antibody drug conjugates, the problem of lack of effective methods for the treatment of metastatic uveal melanoma in the prior art is solved, and efficient antibody drug production and targeting GNAQ/11 carcinogenicity is achieved. The therapeutic potential of mutations.
Patent Information
- Application Number
- CN202411056570.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-10-08
- Filing Date
- 2022-04-15
- Publication Date
- 2024-11-15
AI Technical Summary
Existing uveal melanoma treatments lack effective treatment and management strategies for patients with metastatic disease, and novel biomaterials and manufacturing methods for developing antibody drug conjugates to target GNAQ/11 oncogenic mutations.
Genetically engineer microorganisms such as C. vacciniae, produce ester peptides and prepare antibody drug conjugates, including the use of these microorganisms to increase the titer and isolation yield of the compound and by partial reoxidation and formulations Methods Prepare antibody drug conjugates to target GNAQ/11.
The efficient production of antibody drug conjugates has been achieved, and the therapeutic potential for uveal melanoma, especially metastatic diseases have been improved, and new biomaterials and manufacturing methods have been provided to target GNAQ/11 oncogenic mutations.
Smart Images

Figure CN118955718A_ABST
Abstract
Description
[0001] This application is a divisional application of Chinese patent application 202280028801.1 (PCT / US2022 / 025106), with an application date of April 15, 2022 and an invention name of “Antibody Drug Conjugates and Preparation Methods Thereof”.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims the benefit of U.S. Provisional Application No. 63 / 176,046, filed April 16, 2021, and U.S. Provisional Application No. 63 / 254,031, filed October 8, 2021. The contents of the above applications are hereby incorporated by reference in their entirety.
[0004] Sequence Listing
[0005] This application contains a sequence listing that has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. The ASCII copy was created on April 15, 2022, is named N2067-7179WO_SL.txt, and is 239,071 bytes in size. Background Art
[0006] Uveal melanoma (UM) is a rare malignancy, accounting for 3%-5% of all melanomas, with an incidence of 6-10 cases per 1 million people and 2500-3000 new cases annually in the United States. Despite high local disease control rates (5-year OSR 70%), up to 50% of patients will develop metastatic disease (liver 60%, lung 25%; median OS 13 months, 2-year OSR 8%). For patients who do develop metastatic disease, there is no proven standard of care. To improve outcomes for patients with metastatic UM, there is a pressing need for specifically approved therapies and specialized disease management strategies.
[0007] Oncogenic mutations in GNAQ or GNA11 are hallmark mutations of uveal melanoma. Reduced GNAQ / 11 levels lead to inhibition of cell proliferation and apoptosis. This inhibition can be achieved through targeted delivery of antibody-drug conjugates that inhibit GNAQ / 11 activity. Despite recent progress, there remains a need for novel biomaterials, manufacturing methods, and formulations for antibody-drug conjugates. Summary of the Invention
[0008] The present disclosure provides, at least in part, genetically engineered microorganisms (e.g., Chromobacterium vaccinii) that produce ester peptides (e.g., compound (A1)) in high titer and / or isolated yield. In some embodiments, the microorganism comprises a non-native promoter operably linked to a biosynthetic gene cluster (BGC) for the ester peptide. In some embodiments, the BGC of a natural product that interferes with ester peptide separation is destroyed. Methods for producing ester peptides, such as compound (A1), using the microorganisms described herein are also described. The ester peptides, such as compound (A1), produced by the methods described herein can be used, for example, to produce antibody drug conjugates (e.g., antibody drug conjugates described herein) according to the methods described herein.
[0009] The present disclosure also provides, at least in part, a method for producing a partially reoxidized antibody or its antigen-binding fragment. In certain embodiments, the method includes reducing one or more capped cysteine residues in an antibody or its antigen-binding fragment to provide an antibody or its antigen-binding fragment comprising one or more uncapped cysteine residues. In certain embodiments, the method includes storing an antibody or its antigen-binding fragment comprising one or more uncapped cysteine residues under oxidizing conditions sufficient to produce a partially reoxidized antibody or its antigen-binding fragment. Also described herein is a method for preparing an antibody drug conjugate (e.g., an antibody drug conjugate as described herein), which uses a method for producing a partially reoxidized antibody or its antigen-binding fragment as described herein. The antibody drug conjugate prepared by the method described herein can be formulated as a formulation described herein.
[0010] The present disclosure also provides, at least in part, a formulation of an antibody drug conjugate (e.g., an antibody drug conjugate described herein). In some embodiments, the formulation comprises an antibody drug conjugate as described herein, a buffer, a stabilizer, and a surfactant, and has a pH of about 4.5 to about 6.5. In some embodiments, the formulation is a lyophilized formulation. The formulation described herein can be used to treat or prevent disorders, such as cancer. In some embodiments, the cancer expresses PMEL17 and / or contains mutations in the GNAQ or GNA11 genes. In some embodiments, the cancer is cancer (e.g., hepatocellular carcinoma), sarcoma, leukemia, lymphoma, eye cancer, eye tumor, melanoma (e.g., uveal melanoma, non-uveal melanoma, malignant melanoma, ocular melanoma, subcutaneous melanoma, skin melanoma, or mucosal melanoma), or its metastatic cancer. Engineered microorganisms and methods for producing compounds
[0011] In one aspect, the disclosure features a microorganism comprising a nucleic acid comprising a nucleotide sequence encoding a polypeptide associated with the production of a compound having the structure of Formula (A1), wherein the nucleotide sequence is operably linked to a non-native promoter.
[0012] In some embodiments, the microorganism is a genetically engineered form of a microorganism that naturally produces the compound. In some embodiments, the microorganism is a bacterium. In some embodiments, the microorganism is a Chromobacterium genus. In some embodiments, the microorganism is Chromobacterium vacciniae. In some embodiments, the microorganism is Chromobacterium vacciniae DSM 25150 (=ATCC BAA-2314, =NRRL B-50840, =MWU205). In some embodiments, the microorganism is an isolated microorganism. In some embodiments, the microorganism is a synthetic microorganism.
[0013] In some embodiments, the nucleic acid is located on a chromosome of a microorganism, for example, naturally located on a chromosome or stably integrated into a chromosome. In some embodiments, the nucleotide sequence encoding a polypeptide associated with the production of the compound is located in a biosynthetic gene cluster (BGC). In some embodiments, the BGC is compound (A1)-BGC. In some embodiments, compound (A1)-BGC has Figure 1 The gene organization shown in .
[0014] In some embodiments, the BGC comprises one or more (e.g., two, three, four, five, six, seven, or all) of frsA, frsB, frsC, frsD, frsE, frsF, frsG, or frsH, or homologs thereof. In some embodiments, the BGC comprises frsA, frsB, frsC, frsD, frsE, frsF, frsG, and frsH, or homologs thereof.
[0015] In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound is located in frsA, frsB, frsC, frsD, frsE, frsF, frsG, or frsH, or a homolog thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound is located in a region comprising frsA or a homolog thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound is located in a region comprising frsA and frsB, or a homolog thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound is located in a region comprising frsA, frsB, and frsC, or a homolog thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound is located in a region comprising frsA, frsB, frsC, frsD, or a homolog thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound is located in a region comprising frsA, frsB, frsC, frsD, and frsE, or a homolog thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound is located in a region comprising frsA, frsB, frsC, frsD, frsE, and frsF, or a homolog thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound is located in a region comprising frsA, frsB, frsC, frsD, frsE, frsF and frsG or a homolog thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound is located in a region comprising frsA, frsB, frsC, frsD, frsE, frsF, frsG and FrsH or a homolog thereof.
[0016] In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound comprises the coding sequence of frsA, frsB, frsC, frsD, frsE, frsF, frsG, or frsH, or a homolog thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound comprises the coding sequence of frsA or a homolog thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound comprises the coding sequence of frsA and frsB, or a homolog thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound comprises the coding sequence of frsA, frsB, and frsC, or a homolog thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound comprises the coding sequence of frsA, frsB, frsC, and frsD, or a homolog thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound comprises the coding sequence of frsA, frsB, frsC, frsD, and frsE, or a homolog thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound comprises the coding sequence of frsA, frsB, frsC, frsD, and frsE, or a homolog thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound comprises the coding sequence of frsA, frsB, frsC, frsD, frsE, and frsF, or a homolog thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound comprises the coding sequence of frsA, frsB, frsC, frsD, frsE, frsF and frsG or a homolog thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound comprises the coding sequence of frsA, frsB, frsC, frsD, frsE, frsF, frsG and FrsH or a homolog thereof.
[0017] In some embodiments, the nucleic acid comprises a nucleotide sequence resulting from a homologous recombination event (e.g., for promoter exchange) using the nucleotide sequence of SEQ ID NO: 317, or a functional fragment thereof, or a nucleotide sequence having at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identity thereto, or differing by no more than about 100, about 90, about 80, about 70, about 60, about 50, about 40, about 30, about 20, about 15, about 10, about 5, or about 2 nucleotides.
[0018] In some embodiments, the nucleic acid comprises a nucleotide sequence related to GenBank Accession No.: BankIt2437961BSeq#1MW732719 or a functional fragment thereof, or a nucleotide sequence that is at least about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98% or about 99% identical to a nucleotide sequence related to BankIt2437961BSeq#1MW732719 or a functional fragment thereof.
[0019] In certain embodiments, the non-native promoters are from the same microorganism. In other embodiments, the non-native promoters are from different microorganisms.
[0020] In some embodiments, the non-native promoter comprises a vioP promoter, an nptII promoter, an rbs promoter, a J23119 promoter, a pLpp promoter, a PS12burk promoter, an ErmE* promoter, or a Pem7 promoter. In some embodiments, the non-native promoter comprises a vioP promoter, an nptII promoter, or an rbs promoter.
[0021] In some embodiments, the non-native promoter comprises the nucleotide sequence of any one of SEQ ID NOs: 264-266, 268-271 or 316, or a functional fragment thereof, or a nucleotide sequence that is at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to the nucleotide sequence of any one of SEQ ID NOs: 264-266, 268-271 or 316, or a functional fragment thereof, or that differs by no more than about 60, about 50, about 40, about 30, about 20, about 15, about 10, about 5, or about 2 nucleotides. In some embodiments, the non-native promoter comprises or consists of the nucleotide sequence of any one of SEQ ID NOs: 264-266, 268-271 or 316, or a functional fragment thereof.
[0022] In some embodiments, the non-native promoter comprises a vioP promoter. In some embodiments, the non-native promoter comprises the nucleotide sequence of SEQ ID NO: 264 or a functional fragment thereof, or a nucleotide sequence that is at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to the nucleotide sequence of SEQ ID NO: 264 or a functional fragment thereof, or that differs by no more than about 60, about 50, about 40, about 30, about 20, about 15, about 10, about 5, or about 2 nucleotides. In some embodiments, the non-native promoter comprises or consists of the nucleotide sequence of SEQ ID NO: 264 or a functional fragment thereof.
[0023] In some embodiments, the non-native promoter comprises an nptII promoter. In some embodiments, the non-native promoter comprises the nucleotide sequence of SEQ ID NO: 265 or a functional fragment thereof, or a nucleotide sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 265 or a functional fragment thereof, or that differs by no more than about 60, about 50, about 40, about 30, about 20, about 15, about 10, about 5, or about 2 nucleotides. In some embodiments, the non-native promoter comprises or consists of the nucleotide sequence of SEQ ID NO: 265 or a functional fragment thereof.
[0024] In some embodiments, the non-native promoter comprises an rbs promoter. In some embodiments, the non-native promoter comprises the nucleotide sequence of SEQ ID NO: 266 or a functional fragment thereof, or a nucleotide sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleotide sequence of SEQ ID NO: 266 or a functional fragment thereof, or that differs by no more than 60, 50, 40, 30, 20, 15, 10, 5 or 2 nucleotides. In some embodiments, the non-native promoter comprises or consists of the nucleotide sequence of SEQ ID NO: 266 or a functional fragment thereof.
[0025] In some embodiments, the non-native promoter comprises the J23119 promoter. In some embodiments, the non-native promoter comprises the nucleotide sequence of SEQ ID NO: 316 or a functional fragment thereof, or a nucleotide sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 316 or a functional fragment thereof, or that differs by no more than 60, 50, 40, 30, 20, 15, 10, 5, or 2 nucleotides. In some embodiments, the non-native promoter comprises or consists of the nucleotide sequence of SEQ ID NO: 316 or a functional fragment thereof.
[0026] In some embodiments, the non-native promoter comprises a pLpp promoter. In some embodiments, the non-native promoter comprises the nucleotide sequence of SEQ ID NO: 268 or a functional fragment thereof, or a nucleotide sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 268 or a functional fragment thereof, or that differs by no more than 60, 50, 40, 30, 20, 15, 10, 5, or 2 nucleotides. In some embodiments, the non-native promoter comprises or consists of the nucleotide sequence of SEQ ID NO: 268 or a functional fragment thereof.
[0027] In some embodiments, the non-original promoter comprises a Pem7 promoter. In some embodiments, the non-original promoter comprises the nucleotide sequence of SEQ ID NO: 269 or a functional fragment thereof, or a nucleotide sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity with the nucleotide sequence of SEQ ID NO: 269 or a functional fragment thereof, or a nucleotide sequence that differs by no more than 60, 50, 40, 30, 20, 15, 10, 5 or 2 nucleotides. In some embodiments, the non-original promoter comprises or consists of the nucleotide sequence of SEQ ID NO: 269 or a functional fragment thereof.
[0028] In some embodiments, the non-native promoter comprises the PS12burk promoter. In some embodiments, the non-native promoter comprises the nucleotide sequence of SEQ ID NO: 270 or a functional fragment thereof, or a nucleotide sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleotide sequence of SEQ ID NO: 270 or a functional fragment thereof, or that differs by no more than 60, 50, 40, 30, 20, 15, 10, 5 or 2 nucleotides. In some embodiments, the non-native promoter comprises or consists of the nucleotide sequence of SEQ ID NO: 270 or a functional fragment thereof.
[0029] In some embodiments, the non-native promoter comprises an ErmE* promoter. In some embodiments, the non-native promoter comprises the nucleotide sequence of SEQ ID NO: 271 or a functional fragment thereof, or a nucleotide sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to the nucleotide sequence of SEQ ID NO: 271 or a functional fragment thereof, or that differs by no more than 60, 50, 40, 30, 20, 15, 10, 5 or 2 nucleotides. In some embodiments, the non-native promoter comprises or consists of the nucleotide sequence of SEQ ID NO: 271 or a functional fragment thereof.
[0030] In some embodiments, the non-primary promoter controls the transcription of one or more (e.g., two, three, four, five, six, seven, or all) of FrsA, FrsB, FrsC, FrsD, FrsE, FrsF, FrsG, or FrsH, or a homolog thereof. In some embodiments, the non-primary promoter controls the transcription of FrsA, FrsB, FrsC, FrsD, FrsE, FrsF, FrsG, and FrsH, or a homolog thereof. In some embodiments, the non-primary promoter is inserted upstream of the coding region for FrsA or a homolog thereof, for example, upstream of the coding region for all of FrsA, FrsB, FrsC, FrsD, FrsE, FrsF, FrsG, and FrsH, or a homolog thereof.
[0031] In some embodiments, the polypeptide associated with the production of the compound is a non-ribosomal peptide synthetase (NRPS) or a functional fragment thereof. In some embodiments, the NRPS is FrsA, FrsD, FrsE, FrsF or FrsG, or a homologue thereof.
[0032] In some embodiments, the polypeptide associated with the production of the compound is an MbtH-like protein or a functional fragment thereof. In some embodiments, the MbtH-like protein is FrsB or a homolog thereof.
[0033] In some embodiments, the polypeptide associated with the production of the compound is malate dehydrogenase. In some embodiments, the malate dehydrogenase is FrsC or a homolog thereof.
[0034] In some embodiments, the polypeptide associated with the production of the compound is a hydroxylase. In some embodiments, the hydroxylase is FrsH or a homolog thereof.
[0035] In some embodiments, the nucleic acid comprises a plurality of nucleotide sequences encoding a plurality of polypeptides related to the production of the compound. In some embodiments, the plurality of polypeptides related to the production of the compound comprises a plurality of NRPSs or functional fragments thereof. In some embodiments, the plurality of NRPSs comprises two or more (e.g., three, four, or all) of FrsA, FrsD, FrsE, FrsF, or FrsG, or homologs thereof. In some embodiments, the plurality of polypeptides related to the production of the compound comprises a NRPS, MbtH-like protein, malate dehydrogenase, and hydroxylase, or functional fragments thereof.
[0036] In some embodiments, the plurality of polypeptides associated with the production of a compound comprises FrsA, FrsB, FrsC, FrsD, FrsE, FrsF, FrsG, and FrsH, or homologs thereof.
[0037] In some embodiments, the microorganism has an increased compound titer. In some embodiments, when cultured under conditions that allow compound production, the titer of the compound is increased by at least about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, or about 10 times compared to a reference microorganism (e.g., a microorganism that does not include a non-original promoter in compound (A1)-BGC but is otherwise identical (e.g., wild type). In some embodiments, when cultured under conditions that allow compound production, the titer of the compound is increased by at least about 100 mg / L, about 200 mg / L, about 300 mg / L, about 400 mg / L, about 500 mg / L, about 600 mg / L, about 700 mg / L, about 800 mg / L, about 900 mg / L, or about 1000 mg / L compared to a reference microorganism (e.g., a microorganism that does not include a non-original promoter in compound (A1)-BGC but is otherwise identical (e.g., wild type)).
[0038] In some embodiments, the BGC of the natural product that interferes with compound separation is altered, for example, destroyed. In some embodiments, the natural product comprises one or more (e.g., two, three, or all) of the following: violacein, compound J, compound F5, compound F3, or compound D. In some embodiments, at least a portion of the BGC of the natural product that interferes with compound separation is deleted. In some embodiments, violacein-BGC is altered, for example, destroyed. In some embodiments, compound J-BGC is altered, for example, destroyed. In some embodiments, compound J-BGC is associated with the production of compound J, compound F5, compound F3, and compound D. In some embodiments, both violacein-BGC and compound J-BGC are altered, for example, destroyed. In some embodiments, the yield of the natural product is reduced, for example, by at least about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%.
[0039] In some embodiments, microorganisms have increased compound isolation yields. In some embodiments, the isolation yield of the compound is increased by about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or more compared to a reference microorganism (e.g., an unaltered but otherwise identical microorganism (e.g., wild-type)) whose BGC of the natural product interfering with the separation of the compound is not altered.
[0040] In some embodiments, the BGC of the natural product that interferes with the isolation of the compound is not altered, eg, not destroyed.
[0041] In another aspect, the disclosure features a microorganism that produces a compound having the structure of Formula (A1), wherein the BGC of a natural product that interferes with the isolation of the compound is altered.
[0042] In some embodiments, the natural product comprises one or more (e.g., two, three, or all) of the following: violacein, compound J, compound F5, compound F3, or compound D. In some embodiments, at least a portion of the BGC of the natural product that interferes with compound separation is deleted. In some embodiments, violacein-BGC is altered, for example, destroyed. In some embodiments, compound J-BGC is altered, for example, destroyed. In some embodiments, compound J-BGC is associated with the production of compound J, compound F5, compound F3, and compound D. In some embodiments, both violacein-BGC and compound J-BGC are altered, for example, destroyed. In some embodiments, the yield of the natural product is reduced, for example, by at least about 50%, about 60%, about 70%, about 80%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or 100%.
[0043] In some embodiments, microorganisms have increased compound isolation yields. In some embodiments, the isolation yield of the compound is increased by about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or more compared to a reference microorganism (e.g., an unaltered but otherwise identical microorganism (e.g., wild-type)) whose BGC of the natural product interfering with the separation of the compound is not altered.
[0044] In another aspect, the disclosure features a method of producing a compound having the structure of Formula (A1), the method comprising culturing (e.g., fermenting) a microorganism described herein under conditions that allow expression of the compound, thereby producing the compound.
[0045] In some embodiments, the microorganisms are cultured (fermented) at a scale of about 50 L to about 500 L, e.g., about 50 L, about 100 L, about 150 L, about 200 L, about 250 L, about 300 L, about 350 L, about 400 L, about 450 L, or about 500 L. In some embodiments, the microorganisms are cultured (fermented) at a scale of about 1,000 L to about 20,000 L, e.g., about 1,000 L to about 10,000 L or about 10,000 L to about 20,000 L, e.g., about 1,000 L, about 2,000 L, about 5,000 L, about 7,500 L, about 10,000 L, about 15,000 L, or about 20,000 L.
[0046] In some embodiments, the culture (e.g., fermentation) produces a titer of at least about 200 mL of compound, e.g., at least about 250 mg / mL, about 300 mg / L, about 400 mg / L, about 500 mg / L, about 600 mg / L, about 700 mg / L, about 800 mg / L, about 900 mg / L, about 1000 mg / L, about 1100 mg / L, about 1200 mg / L, about 1300 mg / L, about 1400 mg / L, about 1500 mg / L, about 1600 mg / L, about 1700 mg / L, about 1800 mg / L, about 1900 mg / L, or about 2000 mg / L of compound.
[0047] In some embodiments, the method further comprises isolating the compound, e.g., to a purity of at least about 90%, e.g., at least about 95%, about 96%, about 97%, about 98%, or about 99% purity, e.g., as determined by a method described herein.
[0048] In another aspect, the disclosure features a nucleic acid comprising a nucleotide sequence encoding a polypeptide associated with the production of a compound having the structure of Formula (A1), wherein the nucleotide sequence is operably linked to a non-native promoter.
[0049] In some embodiments, the nucleic acid is located on a chromosome of a microorganism, for example, naturally located on a chromosome or stably integrated into a chromosome. In some embodiments, the nucleotide sequence encoding a polypeptide associated with the production of the compound is located in a biosynthetic gene cluster (BGC). In some embodiments, the BGC is compound (A1)-BGC. In some embodiments, compound (A1)-BGC has Figure 1 The gene organization shown in .
[0050] In some embodiments, the BGC comprises one or more (e.g., two, three, four, five, six, seven, or all) of frsA, frsB, frsC, frsD, frsE, frsF, frsG, or frsH, or homologs thereof. In some embodiments, the BGC comprises frsA, frsB, frsC, frsD, frsE, frsF, frsG, and frsH, or homologs thereof.
[0051] In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound is located in frsA, frsB, frsC, frsD, frsE, frsF, frsG, frsH, or a homologue thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound is located in a region comprising frsA or a homologue thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound is located in a region comprising frsA and frsB, or a homologue thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound is located in a region comprising frsA, frsB, and frsC, or a homologue thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound is located in a region comprising frsA, frsB, frsC, frsD, or a homologue thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound is located in a region comprising frsA, frsB, frsC, frsD, and frsE, or a homologue thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound is located in a region comprising frsA, frsB, frsC, frsD, frsE, and frsF, or a homologue thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound is located in a region comprising frsA, frsB, frsC, frsD, frsE, frsF and frsG or a homolog thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound is located in a region comprising frsA, frsB, frsC, frsD, frsE, frsF, frsG and FrsH or a homolog thereof.
[0052] In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound comprises the coding sequence of frsA, frsB, frsC, frsD, frsE, frsF, frsG, frsH, or a homologue thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound comprises the coding sequence of frsA or a homologue thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound comprises the coding sequence of frsA and frsB, or a homologue thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound comprises the coding sequence of frsA, frsB, and frsC, or a homologue thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound comprises the coding sequence of frsA, frsB, frsC, and frsD, or a homologue thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound comprises the coding sequence of frsA, frsB, frsC, frsD, and frsE, or a homologue thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound comprises the coding sequence of frsA, frsB, frsC, frsD, and frsE, or a homologue thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound comprises the coding sequence of frsA, frsB, frsC, frsD, frsE, and frsF, or a homologue thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound comprises the coding sequence of frsA, frsB, frsC, frsD, frsE, frsF and frsG or a homolog thereof. In some embodiments, the nucleotide sequence encoding the polypeptide associated with the production of the compound comprises the coding sequence of frsA, frsB, frsC, frsD, frsE, frsF, frsG and FrsH or a homolog thereof.
[0053] In some embodiments, the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 317 or a functional fragment thereof, or a nucleotide sequence that is at least 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98% or about 99% identical to the nucleotide sequence of SEQ ID NO: 317 or a functional fragment thereof, or a nucleotide sequence that differs by no more than about 100, about 90, about 80, about 70, about 60, about 50, about 40, about 30, about 20, about 15, about 10, about 5, or about 2 nucleotides.
[0054] In some embodiments, the nucleic acid comprises a nucleotide sequence related to GenBank Accession No.: BankIt2437961BSeq#1MW732719 or a functional fragment thereof, or a nucleotide sequence that is at least about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98% or about 99% identical to a nucleotide sequence related to BankIt2437961BSeq#1MW732719 or a functional fragment thereof.
[0055] In certain embodiments, the non-native promoters are from the same microorganism. In other embodiments, the non-native promoters are from different microorganisms.
[0056] In some embodiments, the non-native promoter comprises a vioP promoter, an nptII promoter, an rbs promoter, a J23119 promoter, a pLpp promoter, a PS12burk promoter, an ErmE* promoter, or a Pem7 promoter. In some embodiments, the non-native promoter comprises a vioP promoter, an nptII promoter, or an rbs promoter.
[0057] In some embodiments, the non-native promoter comprises the nucleotide sequence of any one of SEQ ID NOs: 264-266, 268-271 or 316, or a functional fragment thereof, or a nucleotide sequence that is at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to the nucleotide sequence of any one of SEQ ID NOs: 264-266, 268-271 or 316, or a functional fragment thereof, or that differs by no more than about 60, about 50, about 40, about 30, about 20, about 15, about 10, about 5, or about 2 nucleotides. In some embodiments, the non-native promoter comprises or consists of the nucleotide sequence of any one of SEQ ID NOs: 264-266, 268-271 or 316, or a functional fragment thereof.
[0058] In some embodiments, the non-native promoter comprises a vioP promoter. In some embodiments, the non-native promoter comprises the nucleotide sequence of SEQ ID NO: 264 or a functional fragment thereof, or a nucleotide sequence that is at least 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to the nucleotide sequence of SEQ ID NO: 264 or a functional fragment thereof, or that differs by no more than about 60, about 50, about 40, about 30, about 20, about 15, about 10, about 5, or about 2 nucleotides. In some embodiments, the non-native promoter comprises or consists of the nucleotide sequence of SEQ ID NO: 264 or a functional fragment thereof.
[0059] In some embodiments, the non-native promoter comprises an nptII promoter. In some embodiments, the non-native promoter comprises the nucleotide sequence of SEQ ID NO: 265 or a functional fragment thereof, or a nucleotide sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to the nucleotide sequence of SEQ ID NO: 265 or a functional fragment thereof, or that differs by no more than about 60, about 50, about 40, about 30, about 20, about 15, about 10, about 5, or about 2 nucleotides. In some embodiments, the non-native promoter comprises or consists of the nucleotide sequence of SEQ ID NO: 265 or a functional fragment thereof.
[0060] In some embodiments, the non-native promoter comprises an rbs promoter. In some embodiments, the non-native promoter comprises the nucleotide sequence of SEQ ID NO: 266 or a functional fragment thereof, or a nucleotide sequence that is at least 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to the nucleotide sequence of SEQ ID NO: 266 or a functional fragment thereof, or that differs by no more than about 60, about 50, about 40, about 30, about 20, about 15, about 10, about 5, or about 2 nucleotides. In some embodiments, the non-native promoter comprises or consists of the nucleotide sequence of SEQ ID NO: 266 or a functional fragment thereof.
[0061] In some embodiments, the non-native promoter comprises the J23119 promoter. In some embodiments, the non-native promoter comprises the nucleotide sequence of SEQ ID NO: 316 or a functional fragment thereof, or a nucleotide sequence that is at least 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to the nucleotide sequence of SEQ ID NO: 316 or a functional fragment thereof, or that differs by no more than about 60, about 50, about 40, about 30, about 20, about 15, about 10, about 5, or about 2 nucleotides. In some embodiments, the non-native promoter comprises or consists of the nucleotide sequence of SEQ ID NO: 316 or a functional fragment thereof.
[0062] In some embodiments, the non-native promoter comprises a pLpp promoter. In some embodiments, the non-native promoter comprises the nucleotide sequence of SEQ ID NO: 268 or a functional fragment thereof, or a nucleotide sequence that is at least 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to the nucleotide sequence of SEQ ID NO: 268 or a functional fragment thereof, or that differs by no more than about 60, about 50, about 40, about 30, about 20, about 15, about 10, about 5, or about 2 nucleotides. In some embodiments, the non-native promoter comprises or consists of the nucleotide sequence of SEQ ID NO: 268 or a functional fragment thereof.
[0063] In some embodiments, the non-native promoter comprises a Pem7 promoter. In some embodiments, the non-native promoter comprises the nucleotide sequence of SEQ ID NO: 269 or a functional fragment thereof, or a nucleotide sequence having at least 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98% or about 99% identity with the nucleotide sequence of SEQ ID NO: 269 or a functional fragment thereof, or a nucleotide sequence that differs by no more than about 60, about 50, about 40, about 30, about 20, about 15, about 10, about 5 or about 2 nucleotides. In some embodiments, the non-native promoter comprises or consists of the nucleotide sequence of SEQ ID NO: 269 or a functional fragment thereof.
[0064] In some embodiments, the non-native promoter comprises the PS12burk promoter. In some embodiments, the non-native promoter comprises the nucleotide sequence of SEQ ID NO: 270 or a functional fragment thereof, or a nucleotide sequence that is at least 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to the nucleotide sequence of SEQ ID NO: 270 or a functional fragment thereof, or that differs by no more than about 60, about 50, about 40, about 30, about 20, about 15, about 10, about 5, or about 2 nucleotides. In some embodiments, the non-native promoter comprises or consists of the nucleotide sequence of SEQ ID NO: 270 or a functional fragment thereof.
[0065] In some embodiments, the non-native promoter comprises an ErmE* promoter. In some embodiments, the non-native promoter comprises the nucleotide sequence of SEQ ID NO: 271 or a functional fragment thereof, or a nucleotide sequence that is at least 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identical to the nucleotide sequence of SEQ ID NO: 271 or a functional fragment thereof, or that differs by no more than about 60, about 50, about 40, about 30, about 20, about 15, about 10, about 5, or about 2 nucleotides. In some embodiments, the non-native promoter comprises or consists of the nucleotide sequence of SEQ ID NO: 271 or a functional fragment thereof.
[0066] In some embodiments, the non-primary promoter controls the transcription of one or more (e.g., two, three, four, five, six, seven, or all) of FrsA, FrsB, FrsC, FrsD, FrsE, FrsF, FrsG, or FrsH, or a homolog thereof. In some embodiments, the non-primary promoter controls the transcription of FrsA, FrsB, FrsC, FrsD, FrsE, FrsF, FrsG, and FrsH, or a homolog thereof. In some embodiments, the non-primary promoter is inserted upstream of the coding region for FrsA or a homolog thereof, for example, upstream of the coding region for all of FrsA, FrsB, FrsC, FrsD, FrsE, FrsF, FrsG, and FrsH, or a homolog thereof.
[0067] In some embodiments, the polypeptide associated with the production of the compound is a non-ribosomal peptide synthetase (NRPS) or a functional fragment thereof. In some embodiments, the NRPS is FrsA, FrsD, FrsE, FrsF or FrsG, or a homologue thereof.
[0068] In some embodiments, the polypeptide associated with the production of the compound is an MbtH-like protein or a functional fragment thereof. In some embodiments, the MbtH-like protein is FrsB or a homolog thereof.
[0069] In some embodiments, the polypeptide associated with the production of the compound is malate dehydrogenase. In some embodiments, the malate dehydrogenase is FrsC or a homolog thereof.
[0070] In some embodiments, the polypeptide associated with the production of the compound is a hydroxylase. In some embodiments, the hydroxylase is FrsH or a homolog thereof.
[0071] In some embodiments, the nucleic acid comprises a plurality of nucleotide sequences encoding a plurality of polypeptides related to the production of the compound. In some embodiments, the plurality of polypeptides related to the production of the compound comprises a plurality of NRPSs or functional fragments thereof. In some embodiments, the plurality of NRPSs comprises two or more (e.g., three, four, or all) of FrsA, FrsD, FrsE, FrsF, or FrsG, or homologs thereof. In some embodiments, the plurality of polypeptides related to the production of the compound comprises a NRPS, MbtH-like protein, malate dehydrogenase, and hydroxylase, or functional fragments thereof.
[0072] In some embodiments, the plurality of polypeptides associated with the production of a compound comprises FrsA, FrsB, FrsC, FrsD, FrsE, FrsF, FrsG, and FrsH, or homologs thereof.
[0073] In another aspect, the disclosure features a nucleic acid comprising a nucleotide sequence encoding a polypeptide associated with the production of one or more of Compound J, Compound F5, Compound F3, or Compound D.
[0074] In some embodiments, the nucleic acid is an isolated nucleic acid. In some embodiments, the nucleic acid is a non-naturally occurring nucleic acid. In some embodiments, the nucleic acid is a synthetic nucleic acid. In some embodiments, the nucleic acid comprises a mutation, e.g., a deletion.
[0075] In some embodiments, the nucleic acid comprises a plurality of nucleotide sequences encoding a plurality of polypeptides associated with the production of one or more of Compound J, Compound F5, Compound F3, or Compound D.
[0076] In some embodiments, the nucleotide sequence is from BGC. In some embodiments, BGC is compound J-BGC. In some embodiments, compound J-BGC has Figure 1 The gene organization shown in .
[0077] In some embodiments, the nucleotide sequence comprises one or more (e.g., two, three, or all) of dis1, dis2, dis3, or dis4, or homologs thereof. In some embodiments, the BGC comprises dis1, dis2, dis3, and dis4, or homologs thereof.
[0078] In some embodiments, the nucleic acid comprises a nucleotide sequence related to GenBank Accession No.: BankIt2437961BSeq#1MW732719 or a functional fragment thereof, or a nucleotide sequence related to BankIt2437961BSeq#1MW732719 or a functional fragment thereof having at least about 75%, for example, at least about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98% or about 99% identity.
[0079] In another aspect, the disclosure features a vector comprising a nucleic acid described herein. In another aspect, the disclosure features a cell comprising a nucleic acid described herein or a vector described herein.
[0080] In another aspect, the disclosure features a method of engineering a cell, the method comprising altering a nucleotide sequence encoding a polypeptide associated with the production of one or more of Compound J, Compound F5, Compound F3, or Compound D, thereby engineering the cell.
[0081] In some embodiments, the cell is a microorganism that naturally produces a compound having the structure of Formula (A1). In some embodiments, the microorganism is a bacterium, such as Chromobacterium. In some embodiments, the microorganism is Chromobacterium vacciniae, such as Chromobacterium vacciniae DSM 25150 (=ATCC BAA-2314, =NRRL B-50840, =MWU205).
[0082] In some embodiments, the nucleotide sequence is disrupted, eg, at least a portion of the nucleotide sequence is deleted.
[0083] In some embodiments, the nucleic acid comprises a plurality of nucleotide sequences encoding a plurality of polypeptides associated with the production of one or more of Compound J, Compound F5, Compound F3, or Compound D. In some embodiments, the production of one or more (e.g., two, three, or all) of Compound J, Compound F5, Compound F3, or Compound D is reduced, e.g., by at least about 50%, e.g., by at least about 60%, about 70%, about 80%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%.
[0084] In some embodiments, the nucleotide sequence is from BGC. In some embodiments, BGC is compound J-BGC. In some embodiments, compound J-BGC has Figure 1In some embodiments, the nucleotide sequence comprises one or more (e.g., two, three, or all) of dis1, dis2, dis3, or dis4, or homologs thereof. In some embodiments, the BGC comprises dis1, dis2, dis3, and dis4, or homologs thereof. In some embodiments, the nucleic acid comprises a nucleotide sequence related to GenBank Accession No.: BankIt2437961BSeq#1MW732719, or a functional fragment thereof, or a nucleotide sequence having at least about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identity to a nucleotide sequence related to BankIt2437961BSeq#1MW732719, or a functional fragment thereof.
[0085] In some embodiments, the alteration increases the isolated yield of the compound. In some embodiments, the isolated yield of the compound is increased by about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% or more compared to a reference microorganism (e.g., a microorganism (e.g., wild-type) in which the BGC of the natural product that interferes with the separation of the compound is not altered but is otherwise identical).
[0086] Partial reoxidation and methods for preparing antibody drug conjugates
[0087] In another aspect, the disclosure features a method for producing a partially reoxidized antibody or antigen-binding fragment thereof, the method comprising: providing an antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues; and storing the antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues under oxidizing conditions, thereby producing the partially reoxidized antibody or antigen-binding fragment thereof.
[0088] In some embodiments, the method further includes providing an antibody or antigen-binding fragment thereof comprising one or more capped cysteine residues. In some embodiments, one or more capped cysteine residues are located in the heavy chain constant domain of the antibody or its antigen-binding fragment. In some embodiments, the antibody or its antigen-binding fragment comprises four capped cysteine residues. In some embodiments, the antibody or its antigen-binding fragment comprises two capped cysteine residues. In some embodiments, the antibody or its antigen-binding fragment comprises capped cysteine residues located in the CH1 region of the antibody or its antigen-binding fragment. In some embodiments, the antibody or its antigen-binding fragment comprises capped cysteine residues located in each CH1 region of the antibody or its antigen-binding fragment. In some embodiments, the capped cysteine residues are engineered surface-exposed cysteine residues. In some embodiments, the antibody or its antigen-binding fragment comprises a capped cysteine residue located at residue 152 (EU numbering) in the CH1 region of the antibody or its antigen-binding fragment. In some embodiments, one or more capped cysteine residues are capped with cysteine or glutathione.
[0089] In some embodiments, the method further includes reducing one or more capping cysteine residues to provide an antibody or its antigen-binding fragment comprising one or more uncapping cysteine residues. In some embodiments, one or more uncapping cysteine residues are located in the heavy chain constant domain of the antibody or its antigen-binding fragment. In some embodiments, the antibody or its antigen-binding fragment comprises four uncapping cysteine residues. In some embodiments, the antibody or its antigen-binding fragment comprises two uncapping cysteine residues. In some embodiments, the antibody or its antigen-binding fragment comprises an uncapping cysteine residue located in the CH1 region of the antibody or its antigen-binding fragment. In some embodiments, the antibody or its antigen-binding fragment comprises an uncapping cysteine residue located in each CH1 region of the antibody or its antigen-binding fragment. In some embodiments, the uncapping cysteine residue is an engineered surface-exposed cysteine residue. In some embodiments, the antibody or its antigen-binding fragment comprises an uncapping cysteine residue located at residue 152 (EU numbering) in the CH1 region of the antibody or its antigen-binding fragment.
[0090] In some embodiments, the method comprises reducing the one or more capped cysteine residues by contacting the antibody or antigen-binding fragment thereof comprising the one or more capped cysteine residues with a reducing wash buffer, thereby providing the antibody or antigen-binding fragment comprising the one or more uncapped cysteine residues.
[0091] In some embodiments, the reducing wash buffer comprises about 5 mM to about 50 mM cysteine, e.g., about 10 mM to about 40 mM, about 20 mM to about 30 mM, about 5 mM to about 15 mM, about 5 mM to about 25 mM, about 5 mM to about 35 mM, about 5 mM to about 45 mM, about 40 mM to about 50 mM, about 30 mM to about 50 mM, about 20 mM to about 50 mM, about 10 mM to about 50 mM, about 10 mM to about 20 mM, about 15 mM to about 25 mM, about 25 mM to about 35 mM, about 30 mM to about 40 mM, or about 35 mM to about 45 mM, e.g., about 10 mM, about 12 mM, about 14 mM, about 16 mM, about 20 mM, about 25 mM, or about 30 mM. In some embodiments, the reducing wash buffer comprises about 5 mM to about 15 mM cysteine, eg, about 10 mM cysteine.
[0092] In some embodiments, the reducing wash buffer has a pH of about 6.0 to about 7.5, e.g., about 6.5 to about 7.2 or about 6.8 to about 7.0. In some embodiments, the reducing wash buffer has a pH of about 6.8 to about 7.0, e.g., about 6.9.
[0093] In some embodiments, contacting the antibody or antigen-binding fragment thereof comprising one or more capped cysteine residues with a reducing wash buffer is performed on a column (eg, a cation exchange chromatography column).
[0094] In some embodiments, the method further comprises collecting the antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues in the eluate after contacting with the reducing wash buffer. In some embodiments, the eluate has a pH of about 5.5 to about 6.0, for example, about 5.8. In some embodiments, the concentration of the antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues in the eluate is about 5 g / L to 25 g / L, for example, about 8 g / L to about 20 g / L, about 10 g / L to about 18 g / L, about 12 g / L to about 15 g / L, about 5 g / L to about 20 g / L, about 5 g / L to about 15 g / L, about 5 g / L to about 10 g / L, about 20 g / L to about 25 g / L, about 15 g / L to about 25 g / L, about 10 g / L to about 25 g / L, about 10 g / L to about g / L, about 18 g / L, about 19 g / L, about 20 g / L, about 21 g / L, about 22 g / L, about 23 g / L, about 24 g / L, or about 25 g / L.
[0095] In some embodiments, the antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues is stored in the eluate with agitation. In some embodiments, the antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues is stored in the eluate without agitation.
[0096] In some embodiments, an antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues is stored in a container filled to a maximum of about 50% to about 70% by volume, e.g., for about 12 hours to about 96 hours, e.g., about 12 hours to about 84 hours, about 24 hours to about 84 hours, about 36 hours to about 72 hours, about 48 hours to about 60 hours, about 24 hours to about 72 hours, about 24 hours to about 60 hours, about 24 hours to about 48 hours, about 24 hours to about 36 hours, about 72 hours to about 84 hours, about 60 hours to about 84 hours, about 48 hours to about 84 hours, about 36 hours to about 84 hours, about 12 hours to about 36 hours, about 24 hours to about 48 hours, about 36 hours to about 60 hours, about 48 hours to about 72 hours, or about 72 hours to about 96 hours, e.g., about 12 hours, about 24 hours, about 36 hours, about 48 hours, about 60 hours, about 72 hours, about 84 hours, or about 96 hours. In some embodiments, the antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues is stored in a container filled to a maximum of about 60%. In some embodiments, the antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues is stored, for example, without stirring, for about 48 hours to about 72 hours. In some embodiments, the antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues is stored, for example, with stirring, for about 12 hours to about 36 hours, for example, about 24 hours.
[0097] In some embodiments, the antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues is stored at room temperature. In some embodiments, the antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues is stored at about 2° C. to about 8° C. (e.g., about 4° C.), for example, for at least 48 hours (e.g., at least about 48 hours to about 96 hours).
[0098] In some embodiments, antibodies or antigen-binding fragments thereof comprising one or more uncapped cysteine residues are stored covered with air.
[0099] In some embodiments, the method further comprises purifying the partially reoxidized antibody or antigen-binding fragment thereof.
[0100] In some embodiments, the method further comprises conjugating a linker-drug moiety (e.g., a linker-drug moiety described herein) to the partially reoxidized antibody or antigen-binding fragment thereof to produce an antibody drug conjugate (e.g., an antibody drug conjugate described herein).
[0101] In some embodiments, the method further comprises preforming a linker-drug moiety of the following formula (B):
[0102] R 8 -LB -(D) n (B)
[0103] in:
[0104] D is a GNAQ inhibitor, a GNA11 inhibitor, or an inhibitor of GNAQ and GNA11;
[0105] R 8 It is a reactive group;
[0106] L B is a cleavable linker or a non-cleavable linker, and
[0107] n is 1, 2, 3, or 4;
[0108] In some embodiments, D is a GNAQ inhibitor as described herein. In some embodiments, D is a GNA11 inhibitor as described herein. In some embodiments, D is an inhibitor of GNAQ and GNA11 as described herein. In some embodiments, R is a reactive group as described herein. In some embodiments, L B is a cleavable linker as described herein. In some embodiments, L B is a non-cleavable linker as described herein.
[0109] In some embodiments, the antibody or antigen-binding fragment thereof binds PMEL 17. In some embodiments, the antibody or antigen-binding fragment thereof is an antibody or antigen-binding fragment thereof described herein.
[0110] In some embodiments, the method further comprises purifying the antibody drug conjugate.
[0111] In some embodiments, the method produces at least about 75%, for example, at least about 80%, about 85%, about 90% or about 95% site-specific conjugation, for example, one linker-drug moiety ("HCl") per heavy chain. In some embodiments, the method produces less than about 25%, for example, at least about 20%, about 15%, about 10% or about 5% non-site-specific conjugation, for example, one linker-drug moiety ("LC1") per light chain and / or two linker-drug moieties ("HC2") per heavy chain. In some embodiments, the method produces at least about 70%, for example, at least about 75%, about 80%, about 85%, about 90% or about 95% purity, for example, as determined by non-reducing CE-SDS.
[0112] In another aspect, the disclosure features a method for producing an anti-PMEL17 antibody drug conjugate, the method comprising:
[0113] providing an antibody or antigen-binding fragment thereof comprising one or more capped cysteine residues with a reducing wash buffer, thereby providing an antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues;
[0114] storing an antibody or fragment thereof comprising one or more uncapped cysteine residues under oxidizing conditions, thereby producing a partially reoxidized antibody or antigen-binding fragment thereof; and
[0115] conjugating a linker-drug moiety to the partially reoxidized antibody or antigen-binding fragment thereof to produce an anti-PMEL17 antibody drug conjugate,
[0116] wherein the antibody or antigen-binding fragment thereof binds PMEL17; and
[0117] wherein the linker-drug moiety has the following formula (B):
[0118] R 8 -L B -(D) n (B)
[0119] in:
[0120] D is a GNAQ inhibitor, a GNA11 inhibitor, or an inhibitor of GNAQ and GNA11;
[0121] R 8 It is a reactive group;
[0122] L B is a cleavable linker or a non-cleavable linker, and
[0123] n is 1, 2, 3, or 4.
[0124] Formulations of Antibody Drug Conjugates
[0125] In another aspect, the disclosure features a formulation comprising an antibody drug conjugate, a buffer, a stabilizer, and a surfactant, wherein the formulation has a pH of 4.5 to 6.5, wherein the antibody drug conjugate comprises formula (C)
[0126] Ab-(L A -(D) n ) y (C)
[0127] in:
[0128] D is a GNAQ inhibitor, a GNA11 inhibitor, or an inhibitor of GNAQ and GNA11;
[0129] Ab is an antibody or antigen-binding fragment thereof that binds to human PMEL17 protein;
[0130] L A It is a joint;
[0131] n is 1, 2, 3, or 4, and
[0132] y is 1, 2, 3, or 4.
[0133] In embodiments, D is a GNAQ inhibitor described herein, eg, a GNA11 inhibitor described herein, or an inhibitor of GNAQ and GNA11 described herein.
[0134] In one embodiment, the antibody drug conjugate is present at a concentration of about 5 mg / mL to about 30 mg / mL, e.g., about 10 mg to about 30 mg, about 15 mg / mL to about 25 mg / mL, about 18 mg / mL to about 22 mg / mL, about 10 mg / mL to 25 mg / mL, about 10 mg / mL to about 20 mg / mL, about 10 mg / mL to about 15 mg / mL, about 25 mg to about 30 mg / mL, about 20 mg / mL to about 30 mg / mL, about 5 mg / mL to about 15 mg / mL, about 15 mg / mL to about 25 mg / mL or about 18 mg / mL to about 22 mg / mL, for example, about 5 mg / mL, about 6 mg / mL, about 7 mg / mL, about 8 mg / mL, about 9 mg / mL, about 10 mg / mL, about 11 mg / mL, about 12 mg / mL, about 13 mg / mL, about 14 mg / mL, about 15 mg / mL, about 16 mg / mL, about 17 mg / mL, about 18 mg / mL, about 19 mg / mL, about 20 mg / mL, about 21 mg / mL, about 22 mg / mL, about 23 mg / mL, about 24 mg / mL, or about 25 mg / mL.
[0135] In embodiments, the antibody drug conjugate is present at a concentration of about 15 mg / mL to about 25 mg / mL, e.g., about 20 mg / mL.
[0136] In embodiments, the buffer comprises histidine. In embodiments, the buffer comprises succinate. In embodiments, the buffer is present at a concentration of about 5 mM to about 50 mM, e.g., about 10 mM to about 40 nM, about 15 mM to about 35 mM, about 20 mM to about 30 mM, about 5 mM to about 40 mM, about 5 mM to about 30 mM, about 5 mM to about 20 mM, about 5 mM to about 15 mM, about 5 mM to about 10 mM, about 40 mM to about 50 mM, about 35 mM to about 50 mM, about 30 mM to about 50 mM, about 25 mM to about 30 mM, about 5 mM to about 15 mM, about 5 mM to about 10 mM, about 40 mM to about 50 mM, about 35 mM to about 50 mM, about 30 mM to about 50 mM, about 25 mM to about 30 mM, about In one embodiment, the buffer is present at a concentration of about 15 mM to about 25 mM, about 20 mM to about 50 mM, about 15 mM to about 50 mM, about 10 mM to about 50 mM, about 10 mM to about 20 mM, about 15 mM to about 25 mM, about 25 mM to about 35 mM, about 30 mM to about 40 mM or about 35 mM to about 45 mM, e.g., about 5 mM, about 10 mM, about 15 mM, about 20 mM, about 25 mM, about 30 mM, about 35 mM, about 40 mM, about 45 mM or about 50 mM. In an embodiment, the buffer is present at a concentration of about 15 mM to about 25 mM (e.g., about 20 mM).
[0137] In embodiments, the stabilizer comprises sucrose. In embodiments, the stabilizer comprises trehalose. In embodiments, the stabilizer is present at a concentration of about 100 mM to about 500 mM, for example, about 150 mM to about 450 mM, about 200 mM to about 400 mM, about 250 mM to about 350 mM, about 100 mM to about 450 mM, about 100 mM to about 400 mM, about 100 mM to about 350 mM, about 100 mM to about 300 mM, about 100 mM to about 250 mM, about 100 mM to about 200 mM, about 100 mM to about 150 mM, about 450 mM to about 500 mM, about 400 mM to about 500 mM, about 350 mM In an embodiment, the stabilizer is present at a concentration of about 200 mM to about 300 mM, for example, about 240 mM, about 250 mM, about 300 mM, about 350 mM, about 400 mM, about 450 mM or about 500 mM. In an embodiment, the stabilizer is present at a concentration of about 200 mM to about 300 mM, for example, about 240 mM.
[0138] In an embodiment, the surfactant comprises polysorbate 20. In an embodiment, the surfactant comprises polysorbate 80. In embodiments, the surfactant is present at a concentration of about 0.01% to about 0.06%, e.g., about 0.02% to about 0.05%, about 0.03% to about 0.04%, about 0.01% to about 0.05%, about 0.01% to about 0.04%, about 0.01% to about 0.03%, about 0.01% to about 0.02%, about 0.05% to about 0.06%, about 0.04% to about 0.06%, about 0.03% to about 0.06%, about 0.02% to about 0.06%, about 0.02% to about 0.04%, about 0.03% to about 0.05%, e.g., about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, or about 0.06%. In embodiments, the surfactant is present at a concentration of about 0.01% to about 0.03% (eg, about 0.02%).
[0139] In embodiments, the pH of the formulation is from about 4.7 to about 5.3, from about 5.0 to about 6.0, from about 5.2 to about 5.8, from about 5.4 to about 5.6, from about 5.2 to about 6.0, from about 5.4 to about 6.0, from about 5.6 to about 6.0, from about 5.8 to about 6.0, from about 5 to about 5.8, from about 5 to about 5.6.0, from about 5 to about 5.4, from about 5 to about 5.2, from about 4.8 to about 5.2, from about 5.1 to about 5.3, from about 5.2 to about 5.4, from about 5.3 to about 5.5 , about 5.5 to about 5.7, about 5.6 to about 5.8, about 5.7 to about 5.9, about 4.9 to about 5.5, about 5.5 to about 6.1, or about 5.7 to about 6.3, for example, about 4.5, about 4.6, about 4.7, about 4.8, about 4.9, about 5, about 5.1, about 5.2, about 5.3, about 5.4, about 5.5, about 5.6, about 5.7, about 5.8, about 5.9, about 6.0, about 6.1, about 6.2, about 6.3, about 6.4, or about 6.5. In an embodiment, the formulation has a pH of about 5.0 to about 5.6, for example, about 5.3.
[0140] In embodiments, a formulation comprises about 15 mg / mL to about 25 mg / mL of an antibody drug conjugate, about 15 mM to about 25 mM of a buffer comprising histidine or succinate, about 200 mM to about 300 mM of a stabilizer comprising sucrose or trehalose, and about 0.01% to about 0.03% of a surfactant comprising polysorbate 20 or polysorbate 80, wherein the formulation has a pH of about 5.0 to about 5.6.
[0141] In embodiments, a formulation comprises about 15 mg / mL to about 25 mg / mL of an antibody drug conjugate, about 15 mM to about 25 mM of a buffer comprising histidine, about 200 mM to about 300 mM of a stabilizer comprising sucrose, and about 0.01% to about 0.03% of a surfactant comprising polysorbate 20, wherein the formulation has a pH of about 5.0 to about 5.6.
[0142] In embodiments, a formulation comprises about 20 mg / mL of an antibody drug conjugate, about 20 mM of a buffer comprising histidine or succinate, about 240 mM of a stabilizer comprising sucrose or trehalose, and about 0.02% of a surfactant comprising polysorbate 20 or polysorbate 80, wherein the formulation has a pH of about 5.3.
[0143] In an embodiment, a formulation comprises about 20 mg / mL of an antibody drug conjugate, about 20 mM of a buffer comprising histidine, about 240 mM of a stabilizer comprising sucrose, and about 0.02% of a surfactant comprising polysorbate 20, wherein the formulation has a pH of about 5.3.
[0144] In embodiments, a formulation comprises about 15 mg / mL to about 25 mg / mL of an antibody drug conjugate, about 15 mM to about 25 mM of a buffer comprising histidine or succinate, about 200 mM to about 300 mM of a stabilizer comprising sucrose or trehalose, and about 0.01% to about 0.03% of a surfactant comprising polysorbate 20 or polysorbate 80, wherein the formulation has a pH of about 4.7 to about 5.3.
[0145] In embodiments, a formulation comprises about 15 mg / mL to about 25 mg / mL of an antibody drug conjugate, about 15 mM to about 25 mM of a buffer comprising histidine, about 200 mM to about 300 mM of a stabilizer comprising sucrose, and about 0.01% to about 0.03% of a surfactant comprising polysorbate 20, wherein the formulation has a pH of about 4.7 to about 5.3.
[0146] In embodiments, a formulation comprises about 20 mg / mL of an antibody drug conjugate, about 20 mM of a buffer comprising histidine or succinate, about 240 mM of a stabilizer comprising sucrose or trehalose, and about 0.02% of a surfactant comprising polysorbate 20 or polysorbate 80, wherein the formulation has a pH of about 5.0.
[0147] In an embodiment, a formulation comprises about 20 mg / mL of an antibody drug conjugate, about 20 mM of a buffer comprising histidine, about 240 mM of a stabilizer comprising sucrose, and about 0.02% of a surfactant comprising polysorbate 20, wherein the formulation has a pH of about 5.0.
[0148] In embodiments, a formulation comprises about 15 mg / mL to about 25 mg / mL of an antibody drug conjugate, about 15 mM to about 25 mM of a buffer comprising histidine or succinate, about 200 mM to about 300 mM of a stabilizer comprising sucrose or trehalose, and about 0.01% to about 0.03% of a surfactant comprising polysorbate 20 or polysorbate 80, wherein the formulation has a pH of about 5.2 to about 5.8.
[0149] In embodiments, a formulation comprises about 15 mg / mL to about 25 mg / mL of an antibody drug conjugate, about 15 mM to about 25 mM of a buffer comprising histidine, about 200 mM to about 300 mM of a stabilizer comprising sucrose, and about 0.01% to about 0.03% of a surfactant comprising polysorbate 20, wherein the formulation has a pH of about 5.2 to about 5.8.
[0150] In embodiments, a formulation comprises about 20 mg / mL of an antibody drug conjugate, about 20 mM of a buffer comprising histidine or succinate, about 240 mM of a stabilizer comprising sucrose or trehalose, and about 0.02% of a surfactant comprising polysorbate 20 or polysorbate 80, wherein the formulation has a pH of about 5.5.
[0151] In an embodiment, a formulation comprises about 20 mg / mL of an antibody drug conjugate, about 20 mM of a buffer comprising histidine, about 240 mM of a stabilizer comprising sucrose, and about 0.02% of a surfactant comprising polysorbate 20, wherein the formulation has a pH of about 5.5.
[0152] In embodiments, a formulation comprises about 15 mg / mL to about 25 mg / mL of an antibody drug conjugate, about 15 mM to about 25 mM of a buffer comprising histidine or succinate, about 200 mM to about 300 mM of a stabilizer comprising sucrose or trehalose, and about 0.03% to about 0.05% of a surfactant comprising polysorbate 20 or polysorbate 80, wherein the formulation has a pH of about 5.2 to about 5.8.
[0153] In embodiments, a formulation comprises about 15 mg / mL to about 25 mg / mL of an antibody drug conjugate, about 15 mM to about 25 mM of a buffer comprising histidine, about 200 mM to about 300 mM of a stabilizer comprising sucrose, and about 0.03% to about 0.05% of a surfactant comprising polysorbate 20, wherein the formulation has a pH of about 5.2 to about 5.8.
[0154] In embodiments, a formulation comprises about 20 mg / mL of an antibody drug conjugate, about 20 mM of a buffer comprising histidine or succinate, about 240 mM of a stabilizer comprising sucrose or trehalose, and about 0.04% of a surfactant comprising polysorbate 20 or polysorbate 80, wherein the formulation has a pH of about 5.5.
[0155] In an embodiment, a formulation comprises about 20 mg / mL of an antibody drug conjugate, about 20 mM of a buffer comprising histidine, about 240 mM of a stabilizer comprising sucrose, and about 0.04% of a surfactant comprising polysorbate 20, wherein the formulation has a pH of about 5.5.
[0156] In embodiments, a formulation comprises about 5 mg / mL to about 15 mg / mL of an antibody drug conjugate, about 15 mM to about 25 mM of a buffer comprising histidine or succinate, about 200 mM to about 300 mM of a stabilizer comprising sucrose or trehalose, and about 0.03% to about 0.05% of a surfactant comprising polysorbate 20 or polysorbate 80, wherein the formulation has a pH of about 5.2 to about 5.8.
[0157] In embodiments, a formulation comprises about 5 mg / mL to about 15 mg / mL of an antibody drug conjugate, about 15 mM to about 25 mM of a buffer comprising histidine, about 200 mM to about 300 mM of a stabilizer comprising sucrose, and about 0.03% to about 0.05% of a surfactant comprising polysorbate 20, wherein the formulation has a pH of about 5.2 to about 5.8.
[0158] In embodiments, a formulation comprises about 10 mg / mL of an antibody drug conjugate, about 20 mM of a buffer comprising histidine or succinate, about 240 mM of a stabilizer comprising sucrose or trehalose, and about 0.02% of a surfactant comprising polysorbate 20 or polysorbate 80, wherein the formulation has a pH of about 5.5.
[0159] In an embodiment, a formulation comprises about 10 mg / mL of an antibody drug conjugate, about 20 mM of a buffer comprising histidine, about 240 mM of a stabilizer comprising sucrose, and about 0.02% of a surfactant comprising polysorbate 20, wherein the formulation has a pH of about 5.5.
[0160] In embodiments, a formulation comprises about 15 mg / mL to about 25 mg / mL of an antibody drug conjugate, about 15 mM to about 25 mM of a buffer comprising histidine or succinate, about 200 mM to about 300 mM of a stabilizer comprising sucrose or trehalose, and about 0.01% to about 0.03% of a surfactant comprising polysorbate 20 or polysorbate 80, wherein the formulation has a pH of about 5.7 to about 6.3.
[0161] In embodiments, a formulation comprises about 15 mg / mL to about 25 mg / mL of an antibody drug conjugate, about 15 mM to about 25 mM of a buffer comprising histidine, about 200 mM to about 300 mM of a stabilizer comprising sucrose, and about 0.01% to about 0.03% of a surfactant comprising polysorbate 20, wherein the formulation has a pH of about 5.7 to about 6.3.
[0162] In embodiments, a formulation comprises about 20 mg / mL of an antibody drug conjugate, about 20 mM of a buffer comprising histidine or succinate, about 240 mM of a stabilizer comprising sucrose or trehalose, and about 0.02% of a surfactant comprising polysorbate 20 or polysorbate 80, wherein the formulation has a pH of about 6.0.
[0163] In an embodiment, a formulation comprises about 20 mg / mL of an antibody drug conjugate, about 20 mM of a buffer comprising histidine, about 240 mM of a stabilizer comprising sucrose, and about 0.02% of a surfactant comprising polysorbate 20, wherein the formulation has a pH of about 6.0.
[0164] In embodiments, a formulation comprises about 15 mg / mL to about 25 mg / mL of an antibody drug conjugate, about 15 mM to about 25 mM of a buffer comprising histidine or succinate, about 200 mM to about 300 mM of a stabilizer comprising sucrose or trehalose, and about 0.01% to about 0.03% of a surfactant comprising polysorbate 20 or a polysorbate, wherein the formulation has a pH of about 4.9 to about 5.5.
[0165] In embodiments, a formulation comprises about 15 mg / mL to about 25 mg / mL of an antibody drug conjugate, about 15 mM to about 25 mM of a buffer comprising histidine, about 200 mM to about 300 mM of a stabilizer comprising sucrose, and about 0.01% to about 0.03% of a surfactant comprising polysorbate 20, wherein the formulation has a pH of about 4.9 to about 5.5.
[0166] In embodiments, a formulation comprises about 20 mg / mL of an antibody drug conjugate, about 20 mM of a buffer comprising histidine or succinate, about 240 mM of a stabilizer comprising sucrose or trehalose, and about 0.02% of a surfactant comprising polysorbate 20 or polysorbate 80, wherein the formulation has a pH of about 5.2.
[0167] In an embodiment, a formulation comprises about 20 mg / mL of an antibody drug conjugate, about 20 mM of a buffer comprising histidine, about 240 mM of a stabilizer comprising sucrose, and about 0.02% of a surfactant comprising polysorbate 20, wherein the formulation has a pH of about 5.2.
[0168] In embodiments, a formulation comprises about 15 mg / mL to about 25 mg / mL of an antibody drug conjugate, about 15 mM to about 25 mM of a buffer comprising histidine or succinate, about 200 mM to about 300 mM of a stabilizer comprising sucrose or trehalose, and about 0.01% to about 0.03% of a surfactant comprising polysorbate 20 or polysorbate 80, wherein the formulation has a pH of about 5.5 to about 6.1.
[0169] In embodiments, a formulation comprises about 15 mg / mL to about 25 mg / mL of an antibody drug conjugate, about 15 mM to about 25 mM of a buffer comprising histidine, about 200 mM to about 300 mM of a stabilizer comprising sucrose, and about 0.01% to about 0.03% of a surfactant comprising polysorbate 20, wherein the formulation has a pH of about 5.5 to about 6.1.
[0170] In embodiments, a formulation comprises about 20 mg / mL of an antibody drug conjugate, about 20 mM of a buffer comprising histidine or succinate, about 240 mM of a stabilizer comprising sucrose or trehalose, and about 0.02% of a surfactant comprising polysorbate 20 or polysorbate 80, wherein the formulation has a pH of about 5.8.
[0171] In an embodiment, a formulation comprises about 20 mg / mL of an antibody drug conjugate, about 20 mM of a buffer comprising histidine, about 240 mM of a stabilizer comprising sucrose, and about 0.02% of a surfactant comprising polysorbate 20, wherein the formulation has a pH of about 5.8.
[0172] In another aspect, the disclosure features a lyophilized formulation lyophilized from a formulation described herein.
[0173] In embodiments, about 5 mL to about 5.5 mL of the formulation is lyophilized.
[0174] In embodiments, D in the lyophilized formulation is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10-fold more stable after storage at about 5° C., 25° C., or 40° C. for about 0, about 4, or about 8 weeks, as determined, e.g., by CZE, compared to a non-lyophilized but otherwise identical formulation. In embodiments, the percentage of D in the lyophilized formulation in the ring-open conformation is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10-fold lower after storage at about 5° C., 25° C., or 40° C. for about 0, about 4, or about 8 weeks, as determined, e.g., by CZE, compared to a non-lyophilized but otherwise identical formulation.
[0175] In embodiments, the lyophilized formulation comprises about 80 mg to about 120 mg (eg, about 107 mg) of the antibody drug conjugate.
[0176] In embodiments, the monomer level in the lyophilized formulation is at least about 95%, e.g., at least about 96%, 97%, 98% or 99%, after storage at about 5°C, 25°C or 40°C for about 0, about 4 or about 8 weeks, e.g., as determined by SEC.
[0177] In embodiments, the fragment level in the lyophilized formulation is less than about 3%, e.g., less than about 2.5%, 2%, 1.5%, 1% or 0.5%, after storage at about 5°C, 25°C or 40°C for about 0, about 4 or about 8 weeks, e.g., as determined by SEC.
[0178] In embodiments, the aggregate level in the lyophilized formulation is less than about 3%, e.g., less than about 2.5%, 2%, 1.5%, 1% or 0.5%, after storage at about 5°C, 25°C or 40°C for about 0, about 4 or about 8 weeks, e.g., as determined by SEC.
[0179] In embodiments, the degradation level in the lyophilized formulation is less than about 2%, e.g., less than about 1.5%, 1% or 0.5%, after storage at about 5°C, 25°C or 40°C for about 4 weeks or about 8 weeks, e.g., as determined by SEC.
[0180] In embodiments, the level of particles greater than or equal to 10 μm in the lyophilized formulation is less than about 300 particles / ml, e.g., less than about 280 particles / mL, less than about 260 particles / mL, less than about 240 particles / mL, less than about 220 particles / mL, less than about 200 particles / mL, less than about 180 particles / mL, less than about 160 particles / mL, less than about 140 particles / mL, 120 particles / mL, less than about 100 particles / mL, 80 particles / mL, 60 particles / mL, 40 particles / mL, 20 particles / mL, or 10 particles / mL after storage at about 5°C, 25°C, or 40°C for about 0, about 4, or about 8 weeks, e.g., as determined by opacity.
[0181] In embodiments, the level of particles larger than 10 μm in the lyophilized formulation does not increase by more than about 3-fold, e.g., by more than about 2.5, 2, 1.5, 1, or 0.5-fold, e.g., as determined by opacity, after storage at about 5°C, 25°C, or 40°C for about 4 or about 8 weeks.
[0182] In embodiments, the level of particles larger than 25 μm in the lyophilized formulation does not increase by more than about 3-fold, e.g., by more than about 2.5, 2, 1.5, 1, or 0.5-fold, after storage at about 5°C, 25°C, or 40°C for about 4 or about 8 weeks, e.g., as determined by opacity.
[0183] In embodiments, the level of particles larger than 25 μm in the lyophilized formulation is less than about 20 particles / mL, e.g., less than about 15 particles / mL, 10 particles / mL, 5 particles / mL, or 2 particles / mL, e.g., as determined by opacity, after storage at about 5°C, 25°C, or 40°C for about 0, about 4, or about 8 weeks.
[0184] In embodiments, the impurity level in the lyophilized formulation is less than about 15%, e.g., less than about 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% after storage at about 5°C, 25°C or 40°C for about 0, about 4 or about 8 weeks, e.g., as determined by capillary electrophoresis.
[0185] In embodiments, the impurity level in the lyophilized formulation does not increase by more than 20%, e.g., by no more than about 15%, 10%, 5%, 2% or 1%, after storage at about 5°C, 25°C or 40°C for about 4 weeks or about 8 weeks, e.g., as determined by capillary electrophoresis.
[0186] In embodiments, the level of neutral variant in the lyophilized formulation is greater than about 50%, e.g., greater than about 55%, 60%, 65%, 70%, 75%, 80%, 85% or 90% after storage at about 5°C, 25°C or 40°C for about 0, about 4 or about 8 weeks, e.g., as determined by capillary zone electrophoresis (CZE).
[0187] In embodiments, the level of the neutral variant in the lyophilized formulation decreases by no more than about 20%, e.g., no more than about 15%, 10%, 5% or 2%, after storage at about 5°C, 25°C or 40°C for about 4 weeks or about 8 weeks, e.g., as determined by CZE.
[0188] In embodiments, the level of acidic variant in the lyophilized formulation is less than about 30%, e.g., less than about 25%, 20%, 15%, 5% or 2%, after storage at about 5°C, 25°C or 40°C for about 0, about 4 or about 8 weeks, e.g., as determined by CZE.
[0189] In embodiments, the level of the acidic variant in the lyophilized formulation does not increase by more than about 50%, e.g., by no more than about 40%, 30%, 20%, 10% or 5%, after storage at about 5°C, 25°C or 40°C for about 4 weeks or about 8 weeks, e.g., as determined by CZE.
[0190] In embodiments, the level of basic variants in the lyophilized formulation is less than about 30%, e.g., less than about 25%, 20%, 15%, 5% or 2%, after storage at about 5°C, 25°C or 40°C for about 0, about 4 or about 8 weeks, e.g., as determined by CZE.
[0191] In embodiments, the level of basic variant in the lyophilized formulation does not increase by more than about 50%, e.g., by no more than about 40%, 30%, 20%, 10%, or 5%, after storage at about 5°C, 25°C, or 40°C for about 4 weeks or about 8 weeks, e.g., as determined by CZE.
[0192] In embodiments, the potency of the lyophilized formulation does not decrease by more than about 25%, e.g., by more than about 20%, 15%, 10%, 5% or 2%, after storage at about 5°C, 25°C or 40°C for about 8 weeks, e.g., as determined by a bioactivity assay.
[0193] In embodiments, the osmolarity of the lyophilized formulation is about 200 mOsm / L to 400 mOsm / L, e.g., 200 mOsm / L to 300 mOsm / L, 250 mOsm / L to 350 mOsm / L, 270 mOsm / L to 330 mOsm / L, 290 mOsm / L to 310 mOsm / L, 270 mOsm / L to 350 mOsm / L, 0mOsm / L, 290mOsm / L to 350mOsm / L, 310mOsm / L to 350mOsm / L, 330mOsm / L to 350mOsm / L, 250mOsm / L to 330mOsm / L, 250mOsm / L to 310mOsm / L, 250mOsm / L to 290mOsm / L, 250mOsm / L to 330mOsm / L mOsm / L to 270 mOsm / L, 260 mOsm / L to 280 mOsm / L, 270 mOsm / L to 290 mOsm / L, 280 mOsm / L to 300 mOsm / L, 300 mOsm / L to 320 mOsm / L, 310 mOsm / L to 330 mOsm / L, or 320 mOsm / L to 340 mOsm / L , for example, 200 mOsm / L, 250 mOsm / L, 260 mOsm / L, 270 mOsm / L, 280 mOsm / L, 290 mOsm / L, 300 mOsm / L, 310 mOsm / L, 320 mOsm / L, 330 mOsm / L, 340 mOsm / L, 350 mOsm / L, or 400 mOsm / L.
[0194] In another aspect, the disclosure features a liquid formulation reconstituted from a lyophilized formulation described herein.
[0195] In another aspect, the disclosure features a container comprising a lyophilized formulation described herein.
[0196] In an embodiment, the container is a vial, e.g., a 25R glass vial. In an embodiment, the container further comprises a stopper and a lid (e.g., a flip-top aluminum lid).
[0197] Treatment
[0198] In another aspect, the disclosure features a method of treating cancer, the method comprising administering an antibody drug conjugate (ADC) described herein or a formulation described herein to a subject in need thereof at a dose of 1 mg / kg to 16 mg / kg, thereby treating the cancer.
[0199] In an embodiment, the ADC is administered at a dose of 2 mg / kg to 15 mg / kg. In an embodiment, the ADC is administered at a dose of 1 mg / kg, 2 mg / kg, 4 mg / kg, 8 mg / kg, 12 mg / kg, or 16 mg / kg. In an embodiment, the ADC is administered once a week, once every two weeks, or once every four weeks. In an embodiment, the ADC is administered once every two weeks. In an embodiment, the ADC is administered intravenously.
[0200] In embodiments, the subject has been treated with tebentafusp prior to administration of the ADC. In embodiments, the subject has not been treated with tebentafusp prior to administration of the ADC.
[0201] In embodiments, the cancer expresses PMEL17 and contains mutations in the GNAQ or GNA11 genes, or the melanoma expresses PMEL17 and contains mutations in GNAQ, GNA11, or both. In embodiments, the cancer is melanoma. In embodiments, the cancer is malignant melanoma, uveal melanoma, ocular melanoma, eye cancer, eye tumor, cutaneous melanoma, or mucosal melanoma.
[0202] In an embodiment, the ADC has the following structure:
[0203]
[0204] in:
[0205] Ab is an antibody or an antigen-binding fragment thereof that binds to human PMEL17 protein, and y is 1, 2, 3 or 4. In an embodiment, y is 2.
[0206] In an embodiment, Ab comprises:
[0207] (a) the heavy chain CDR1 of SEQ ID NO: 1, the heavy chain CDR2 of SEQ ID NO: 2, the heavy chain CDR3 of SEQ ID NO: 3, the light chain CDR1 of SEQ ID NO: 14, the light chain CDR2 of SEQ ID NO: 15, and the light chain CDR3 of SEQ ID NO: 16;
[0208] (b) the heavy chain CDR1 of SEQ ID NO:4, the heavy chain CDR2 of SEQ ID NO:2, the heavy chain CDR3 of SEQ ID NO:3, the light chain CDR1 of SEQ ID NO:14, the light chain CDR2 of SEQ ID NO:15, and the light chain CDR3 of SEQ ID NO:16;
[0209] (c) the heavy chain CDR1 of SEQ ID NO: 5, the heavy chain CDR2 of SEQ ID NO: 6, the heavy chain CDR3 of SEQ ID NO: 3, the light chain CDR1 of SEQ ID NO: 17, the light chain CDR2 of SEQ ID NO: 18, and the light chain CDR3 of SEQ ID NO: 19; or
[0210] (d) heavy chain CDR1 of SEQ ID NO:7, heavy chain CDR2 of SEQ ID NO:8, heavy chain CDR3 of SEQ ID NO:9, light chain CDR1 of SEQ ID NO:20, light chain CDR2 of SEQ ID NO:18, and light chain CDR3 of SEQ ID NO:16.
[0211] In an embodiment, the Ab comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 10 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 25. In an embodiment, the Ab comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 283 and a light chain comprising the amino acid sequence of SEQ ID NO: 27.
[0212] In an embodiment, the Ab comprises a heavy chain amino acid sequence comprising an N-glycosylation site. In an embodiment, the N-glycosylation site is located at Asn306.
[0213] In embodiments, the method further comprises determining the expression of one or more biomarkers. In embodiments, the one or more biomarkers are selected from premelanosomal protein 17 (PMEL17), phosphorylated ERK (pERK), cluster of differentiation 8 (CD8), programmed death ligand 1 (PD-L1), dual specificity phosphatase 6 (DUSP6), Ras guanosine releasing protein 3 (RASGRP3), or any combination thereof.
[0214] In an embodiment, the expression of one or more biomarkers is determined in a sample from a subject. In an embodiment, the sample is obtained from the subject before, during, and / or after administration of the ADC. In an embodiment, the sample is a tumor sample. For example, the tumor sample can be an archived tissue block or obtained by needle biopsy. In an embodiment, the mRNA expression of one or more biomarkers is determined. In an embodiment, the protein expression of one or more biomarkers is determined. In an embodiment, the method further comprises detecting one or more cancer-related genes by next-generation DNA sequencing, performing whole transcriptome analysis, determining the expression of one or more immune and cancer-related genes, or a combination thereof.
[0215] In embodiments, the method further comprises assessing cell-free DNA (cfDNA) in a sample from the subject. In embodiments, the sample is obtained from the subject before, during, and / or after administration of the ADC. In embodiments, the sample is a blood sample. In embodiments, the cell-free DNA is assessed to determine one or more of: driver mutation status, predicted pharmacodynamics, tumor mutation burden (TMB), or resistance markers.
[0216] In one aspect, the disclosure features a method of evaluating a subject (e.g., a subject described herein) for a treatment (e.g., a treatment described herein) for a disease (e.g., a disease described herein) comprising determining the expression of one or more biomarkers and / or assessing cell-free DNA (cfDNA) in a sample from the subject (e.g., a sample described herein) according to a method described herein.
[0217] In one aspect, the disclosure features a method of assessing the progression of a disease (e.g., a disease described herein) in a subject (e.g., a subject described herein), the method comprising determining the expression of one or more biomarkers and / or assessing cell-free DNA (cfDNA) in a sample from the subject (e.g., a sample described herein) according to a method described herein.
[0218] In one aspect, the disclosure features a method of selecting a treatment (e.g., a treatment described herein) for a disease (e.g., a disease described herein) in a subject (e.g., a subject described herein), the method comprising determining the expression of one or more biomarkers and / or assessing cell-free DNA (cfDNA) in a sample from the subject (e.g., a sample described herein) according to a method described herein.
[0219] In one aspect, the disclosure features a method of selecting a subject (e.g., a subject described herein) for a treatment (e.g., a treatment described herein) for a disease (e.g., a disease described herein), the method comprising determining the expression of one or more biomarkers and / or assessing cell-free DNA (cfDNA) in a sample (e.g., a sample described herein) from the subject according to a method described herein.
[0220] Other embodiments
[0221] Aspects and embodiments described herein may include any of the following embodiments.
[0222] In some embodiments, the antibody or antigen-binding fragment thereof that binds PMEL17 comprises:
[0223] (a) a heavy chain variable region comprising a heavy chain CDR1 (complementarity determining region 1) of SEQ ID NO: 1, 4, 5 or 7, a heavy chain CDR2 (complementarity determining region 2) of SEQ ID NO: 2, 6 or 8, and a heavy chain CDR3 (complementarity determining region 3) of SEQ ID NO: 3 or 9; and a light chain variable region comprising a light chain CDR1 (complementarity determining region 1) of SEQ ID NO: 14, 17 or 20, a light chain CDR2 (complementarity determining region 2) of SEQ ID NO: 15 or 18, and a light chain CDR3 (complementarity determining region 3) of SEQ ID NO: 16 or 19;
[0224] (b) a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 33, 36, 37 or 39, a heavy chain CDR2 of SEQ ID NO: 34, 38 or 40; a heavy chain CDR3 of SEQ ID NO: 35 or 41; a light chain CDR1 of SEQ ID NO: 46, 49 or 52; a light chain CDR2 of SEQ ID NO: 47 or 50; and a light chain CDR3 of SEQ ID NO: 48 or 51;
[0225] (c) a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 5, 7, 57 or 60, a heavy chain CDR2 of SEQ ID NO: 58, 61 or 62; a heavy chain CDR3 of SEQ ID NO: 59 or 63; a light chain CDR1 of SEQ ID NO: 68, 71 or 74; a light chain CDR2 of SEQ ID NO: 69 or 72; and a light chain CDR3 of SEQ ID NO: 70 or 73;
[0226] (d) a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 79, 82, 83 or 85, a heavy chain CDR2 of SEQ ID NO: 80, 84 or 86; a heavy chain CDR3 of SEQ ID NO: 81 or 87; a light chain CDR1 of SEQ ID NO: 92, 95 or 98; a light chain CDR2 of SEQ ID NO: 93 or 96; and a light chain CDR3 of SEQ ID NO: 94 or 97;
[0227] (e) a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 103, 106, 107 or 109, a heavy chain CDR2 of SEQ ID NO: 104, 108 or 110; a heavy chain CDR3 of SEQ ID NO: 105 or 111; a light chain CDR1 of SEQ ID NO: 49, 52 or 116; a light chain CDR2 of SEQ ID NO: 47 or 50; and a light chain CDR3 of SEQ ID NO: 117 or 118;
[0228] (f) a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 123, 126, 127 or 129, a heavy chain CDR2 of SEQ ID NO: 124, 128 or 130; a heavy chain CDR3 of SEQ ID NO: 125 or 131; a light chain CDR1 of SEQ ID NO: 136, 139 or 142; a light chain CDR2 of SEQ ID NO: 137 or 140; and a light chain CDR3 of SEQ ID NO: 138 or 141;
[0229] (g) a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 123, 126, 127 or 129, a heavy chain CDR2 of SEQ ID NO: 124, 128 or 130; a heavy chain CDR3 of SEQ ID NO: 147 or 148; a light chain CDR1 of SEQ ID NO: 153, 156 or 158; a light chain CDR2 of SEQ ID NO: 50 or 154; and a light chain CDR3 of SEQ ID NO: 155 or 157;
[0230] (h) a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 103, 106, 107 or 109, a heavy chain CDR2 of SEQ ID NO: 104, 108 or 110; a heavy chain CDR3 of SEQ ID NO: 163 or 164; a light chain CDR1 of SEQ ID NO: 49, 52 or 116; a light chain CDR2 of SEQ ID NO: 47 or 50; and a light chain CDR3 of SEQ ID NO: 169 or 170;
[0231] (i) a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 175, 178, 179 or 181, a heavy chain CDR2 of SEQ ID NO: 176, 180 or 182; a heavy chain CDR3 of SEQ ID NO: 177 or 183; a light chain CDR1 of SEQ ID NO: 49, 52 or 116; a light chain CDR2 of SEQ ID NO: 47 or 50; and a light chain CDR3 of SEQ ID NO: 188 or 189;
[0232] (j) a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 103, 106, 107 or 109, a heavy chain CDR2 of SEQ ID NO: 104, 108 or 110; a heavy chain CDR3 of SEQ ID NO: 194 or 195; a light chain CDR1 of SEQ ID NO: 49, 52 or 116; a light chain CDR2 of SEQ ID NO: 47 or 50; and a light chain CDR3 of SEQ ID NO: 200 or 201;
[0233] (k) a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 206, 209, 210, or 212, a heavy chain CDR2 of SEQ ID NO: 207, 211, or 213; a heavy chain CDR3 of SEQ ID NO: 208 or 214; a light chain CDR1 of SEQ ID NO: 153, 156, or 158; a light chain CDR2 of SEQ ID NO: 50 or 154; and a light chain CDR3 of SEQ ID NO: 219 or 220;
[0234] (1) a heavy chain variable region comprising a heavy chain CDR1 of SEQ ID NO: 206, 209, 210, or 212, a heavy chain CDR2 of SEQ ID NO: 207, 211, or 213; a heavy chain CDR3 of SEQ ID NO: 225 or 226; a light chain CDR1 of SEQ ID NO: 136, 139, or 142; a light chain CDR2 of SEQ ID NO: 137 or 140; and a light chain CDR3 of SEQ ID NO: 231 or 232;
[0235] (m) a heavy chain variable region comprising a HCDR1 of SEQ ID NO: 206, 209, 210, or 212, a HCDR2 of SEQ ID NO: 207, 211, or 213, and a HCDR3 of SEQ ID NO: 237 or 238; and a light chain variable region comprising a LCDR1 of SEQ ID NO: 243, 245, or 247, a LCDR2 of SEQ ID NO: 47 or 50, and a LCDR3 of SEQ ID NO: 244 or 246;
[0236] (n) a heavy chain variable region comprising a HCDR1 of SEQ ID NO: 206, 209, 210, or 212, a HCDR2 of SEQ ID NO: 207, 211, or 213, and a HCDR3 of SEQ ID NO: 252 or 253; and a light chain variable region comprising a LCDR1 of SEQ ID NO: 153, 156, or 158, a LCDR2 of SEQ ID NO: 50 or 154, and a LCDR3 of SEQ ID NO: 258 or 259;
[0237] (o) the heavy chain CDR1 of SEQ ID NO: 1, the heavy chain CDR2 of SEQ ID NO: 2, the heavy chain CDR3 of SEQ ID NO: 3, the light chain CDR1 of SEQ ID NO: 14, the light chain CDR2 of SEQ ID NO: 15, and the light chain CDR3 of SEQ ID NO: 16;
[0238] (p) the heavy chain CDR1 of SEQ ID NO:4, the heavy chain CDR2 of SEQ ID NO:2, the heavy chain CDR3 of SEQ ID NO:3, the light chain CDR1 of SEQ ID NO:14, the light chain CDR2 of SEQ ID NO:15, and the light chain CDR3 of SEQ ID NO:16;
[0239] (q) heavy chain CDR1 of SEQ ID NO:5, heavy chain CDR2 of SEQ ID NO:6, heavy chain CDR3 of SEQ ID NO:3, light chain CDR1 of SEQ ID NO:17, light chain CDR2 of SEQ ID NO:18, and light chain CDR3 of SEQ ID NO:19;
[0240] (r) the heavy chain CDR1 of SEQ ID NO:7, the heavy chain CDR2 of SEQ ID NO:8, the heavy chain CDR3 of SEQ ID NO:9, the light chain CDR1 of SEQ ID NO:20, the light chain CDR2 of SEQ ID NO:18, and the light chain CDR3 of SEQ ID NO:16;
[0241] (s) the heavy chain CDR1 of SEQ ID NO:33, the heavy chain CDR2 of SEQ ID NO:34, the heavy chain CDR3 of SEQ ID NO:35, the light chain CDR1 of SEQ ID NO:46, the light chain CDR2 of SEQ ID NO:47, and the light chain CDR3 of SEQ ID NO:48;
[0242] (t) the heavy chain CDR1 of SEQ ID NO:36, the heavy chain CDR2 of SEQ ID NO:34, the heavy chain CDR3 of SEQ ID NO:35, the light chain CDR1 of SEQ ID NO:46, the light chain CDR2 of SEQ ID NO:47, and the light chain CDR3 of SEQ ID NO:48;
[0243] (u) the heavy chain CDR1 of SEQ ID NO:37, the heavy chain CDR2 of SEQ ID NO:38, the heavy chain CDR3 of SEQ ID NO:35, the light chain CDR1 of SEQ ID NO:49, the light chain CDR2 of SEQ ID NO:50, and the light chain CDR3 of SEQ ID NO:51;
[0244] (v) the heavy chain CDR1 of SEQ ID NO:39, the heavy chain CDR2 of SEQ ID NO:40, the heavy chain CDR3 of SEQ ID NO:41, the light chain CDR1 of SEQ ID NO:52, the light chain CDR2 of SEQ ID NO:50, and the light chain CDR3 of SEQ ID NO:48;
[0245] (w) the heavy chain CDR1 of SEQ ID NO:57, the heavy chain CDR2 of SEQ ID NO:58, the heavy chain CDR3 of SEQ ID NO:59, the light chain CDR1 of SEQ ID NO:68, the light chain CDR2 of SEQ ID NO:69, and the light chain CDR3 of SEQ ID NO:70;
[0246] (x) the heavy chain CDR1 of SEQ ID NO:60, the heavy chain CDR2 of SEQ ID NO:58, the heavy chain CDR3 of SEQ ID NO:59, the light chain CDR1 of SEQ ID NO:68, the light chain CDR2 of SEQ ID NO:69, and the light chain CDR3 of SEQ ID NO:70;
[0247] (y) the heavy chain CDR1 of SEQ ID NO: 5, the heavy chain CDR2 of SEQ ID NO: 61, the heavy chain CDR3 of SEQ ID NO: 59, the light chain CDR1 of SEQ ID NO: 71, the light chain CDR2 of SEQ ID NO: 72, and the light chain CDR3 of SEQ ID NO: 73;
[0248] (z) the heavy chain CDR1 of SEQ ID NO: 7, the heavy chain CDR2 of SEQ ID NO: 62, the heavy chain CDR3 of SEQ ID NO: 63, the light chain CDR1 of SEQ ID NO: 74, the light chain CDR2 of SEQ ID NO: 72, and the light chain CDR3 of SEQ ID NO: 70;
[0249] (aa) heavy chain CDR1 of SEQ ID NO:79, heavy chain CDR2 of SEQ ID NO:80, heavy chain CDR3 of SEQ ID NO:81, light chain CDR1 of SEQ ID NO:92, light chain CDR2 of SEQ ID NO:93, and light chain CDR3 of SEQ ID NO:94;
[0250] (bb) the heavy chain CDR1 of SEQ ID NO:82, the heavy chain CDR2 of SEQ ID NO:80, the heavy chain CDR3 of SEQ ID NO:81, the light chain CDR1 of SEQ ID NO:92, the light chain CDR2 of SEQ ID NO:93, and the light chain CDR3 of SEQ ID NO:94;
[0251] (cc) the heavy chain CDR1 of SEQ ID NO:83, the heavy chain CDR2 of SEQ ID NO:84, the heavy chain CDR3 of SEQ ID NO:81, the light chain CDR1 of SEQ ID NO:95, the light chain CDR2 of SEQ ID NO:96, and the light chain CDR3 of SEQ ID NO:97;
[0252] (dd) the heavy chain CDR1 of SEQ ID NO:85, the heavy chain CDR2 of SEQ ID NO:86, the heavy chain CDR3 of SEQ ID NO:87, the light chain CDR1 of SEQ ID NO:98, the light chain CDR2 of SEQ ID NO:96, and the light chain CDR3 of SEQ ID NO:94;
[0253] (ee) the heavy chain CDR1 of SEQ ID NO: 103, the heavy chain CDR2 of SEQ ID NO: 104, the heavy chain CDR3 of SEQ ID NO: 105, the light chain CDR1 of SEQ ID NO: 116; the light chain CDR2 of SEQ ID NO: 47; and the light chain CDR3 of SEQ ID NO: 117;
[0254] (ff) heavy chain CDR1 of SEQ ID NO: 106, heavy chain CDR2 of SEQ ID NO: 104, heavy chain CDR3 of SEQ ID NO: 105, light chain CDR1 of SEQ ID NO: 116, light chain CDR2 of SEQ ID NO: 47, and light chain CDR3 of SEQ ID NO: 117;
[0255] (gg) heavy chain CDR1 of SEQ ID NO: 107, heavy chain CDR2 of SEQ ID NO: 108, heavy chain CDR3 of SEQ ID NO: 105, light chain CDR1 of SEQ ID NO: 49, light chain CDR2 of SEQ ID NO: 50, and light chain CDR3 of SEQ ID NO: 118;
[0256] (hh) the heavy chain CDR1 of SEQ ID NO: 109, the heavy chain CDR2 of SEQ ID NO: 110, the heavy chain CDR3 of SEQ ID NO: 111, the light chain CDR1 of SEQ ID NO: 52, the light chain CDR2 of SEQ ID NO: 50, and the light chain CDR3 of SEQ ID NO: 117;
[0257] (ii) the heavy chain CDR1 of SEQ ID NO: 123, the heavy chain CDR2 of SEQ ID NO: 124, the heavy chain CDR3 of SEQ ID NO: 125, the light chain CDR1 of SEQ ID NO: 136, the light chain CDR2 of SEQ ID NO: 137, and the light chain CDR3 of SEQ ID NO: 138;
[0258] (jj) the heavy chain CDR1 of SEQ ID NO: 126, the heavy chain CDR2 of SEQ ID NO: 124, the heavy chain CDR3 of SEQ ID NO: 125, the light chain CDR1 of SEQ ID NO: 136, the light chain CDR2 of SEQ ID NO: 137, and the light chain CDR3 of SEQ ID NO: 138;
[0259] (kk) the heavy chain CDR1 of SEQ ID NO: 127, the heavy chain CDR2 of SEQ ID NO: 128, the heavy chain CDR3 of SEQ ID NO: 125, the light chain CDR1 of SEQ ID NO: 139, the light chain CDR2 of SEQ ID NO: 140, and the light chain CDR3 of SEQ ID NO: 141;
[0260] (11) the heavy chain CDR1 of SEQ ID NO: 129, the heavy chain CDR2 of SEQ ID NO: 130, the heavy chain CDR3 of SEQ ID NO: 131, the light chain CDR1 of SEQ ID NO: 142, the light chain CDR2 of SEQ ID NO: 140, and the light chain CDR3 of SEQ ID NO: 138;
[0261] (mm) heavy chain CDR1 of SEQ ID NO: 123, heavy chain CDR2 of SEQ ID NO: 124, heavy chain CDR3 of SEQ ID NO: 147, light chain CDR1 of SEQ ID NO: 153, light chain CDR2 of SEQ ID NO: 154, and light chain CDR3 of SEQ ID NO: 155;
[0262] (nn) heavy chain CDR1 of SEQ ID NO: 126, heavy chain CDR2 of SEQ ID NO: 124, heavy chain CDR3 of SEQ ID NO: 147, light chain CDR1 of SEQ ID NO: 153, light chain CDR2 of SEQ ID NO: 154, and light chain CDR3 of SEQ ID NO: 155;
[0263] (oo) the heavy chain CDR1 of SEQ ID NO: 127, the heavy chain CDR2 of SEQ ID NO: 128, the heavy chain CDR3 of SEQ ID NO: 147, the light chain CDR1 of SEQ ID NO: 156, the light chain CDR2 of SEQ ID NO: 50, and the light chain CDR3 of SEQ ID NO: 157;
[0264] (pp) heavy chain CDR1 of SEQ ID NO: 129, heavy chain CDR2 of SEQ ID NO: 130, heavy chain CDR3 of SEQ ID NO: 148, light chain CDR1 of SEQ ID NO: 158, light chain CDR2 of SEQ ID NO: 50, and light chain CDR3 of SEQ ID NO: 155;
[0265] (qq) heavy chain CDR1 of SEQ ID NO: 103, heavy chain CDR2 of SEQ ID NO: 104, heavy chain CDR3 of SEQ ID NO: 163, light chain CDR1 of SEQ ID NO: 116, light chain CDR2 of SEQ ID NO: 47, and light chain CDR3 of SEQ ID NO: 169;
[0266] (rr) the heavy chain CDR1 of SEQ ID NO: 106, the heavy chain CDR2 of SEQ ID NO: 104, the heavy chain CDR3 of SEQ ID NO: 163, the light chain CDR1 of SEQ ID NO: 116, the light chain CDR2 of SEQ ID NO: 47, and the light chain CDR3 of SEQ ID NO: 169;
[0267] (ss) heavy chain CDR1 of SEQ ID NO: 107, heavy chain CDR2 of SEQ ID NO: 108, heavy chain CDR3 of SEQ ID NO: 163, light chain CDR1 of SEQ ID NO: 49, light chain CDR2 of SEQ ID NO: 50, and light chain CDR3 of SEQ ID NO: 170;
[0268] (tt) the heavy chain CDR1 of SEQ ID NO: 109, the heavy chain CDR2 of SEQ ID NO: 110, the heavy chain CDR3 of SEQ ID NO: 164, the light chain CDR1 of SEQ ID NO: 52, the light chain CDR2 of SEQ ID NO: 50, and the light chain CDR3 of SEQ ID NO: 169;
[0269] (uu) heavy chain CDR1 of SEQ ID NO: 175, heavy chain CDR2 of SEQ ID NO: 176, heavy chain CDR3 of SEQ ID NO: 177, light chain CDR1 of SEQ ID NO: 116, light chain CDR2 of SEQ ID NO: 47, and light chain CDR3 of SEQ ID NO: 188;
[0270] (vv) the heavy chain CDR1 of SEQ ID NO: 178, the heavy chain CDR2 of SEQ ID NO: 176, the heavy chain CDR3 of SEQ ID NO: 177, the light chain CDR1 of SEQ ID NO: 116, the light chain CDR2 of SEQ ID NO: 47, and the light chain CDR3 of SEQ ID NO: 188;
[0271] (ww) heavy chain CDR1 of SEQ ID NO: 179, heavy chain CDR2 of SEQ ID NO: 180, heavy chain CDR3 of SEQ ID NO: 177, light chain CDR1 of SEQ ID NO: 49, light chain CDR2 of SEQ ID NO: 50, and light chain CDR3 of SEQ ID NO: 189;
[0272] (xx) heavy chain CDR1 of SEQ ID NO: 181, heavy chain CDR2 of SEQ ID NO: 182; heavy chain CDR3 of SEQ ID NO: 183, light chain CDR1 of SEQ ID NO: 52, light chain CDR2 of SEQ ID NO: 50, and light chain CDR3 of SEQ ID NO: 188;
[0273] (yy) the heavy chain CDR1 of SEQ ID NO: 103, the heavy chain CDR2 of SEQ ID NO: 104, the heavy chain CDR3 of SEQ ID NO: 194, the light chain CDR1 of SEQ ID NO: 116, the light chain CDR2 of SEQ ID NO: 47, and the light chain CDR3 of SEQ ID NO: 200;
[0274] (zz) the heavy chain CDR1 of SEQ ID NO: 106, the heavy chain CDR2 of SEQ ID NO: 104, the heavy chain CDR3 of SEQ ID NO: 194, the light chain CDR1 of SEQ ID NO: 116, the light chain CDR2 of SEQ ID NO: 47, and the light chain CDR3 of SEQ ID NO: 200;
[0275] (aaa) heavy chain CDR1 of SEQ ID NO: 107, heavy chain CDR2 of SEQ ID NO: 108, heavy chain CDR3 of SEQ ID NO: 194, light chain CDR1 of SEQ ID NO: 49, light chain CDR2 of SEQ ID NO: 50, and light chain CDR3 of SEQ ID NO: 201;
[0276] (bbb) the heavy chain CDR1 of SEQ ID NO: 109, the heavy chain CDR2 of SEQ ID NO: 110, the heavy chain CDR3 of SEQ ID NO: 195, the light chain CDR1 of SEQ ID NO: 52, the light chain CDR2 of SEQ ID NO: 50, and the light chain CDR3 of SEQ ID NO: 200;
[0277] (ccc) the heavy chain CDR1 of SEQ ID NO:206, the heavy chain CDR2 of SEQ ID NO:207, the heavy chain CDR3 of SEQ ID NO:208, the light chain CDR1 of SEQ ID NO:153, the light chain CDR2 of SEQ ID NO:154, and the light chain CDR3 of SEQ ID NO:219;
[0278] (ddd) the heavy chain CDR1 of SEQ ID NO:209, the heavy chain CDR2 of SEQ ID NO:207, the heavy chain CDR3 of SEQ ID NO:208, the light chain CDR1 of SEQ ID NO:153, the light chain CDR2 of SEQ ID NO:154, and the light chain CDR3 of SEQ ID NO:219;
[0279] (eee) the heavy chain CDR1 of SEQ ID NO:210, the heavy chain CDR2 of SEQ ID NO:211, the heavy chain CDR3 of SEQ ID NO:208, the light chain CDR1 of SEQ ID NO:156, the light chain CDR2 of SEQ ID NO:50, and the light chain CDR3 of SEQ ID NO:220;
[0280] (fff) heavy chain CDR1 of SEQ ID NO:212, heavy chain CDR2 of SEQ ID NO:213, heavy chain CDR3 of SEQ ID NO:214, light chain CDR1 of SEQ ID NO:158, light chain CDR2 of SEQ ID NO:50, and light chain CDR3 of SEQ ID NO:219;
[0281] (ggg) heavy chain CDR1 of SEQ ID NO:206, heavy chain CDR2 of SEQ ID NO:207, heavy chain CDR3 of SEQ ID NO:225, light chain CDR1 of SEQ ID NO:136, light chain CDR2 of SEQ ID NO:137, and light chain CDR3 of SEQ ID NO:231;
[0282] (hhh) the heavy chain CDR1 of SEQ ID NO:209, the heavy chain CDR2 of SEQ ID NO:207, the heavy chain CDR3 of SEQ ID NO:225, the light chain CDR1 of SEQ ID NO:136, the light chain CDR2 of SEQ ID NO:137, and the light chain CDR3 of SEQ ID NO:231;
[0283] (iii) the heavy chain CDR1 of SEQ ID NO: 210, the heavy chain CDR2 of SEQ ID NO: 211, the heavy chain CDR3 of SEQ ID NO: 225, the light chain CDR1 of SEQ ID NO: 139, the light chain CDR2 of SEQ ID NO: 140, and the light chain CDR3 of SEQ ID NO: 232;
[0284] (jjj) the heavy chain CDR1 of SEQ ID NO:212, the heavy chain CDR2 of SEQ ID NO:213, the heavy chain CDR3 of SEQ ID NO:226, the light chain CDR1 of SEQ ID NO:142; the light chain CDR2 of SEQ ID NO:140; and the light chain CDR3 of SEQ ID NO:231;
[0285] (kkk) a heavy chain variable region comprising HCDR1 of SEQ ID NO: 206, HCDR2 of SEQ ID NO: 207, and HCDR3 of SEQ ID NO: 237; and a light chain variable region comprising LCDR1 of SEQ ID NO: 243, LCDR2 of SEQ ID NO: 47, and LCDR3 of SEQ ID NO: 244;
[0286] (111) a heavy chain variable region comprising HCDR1 of SEQ ID NO: 209, HCDR2 of SEQ ID NO: 207, and HCDR3 of SEQ ID NO: 237; and a light chain variable region comprising LCDR1 of SEQ ID NO: 243, LCDR2 of SEQ ID NO: 47, and LCDR3 of SEQ ID NO: 244;
[0287] (mmm) a heavy chain variable region comprising HCDR1 of SEQ ID NO: 210, HCDR2 of SEQ ID NO: 211, and HCDR3 of SEQ ID NO: 237; and a light chain variable region comprising LCDR1 of SEQ ID NO: 245, LCDR2 of SEQ ID NO: 50, and LCDR3 of SEQ ID NO: 246;
[0288] (nnn) a heavy chain variable region comprising HCDR1 of SEQ ID NO: 212, HCDR2 of SEQ ID NO: 213, and HCDR3 of SEQ ID NO: 238; and a light chain variable region comprising LCDR1 of SEQ ID NO: 247, LCDR2 of SEQ ID NO: 50, and LCDR3 of SEQ ID NO: 244;
[0289] (ooo) a heavy chain variable region comprising HCDR1 of SEQ ID NO: 206, HCDR2 of SEQ ID NO: 207, and HCDR3 of SEQ ID NO: 252; and a light chain variable region comprising LCDR1 of SEQ ID NO: 153, LCDR2 of SEQ ID NO: 154, and LCDR3 of SEQ ID NO: 258;
[0290] (ppp) a heavy chain variable region comprising HCDR1 of SEQ ID NO: 209, HCDR2 of SEQ ID NO: 207, and HCDR3 of SEQ ID NO: 252; and a light chain variable region comprising LCDR1 of SEQ ID NO: 153, LCDR2 of SEQ ID NO: 154, and LCDR3 of SEQ ID NO: 258;
[0291] (qqq) a heavy chain variable region comprising HCDR1 of SEQ ID NO: 210, HCDR2 of SEQ ID NO: 211, and HCDR3 of SEQ ID NO: 252; and a light chain variable region comprising LCDR1 of SEQ ID NO: 156, LCDR2 of SEQ ID NO: 50, and LCDR3 of SEQ ID NO: 259; or
[0292] (rrr) a heavy chain variable region comprising HCDR1 of SEQ ID NO: 212, HCDR2 of SEQ ID NO: 213, and HCDR3 of SEQ ID NO: 253; and a light chain variable region comprising LCDR1 of SEQ ID NO: 158, LCDR2 of SEQ ID NO: 50, and LCDR3 of SEQ ID NO: 258.
[0293] In some embodiments, the antibody or antigen-binding fragment thereof that binds PMEL17 comprises:
[0294] (a) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 10 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 21;
[0295] (b) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 10 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 25;
[0296] (c) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 10 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 29;
[0297] (d) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 42 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 53;
[0298] (e) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 64 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 75;
[0299] (f) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 88 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 99;
[0300] (g) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 112 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 119;
[0301] (h) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 132 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 143;
[0302] (i) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 149 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 159;
[0303] (j) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 165 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 171;
[0304] (k) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 184 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 190;
[0305] (1) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 196 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 202;
[0306] (m) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 215 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 221;
[0307] (n) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 227 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 233;
[0308] (o) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 239 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 248; or
[0309] (p) a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 254 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 260.
[0310] In some embodiments, the antibody or antigen-binding fragment thereof that binds PMEL17 comprises:
[0311] (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 12 and a light chain comprising the amino acid sequence of SEQ ID NO: 23;
[0312] (b) a heavy chain comprising the amino acid sequence of SEQ ID NO: 12 and a light chain comprising the amino acid sequence of SEQ ID NO: 27;
[0313] (c) a heavy chain comprising the amino acid sequence of SEQ ID NO: 12 and a light chain comprising the amino acid sequence of SEQ ID NO: 31;
[0314] (d) a heavy chain comprising the amino acid sequence of SEQ ID NO: 44 and a light chain comprising the amino acid sequence of SEQ ID NO: 55;
[0315] (e) a heavy chain comprising the amino acid sequence of SEQ ID NO: 66 and a light chain comprising the amino acid sequence of SEQ ID NO: 77;
[0316] (f) a heavy chain comprising the amino acid sequence of SEQ ID NO: 90 and a light chain comprising the amino acid sequence of SEQ ID NO: 101;
[0317] (g) a heavy chain comprising the amino acid sequence of SEQ ID NO: 114 and a light chain comprising the amino acid sequence of SEQ ID NO: 121;
[0318] (h) a heavy chain comprising the amino acid sequence of SEQ ID NO: 134 and a light chain comprising the amino acid sequence of SEQ ID NO: 145;
[0319] (i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 151 and a light chain comprising the amino acid sequence of SEQ ID NO: 161;
[0320] (j) a heavy chain comprising the amino acid sequence of SEQ ID NO: 167 and a light chain comprising the amino acid sequence of SEQ ID NO: 173;
[0321] (k) a heavy chain comprising the amino acid sequence of SEQ ID NO: 186 and a light chain comprising the amino acid sequence of SEQ ID NO: 192;
[0322] (1) a heavy chain comprising the amino acid sequence of SEQ ID NO: 198 and a light chain comprising the amino acid sequence of SEQ ID NO: 204;
[0323] (m) a heavy chain comprising the amino acid sequence of SEQ ID NO: 217 and a light chain comprising the amino acid sequence of SEQ ID NO: 223;
[0324] (n) a heavy chain comprising the amino acid sequence of SEQ ID NO: 229 and a light chain comprising the amino acid sequence of SEQ ID NO: 235;
[0325] (o) a heavy chain comprising the amino acid sequence of SEQ ID NO: 241 and a light chain comprising the amino acid sequence of SEQ ID NO: 250;
[0326] (p) a heavy chain comprising the amino acid sequence of SEQ ID NO: 256 and a light chain comprising the amino acid sequence of SEQ ID NO: 262;
[0327] (q) a heavy chain comprising the amino acid sequence of SEQ ID NO: 283 and a light chain comprising the amino acid sequence of SEQ ID NO: 27;
[0328] (r) a heavy chain comprising the amino acid sequence of SEQ ID NO: 283 and a light chain comprising the amino acid sequence of SEQ ID NO: 31;
[0329] (s) a heavy chain comprising the amino acid sequence of SEQ ID NO: 315 and a light chain comprising the amino acid sequence of SEQ ID NO: 101.
[0330] In some embodiments, the antibody or antigen-binding fragment thereof comprises one or more cysteine substitutions. In some embodiments, the antibody or antigen-binding fragment thereof comprises one or more cysteine substitutions selected from E152C, S375C, or both E152C and S375C of the heavy chain of the antibody or antigen-binding fragment thereof, wherein the position is numbered according to the EU system. In some embodiments, the antibody or antigen-binding fragment thereof comprises an E152C substitution of the heavy chain of the antibody or antigen-binding fragment thereof, wherein the position is numbered according to the EU system.
[0331] In some embodiments, the antibody molecule is a monoclonal antibody. In some embodiments, the antibody molecule is an isolated antibody. In some embodiments, the antibody molecule is a synthetic antibody. In some embodiments, the antibody molecule is an engineered antibody.
[0332] In some embodiments, the antibody or antigen-binding fragment is encoded by a nucleic acid described herein. In some embodiments, the nucleic acid comprises the nucleotide sequence of SEQ ID NO: 13, 24, 28, 32, 45, 56, 67, 78, 91, 102, 115, 122, 135, 146, 152, 162, 168, 174, 187, 193, 199, 205, 218, 224, 230, 236, 242, 251, 257, 263, 319 or 320. In some embodiments, the nucleic acid is present in a vector, e.g., a vector described herein. In some embodiments, the nucleic acid or vector is present in a host cell, e.g., a host cell described herein.
[0333] In some embodiments, the antibody or antigen-binding fragment is produced by a method comprising culturing host cells and recovering the antibody or antigen-binding fragment from the cell culture. In some embodiments, recovering the antibody from the cell culture comprises the steps of: removing cells and filtering the culture; purifying the culture by affinity chromatography; inactivating any viruses in the culture by adjusting the pH to 3.4-3.6, then readjusting the pH to 5.8-6.2 and filtering the culture; purifying the culture by cation exchange chromatography and subjecting the culture to on-column reduction; subjecting the culture to anion exchange chromatography; removing viruses by nanofiltration; filtering the culture containing the antibody; and obtaining a purified antibody.
[0334] In some embodiments, the antibody drug conjugate is an antibody drug conjugate prepared by the methods described herein.
[0335] In some embodiments, the antibody drug conjugate comprises formula (C)
[0336] Ab-(L A -(D) n ) y (C)
[0337] in:
[0338] D is a GNAQ inhibitor, a GNA11 inhibitor, or an inhibitor of GNAQ and GNA11;
[0339] Ab is an antibody or antigen-binding fragment thereof that binds to human PMEL17 protein;
[0340] L A It is a joint;
[0341] n is 1, 2, 3, or 4, and
[0342] y is 1, 2, 3, or 4.
[0343] In some embodiments, n is 1. In some embodiments, y is about 1 to about 4. In some embodiments, the linker is a cleavable linker or a non-cleavable linker. In some embodiments, the linker comprises a ValCit peptide linker.
[0344] In some embodiments, the drug moiety is an inhibitor of GNAQ and GNA11.
[0345] In some embodiments, D is
[0346]
[0347] In some embodiments, the antibody drug conjugate has the structure,
[0348]
[0349] In some embodiments, the antibody drug conjugate has the following formula (C-2):
[0350]
[0351] in:
[0352] R 0 is methyl or ethyl;
[0353] R 1 is methyl or isopropyl;
[0354] R 2 is methyl or ethyl;
[0355] Ab is an antibody or antigen-binding fragment thereof that binds to human PMEL17 protein; X1 is a divalent coupling group;
[0356] X2 is a suicide spacer;
[0357] L1 is a divalent peptide linker;
[0358] L2 is a key or linker, and
[0359] y is 1, 2, 3, or 4.
[0360] In some embodiments, the antibody drug conjugate is present in a pharmaceutical composition comprising the antibody drug conjugate and a pharmaceutically acceptable carrier. In some embodiments, the antibody drug conjugate is present in a formulation described herein.
[0361] In some embodiments, the antibody drug conjugate or formulation is used as a medicament.
[0362] In some embodiments, the antibody drug conjugate or formulation is used in a method of treating or preventing cancer in a patient in need thereof, the method comprising administering an antibody drug conjugate or formulation to the patient, wherein the cancer expresses PMEL17 and contains a GNAQ or GNA11 gene mutation, or the cancer expresses PMEL17 and contains a GNAQ mutation, a GNA11 mutation, or a mutation of both. In some embodiments, the cancer is carcinoma (e.g., hepatocellular carcinoma), sarcoma, leukemia, lymphoma, eye cancer, eye tumor, melanoma (e.g., uveal melanoma, non-uveal melanoma, malignant melanoma, ocular melanoma, subcutaneous melanoma, cutaneous melanoma, or mucosal melanoma) or a metastatic cancer thereof.
[0363] In some embodiments, the antibody drug conjugate or formulation is administered to a patient in combination with one or more additional therapeutic compounds.
[0364] In some embodiments, the one or more additional therapeutic compounds are selected from a standard of care chemotherapeutic agent, an MDM2 inhibitor, an MRC2 inhibitor, a PKC inhibitor, a MAPK inhibitor, a co-stimulatory molecule, or a checkpoint inhibitor.
[0365] In some embodiments, the co-stimulatory molecule is selected from an agonist of OX40, CD2, CD27, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3, STING, or a CD83 ligand.
[0366] In some embodiments, the checkpoint inhibitor is selected from an inhibitor of PD-1, PD-L1, PD-L2, CTLA4, TIM3, LAG3, VISTA, BTLA, TIGIT, LAIR1, CD160, 2B4 and / or TGFRβ. BRIEF DESCRIPTION OF THE DRAWINGS
[0367] Figure 1 The genetic organization and transposable element (76974 bp) of the BGC containing compound (A1) (frsA-H) and compound J (dis1-4) in Chromobacterium vacciniae are depicted.
[0368] Figure 2 A scheme of the insertion strategy for promoter swapping is depicted.
[0369] Figure 3 The production of Compound J in the disruption mutant compared to the wild type is depicted.
[0370] Figure 4 The MS / MS spectrum of Compound J is depicted.
[0371] Figure 5 The MS / MS spectrum of compound F5 is depicted.
[0372] Figure 6 The MS / MS spectrum of compound F3 is depicted.
[0373] Figure 7 The MS / MS spectrum of Compound D is depicted.
[0374] Figure 8 Depicted is a schematic diagram of the biosynthesis of Compound J. The figure discloses "Ser Val His Val Leu Val" as SEQ ID NO: 324.
[0375] Figure 9Exemplary on-site and off-site binding are depicted.
[0376] Figure 10A The organization of compound (A1)-BGC (white: NRPS genes, black: genes encoding modification enzymes) and the representation of the exchanged promoters are depicted.
[0377] Figure 10B Depicted is a bar graph of compound (A1) titers from different Chromobacterium vacciniae promoter swap mutants, including fold changes compared to wild type.
[0378] Figure 11A Depicted are HPLC-MS extracted ion chromatograms (EIC) 1002.535-1002.545 Da of culture extracts of Chromobacterium vacciniae wild type and Chromobacterium vacciniae vioP mutant.
[0379] Figure 11B HPLC-MSEIC 1020.49-1020.50 Da of a culture extract of a Chromobacterium vacciniae vioP mutant fed with L-Met is depicted, revealing three novel analogs of compound (A1).
[0380] Figure 12A Depicted are HPLC-MS extracted ion chromatograms (EIC) of compound (A1) at m / z 1002.52-1002.57 in the same sample after incubation at 5 μg / mL in human plasma at 37°C for 8 hours and with the additional addition of 100 ng of compound 5 (final concentration 6 μg / mL) (bottom).
[0381] Figure 12B Depicted are the absolute quantification and fraction of Compound (A1) and 5 after incubation of Compound (A1) in human plasma at 5 μg / mL and 37° C. for 24 hours.
[0382] Figure 13A The effects of compounds (A1) and 2-8 on the proliferation of Gq or G11 mutant uveal melanoma (UM) cell lines and Gq or G11 wild-type cutaneous melanoma cell lines are depicted. The growth of UM cell lines driven by constitutively active Gq or G11 mutants was inhibited by compound (A1), which had sub-nM GI50s against 92.1 and MP41 cell lines, whereas the cutaneous melanoma cell lines harboring homozygous BRAF V600E mutation A375 and heterozygous NRAS Q61K mutation SK-MEL-30 were not affected by compound (A1).
[0383] Figure 13BThe effects of compounds 9-15 on the proliferation of Gq or G11 mutant UM cell lines and Gq or G11 wild-type cutaneous melanoma cell lines are depicted. The growth of UM cell lines driven by constitutively active Gq or G11 mutants was inhibited by compound (A1), which had sub-nM GI50s for 92.1 and MP41 cell lines, while the cutaneous melanoma cell lines harboring homozygous BRAF V600E mutations A375 and heterozygous NRASQ61K mutations SK-MEL-30 were not affected by compound (A1).
[0384] Figure 14 Depicted are SEC data for exemplary ADC formulations.
[0385] Figure 15 Depicted are opacity data for exemplary ADC formulations.
[0386] Figure 16 Depicted are capillary electrophoresis analyses of exemplary ADC formulations.
[0387] Figure 17 Capillary zone electrophoresis (CZE) analysis of exemplary ADC formulations is depicted.
[0388] Figure 18 Analysis of exemplary lyophilized ADC formulations is depicted.
[0389] Figure 19 pH and open-loop data for loading using (CZE) are depicted.
[0390] Figure 20 Depicted are potency decay data for exemplary ADC formulations after a 2-month storage period.
[0391] Figure 21 Depicted are the mean exposure profiles of total antibody (tmAb), active ADC (tADCa), and inactive ADC (tADCi) following a single 3 mg / kg intravenous dose of compound (E) in cynomolgus monkeys. DETAILED DESCRIPTION
[0392] The present disclosure is based, at least in part, on the discovery that certain microorganisms (e.g., Chromobacterium) can be genetically engineered to increase production of certain ester peptides (e.g., Compound (A1)). Compound (A1) can be isolated from the leaves of the root of Cinnabar, but very low quantities and a complex matrix can hinder obtaining sufficient quantities of Compound (A1) for drug development and commercial manufacturing. The genetically engineered microorganisms (e.g., Chromobacterium), nucleic acids, and methods described herein provide a developable production route for preparing Compound (A1) with increased titer and / or increased isolated yield, thereby enabling sufficient quantities of the active pharmaceutical ingredient precursor to be obtained.
[0393] The present disclosure is also based, at least in part, on the discovery that by targeting higher overreduction and designing a robust partial reoxidation step, effective decapping of engineered cysteine residues and desired drug-to-antibody ratios can be achieved without compromising antibody purity. Overreduction and opening of intrachain disulfide bridges can lead to undesirable off-site conjugation. In some embodiments, inherent LC-HC instability can lead to sensitivity to overreduction. Without wishing to be bound by theory, it is believed that in some embodiments, effective, partial reoxidation of opened intrachain disulfide bridges is important for minimizing off-site conjugation to achieve high efficacy in vivo and reduce linker load release. Factors that can be evaluated for the partial reoxidation step include, but are not limited to, one or more of the following: different container geometries, whether headspace is defined (e.g., 60%), whether mixing is performed (e.g., 100 rpm), or room temperature or cold room. In some embodiments, by adding the partial reoxidation step described herein to the GMP manufacturing process, the purity of the final drug substance can be increased to about 95%, for example, as determined by non-reducing CE SDS. In certain embodiments, a drug-to-antibody ratio of about 2 is achieved. In other embodiments, a drug-to-antibody ratio of about 4 is achieved.
[0394] definition
[0395] Unless otherwise stated, the following terms and phrases as used herein are intended to have the following meanings.
[0396] As used herein, the singular form "a" or "an" includes plural referents unless otherwise indicated.
[0397] Unless the context clearly indicates otherwise, the term "or" is intended herein to mean and is used interchangeably with the term "and / or."
[0398] "About" and "approximately" generally mean an acceptable degree of error for the amount measured given the nature or precision of the measurements. Exemplary degrees of error are within 20%, typically within 10%, and more typically within 5% of a given value or range of values.
[0399] The term "biosynthetic gene cluster" or "BGC" interchangeably refers to a localized cluster of two or more genes that together encode a biosynthetic pathway for producing a metabolite. In some embodiments, the metabolite is a secondary or specialized metabolite that is not directly involved in the normal growth, development, or reproduction of the organism that produces the metabolite.
[0400] The term "alkyl" refers to a monovalent saturated hydrocarbon chain having a specified number of carbon atoms. For example, a C1-C6 alkyl group refers to an alkyl group having from 1 to 6 carbon atoms. An alkyl group can be straight or branched. Representative branched alkyl groups have one, two or three branches. Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl (n-propyl and isopropyl), butyl (n-butyl, isobutyl, sec-butyl and tert-butyl), pentyl (n-pentyl, isopentyl and neopentyl) and hexyl.
[0401] As used herein, "cleavable" refers to a linker group or linker component that connects two moieties by covalent bonding, but that decomposes under physiologically relevant conditions to sever the covalent bond between the moieties. Typically, a cleavable linker group is cleaved more rapidly in vivo within the intracellular environment than in the extracellular environment, resulting in release of the payload preferentially within the target cell. Cleavage can be enzymatic or non-enzymatic, but generally releases the payload from the antibody without degrading the antibody. Cleavage can leave some portion of the attachment group or linker component attached to the payload, or it can release the payload without any residues of the attachment group.
[0402] As used herein, "non-cleavable" refers to a linker or linker group that is not particularly susceptible to decomposition under physiological conditions, e.g., it is at least as stable as the antibody or antigen-binding fragment portion of the conjugate. Such linking groups are sometimes referred to as "stable," meaning that they are sufficiently resistant to degradation to keep the payload attached to the antibody or antigen-binding fragment until the antibody or antigen-binding fragment itself is at least partially degraded, i.e., degradation of the antibody or antigen-binding fragment precedes cleavage of the linking group in vivo. Degradation of the antibody portion of an ADC with a stable or non-cleavable attachment group can leave some or all of the attachment group (e.g., one or more amino acid groups from the antibody) attached to the payload or drug portion that is delivered in vivo.
[0403] As used herein, the term "antibody" refers to a polypeptide of the immunoglobulin family that is capable of non-covalently, reversibly, and specifically binding to a corresponding antigen. For example, a naturally occurring IgG antibody is a tetramer comprising at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each heavy chain comprises a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region is composed of three domains (CH1, CH2, and CH3). Each light chain comprises a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region comprises one domain, the CL. The VH and VL regions can be further subdivided into hypervariable regions, termed complementarity determining regions (CDRs), interspersed with more conserved regions called framework regions (FRs). Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxyl-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The variable regions of the heavy and light chains contain binding domains that interact with antigens. The constant regions of antibodies mediate the binding of immunoglobulins to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system.
[0404] The term "antibody" includes, but is not limited to, monoclonal antibodies, human antibodies, humanized antibodies, chimeric antibodies, and anti-idiotypic (anti-Id) antibodies (including, for example, anti-Id antibodies to antibodies of the disclosure). Antibodies can be of any isotype / class (e.g., IgG, IgE, IgM, IgD, IgA, and IgY) or subclass (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2).
[0405] "Complementarity determining domain" or "complementarity determining region" ("CDR") refers interchangeably to the hypervariable regions of VL and VH. CDRs are the target protein binding sites of the antibody chain that carry the specificity for that target protein. There are three CDRs (CDR1-3, numbered sequentially from the N-terminus) in each human VL or VH, constituting approximately 15%-20% of the variable domain. The CDRs are structurally complementary to the epitope of the target protein and are therefore directly responsible for binding specificity. The remaining VL or VH segments (the so-called framework regions) exhibit less amino acid sequence variation (Kuby, Immunology, 4th ed., Chapter 4, WH Freeman & Co., New York, 2000).
[0406] The positions of the CDRs and framework regions can be determined using various definitions well known in the art, e.g., Kabat, Chothia, the International Immunogenetics Database (IMGT) (available on the Internet at www.imgt.org / ), and AbM (see, e.g., Johnson et al., Nucleic Acids Res., 29:205-206 (2001); Chothia and Lesk, J. Mol. Biol., 196:901-917 (1987); Chothia et al., Nature, 342:877-883 (1989); Chothia et al., J. Mol. Biol., 227:799-817 (1992); Al-Lazikani et al., J. Mol. Biol., 273:927-748 (1997)). The definition of antigen binding sites is also described in Ruiz et al., Nucleic Acids Res., 28:219-221 (2000); and Lefranc, MP, Nucleic Acids Res., 29:207-209 (2001); MacCallum et al., J. Mol. Biol., 262:732-745 (1996); and Martin et al., Proc. Natl. Acad. Sci. USA, 86:9268-9272 (1989); Martin et al., Methods Enzymol., 203:121-153 (1991); and Rees et al., in Sternberg MJE (ed.), Protein Structure Prediction, Oxford University Press. Oxford University Press, Oxford, 141–172 (1996).
[0407] Both the light and heavy chains are divided into regions of structural homology and regions of functional homology. The terms "constant" and "variable" are used functionally. In this regard, it should be understood that the variable domains of both the light (VL) and heavy (VH) chains determine antigen recognition and specificity. Conversely, the constant domains of the light (CL) and heavy (CH1, CH2, or CH3) chains confer important biological properties such as secretion, transplacental mobility, Fc receptor binding, complement fixation, etc. By convention, the farther the constant region domain is from the antigen binding site or amino terminus of the antibody, the larger its number. The N-terminus is the variable region and the C-terminus is the constant region; the CH3 and CL domains actually contain the carboxyl terminal domains of the heavy and light chains, respectively.
[0408] As used herein, the term "antigen-binding fragment" refers to one or more portions of an antibody that retain the ability to specifically interact with an epitope of an antigen (e.g., by binding, steric hindrance, stabilization / destabilization, spatial distribution). Examples of binding fragments include, but are not limited to, single-chain Fv (scFv), camelid antibodies, disulfide-linked Fv (sdFv), Fab fragments, F(ab') fragments, a monovalent fragment consisting of the VL, VH, CL, and CH1 domains; F(ab)2 fragments, which are bivalent fragments comprising two Fab fragments linked by a disulfide bridge at the hinge region; Fd fragments consisting of the VH and CH1 domains; Fv fragments consisting of the VL and VH domains of a single arm of an antibody; dAb fragments consisting of the VH domain (Ward et al., Nature 341:544-546, 1989); and isolated complementarity-determining regions (CDRs), or other epitope-binding fragments of an antibody.
[0409] In addition, although the two domains of the Fv fragment, VL and VH, are encoded by separate genes, recombinant methods can be used to connect the two domains through a synthetic linker that enables them to form a single protein chain, wherein the VL region and the VH region pair to form a monovalent molecule (referred to as a single-chain Fv ("scFv"); see, for example, Bird et al., Science [Science] 242:423-426, 1988; and Huston et al. Proc. Natl. Acad. Sci. [Proceedings of the National Academy of Sciences of the United States of America] 85:5879-5883, 1988). The term "antigen-binding fragment" is also intended to encompass such single-chain antibodies. These antigen-binding fragments are obtained using conventional techniques known to those skilled in the art, and these fragments are screened for utility in the same manner as intact antibodies.
[0410] Antigen binding fragments can also be incorporated into single domain antibodies, maxibodies, minibodies, single domain antibodies, intrabodies, diabodies, triabodies, tetrabodies, v-NARs and bis-scFvs (see, e.g., Hollinger and Hudson, Nature Biotechnology 23: 1126-1136, 2005). Antigen binding fragments can be grafted into scaffolds based on polypeptides such as type III fibronectin (Fn3) (see U.S. Pat. No. 6,703,199, which describes fibronectin polypeptide monomers).
[0411] The antigen-binding fragment can be incorporated into a single-chain molecule comprising a pair of tandem Fv segments (VH-CH1-VH-CH1), which together with complementary light chain polypeptides form a pair of antigen-binding regions (Zapata et al., Protein Eng. 8:1057-1062, 1995; and U.S. Pat. No. 5,641,870).
[0412] As used herein, the term "monoclonal antibody" or "monoclonal antibody composition" refers to polypeptides, including antibodies and antigen-binding fragments, that have substantially identical amino acid sequences or are derived from the same genetic source. The term also includes preparations of antibody molecules having a single molecular composition. A monoclonal antibody composition exhibits a single binding specificity and affinity for a particular epitope.
[0413] As used herein, the term "human antibody" includes antibodies having variable regions in which both the framework and CDR regions are derived from human sequences. In addition, if the antibody contains a constant region, the constant region is also derived from such human sequences, such as human germline sequences or mutant forms of human germline sequences, or antibodies containing a consensus framework sequence derived from human framework sequence analysis, for example, as described in Knappik et al., J. Mol. Biol. 296:57-86, 2000). Also included are antibodies derived from human sequences in which one or more CDRs have been mutated for affinity maturation or for manufacturing / load conjugation purposes. See Kilpatrick et al., "Rapid development of affinity matured monoclonal antibodies using RIMMS," Hybridoma. 1997 Aug; 16(4):381-9.
[0414] The human antibodies of the disclosure may include amino acid residues not encoded by human sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro, or by somatic mutation in vivo, or conservative substitutions to improve stability or production).
[0415] As used herein, the term "recognition" refers to an antibody or its antigen-binding fragment that finds its epitope and interacts therewith (e.g., in combination), regardless of whether the epitope is linear or conformational. The term "epitope" refers to a site on an antigen that specifically binds to an antibody or antigen-binding fragment of the present disclosure. An epitope can be formed from continuous amino acids or non-continuous amino acids juxtaposed due to the three-dimensional folding of a protein. The epitope formed from continuous amino acids is generally retained when exposed to a denaturing solvent, while the epitope formed due to the three-dimensional folding is generally lost when treated with a denaturing solvent. An epitope typically includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids in a unique spatial conformation. The method for determining the spatial conformation of an epitope includes the technology in this area, e.g., x-ray crystallography and two-dimensional nuclear magnetic resonance (see, e.g., Epitope Mapping Protocols in Methods in Molecular Biology [epitope mapping protocol in the method in molecular biology], Vol. 66, G.E. Morris, ed. (1996)).
[0416] As used herein, the term "affinity" refers to the strength of the interaction between an antibody and an antigen at a single antigenic site. Within each antigenic site, the variable region of the antibody "arm" interacts with the antigen at many sites through weak non-covalent forces; the more interactions, the stronger the affinity.
[0417] The term "isolated antibody" refers to an antibody that is substantially free of other antibodies having different antigenic specificities. However, an isolated antibody that specifically binds to one antigen may have cross-reactivity to other antigens. Furthermore, an isolated antibody may be substantially free of other cellular material and / or chemicals.
[0418] The term "corresponding human germline sequence" refers to a nucleic acid sequence encoding a human variable region amino acid sequence or subsequence that shares a determined highest amino acid sequence identity with a reference variable region amino acid sequence or subsequence, compared to all other known variable region amino acid sequences encoded by human germline immunoglobulin variable region sequences. A corresponding human germline sequence can also refer to a human variable region amino acid sequence or subsequence that has the highest amino acid sequence identity with a reference variable region amino acid sequence or subsequence, compared to all other evaluated variable region amino acid sequences. A corresponding human germline sequence can be only framework regions, only complementarity determining regions, both framework regions and complementarity determining regions, variable segments (as defined above), or other combinations of sequences or subsequences comprising a variable region. Sequence identity can be determined by aligning two sequences using methods described herein, for example, using BLAST, ALIGN, or another alignment algorithm known in the art. The corresponding human germline nucleic acid or amino acid sequence can have at least about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to the reference variable region nucleic acid or amino acid sequence. The corresponding human germline sequence can be determined, for example, by the publicly available International Immunogenetics Database (IMGT) (available on the Internet at www.imgt.org / ) and V-base (available on the Internet at vbase.mrc-cpe.cam.ac.uk).
[0419] When used in the context of describing the interaction between an antigen (e.g., a protein) and an antibody, antibody fragment, or antibody-derived binding agent, the phrase "specifically binds" or "selectively binds" refers to a binding reaction that determines the presence of an antigen in a heterogeneous population of proteins and other biological products, such as in a biological sample (e.g., blood, serum, plasma, or tissue sample). Thus, under certain specified immunoassay conditions, antibodies or binding agents with a particular binding specificity bind to a particular antigen at least two times above background and these antibodies or binding agents do not substantially bind to other antigens present in the sample in significant amounts. In one embodiment, under specified immunoassay conditions, antibodies or binding agents with a particular binding specificity bind to a particular antigen at least ten (10) times above background and these antibodies or binding agents do not substantially bind to other antigens present in the sample in significant amounts. Specific binding to an antibody or binding agent under such conditions may require that the antibody or agent has been selected for specificity for the particular protein. If desired or appropriate, such selection can be achieved by subtracting antibodies that cross-react with molecules from other species (e.g., mouse or rat) or other subtypes. Alternatively, in some embodiments, antibodies or antibody fragments are selected that cross-react with certain desired molecules.
[0420] A variety of immunoassay formats can be used to select antibodies that specifically immunoreact with a particular protein. For example, solid-phase ELISA immunoassays are routinely used to select antibodies that specifically immunoreact with a protein (for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity, see, for example, Harlow and Lane, Using Antibodies, A Laboratory Manual (1998)). Typically, a specific or selective binding reaction will produce a signal that is at least 2 times higher than the background signal and more typically at least 10 to 100 times higher than the background signal.
[0421] The term "equilibrium dissociation constant (KD, M)" refers to the dissociation rate constant (kd, time-1) divided by the association rate constant (ka, time-1, M-1). The equilibrium dissociation constant can be measured using any method known in the art. The antibodies disclosed herein will typically have a KD of less than about 10 -7 or 10 -8 M, for example, is less than about 10 -9 M or 10 -10 M, in some embodiments, is less than about 10 -11 M, 10 -12 M or 10 -13 The equilibrium dissociation constant of M.
[0422] The term "bioavailability" refers to the systemic availability (i.e., blood / plasma levels) of a given amount of drug administered to a patient. Bioavailability is an absolute term that indicates a measure of both the time (rate) and the total amount (extent) of drug that reaches the general circulation from an administered dosage form.
[0423] As used herein, the phrase "consisting essentially of" refers to the genus or species of active agent included in the method or composition and any excipients that are inactive for the intended purpose of the method or composition. In some embodiments, the phrase "consisting essentially of" explicitly excludes the inclusion of one or more additional active agents in addition to the antibody drug conjugates of the disclosure. In some embodiments, the phrase "consisting essentially of" explicitly excludes the inclusion of one or more additional active agents in addition to the antibody drug conjugates of the disclosure and a second co-administered agent.
[0424] The term "amino acid" refers to naturally occurring, synthetic, and unnatural amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those that are later modified, such as hydroxyproline, γ-carboxyglutamate, and O-o-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as naturally occurring amino acids (i.e., an α-carbon bound to a hydrogen, a carboxyl group, an amino group, and an R group), such as homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as naturally occurring amino acids. Amino acid mimetics refer to chemical compounds that have a structure that is different from the general chemical structure of an amino acid but functions in a manner similar to naturally occurring amino acids.
[0425] The term "conservatively modified variant" applies to both amino acid sequences and nucleic acid sequences. For a particular nucleic acid sequence, conservatively modified variants refer to those nucleic acids that encode the same or substantially the same amino acid sequence, or, where the nucleic acid does not encode an amino acid sequence, to substantially the same sequence. Due to the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode any given protein. For example, the codons GCA, GCC, GCG, and GCU all encode the amino acid alanine. Therefore, at each position where a codon specifies alanine, the codon can be changed to any of the corresponding codons described without changing the encoded polypeptide. Such nucleic acid variations are "silent variations," which are a type of conservatively modified variation. Each nucleic acid sequence encoding a polypeptide herein also describes each possible silent variation of the nucleic acid. The skilled person will recognize that each codon in the nucleic acid (except AUG, which is typically the only codon for methionine, and TGG, which is typically the only codon for tryptophan) can be modified to produce functionally identical molecules. Therefore, each silent variation of the nucleic acid encoding a polypeptide is implied in each of the described sequences.
[0426] For polypeptide sequences, "conservatively modified variants" include individual substitutions, deletions, or additions to a polypeptide sequence that result in the substitution of an amino acid for a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to, and do not exclude, the polymorphic variants, interspecies homologs, and alleles disclosed herein. The following eight groups contain amino acids that are conservative substitutions for each other: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K);
[0427] 5) isoleucine (I), leucine (L), methionine (M), valine (V); 6) phenylalanine (F), tyrosine (Y), tryptophan (W); 7) serine (S), threonine (T); and 8) cysteine (C), methionine (M) (see, e.g., Creighton, Proteins (1984). In some embodiments, the term "conservative sequence modification" is used to refer to amino acid modifications that do not significantly affect or alter the binding characteristics of the antibody containing the amino acid sequence.
[0428] As used herein, the term "optimized" refers to a nucleotide sequence that has been altered to encode an amino acid sequence using codons that are preferred in a production cell or organism (typically a eukaryotic cell, such as a yeast cell, a Pichia cell, a fungal cell, a Trichoderma cell, a Chinese hamster ovary cell (CHO), or a human cell). The optimized nucleotide sequence is engineered to retain, in full or as much as possible, the amino acid sequence originally encoded by the starting nucleotide sequence, also referred to as the 'parent' sequence.
[0429] In the context of two or more nucleic acid sequences or polypeptide sequences, the term "percentage identity" or "percentage identity" refers to the degree to which two or more sequences or subsequences are identical. If two sequences have the same amino acid sequence or nucleotide sequence in the region being compared, they are "identical". When comparing and alignment in a comparison window or a specified region to seek the maximum correspondence measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection, if two sequences have the same amino acid residues or nucleotides of a specified percentage (i.e., on a specified region or when there is no provision, on the entire sequence, 60% identity, optionally 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99% identity), then two sequences are "substantially identical". Optionally, identity is present in a region that is at least about 30 nucleotides (or 10 amino acids) in length, or more preferably in a region that is 100 to 500 or 1000 or more nucleotides (or 20, 50, 200 or more amino acids) in length.
[0430] For sequence comparison, typically a sequence serves as a reference sequence, and a test sequence is compared with the reference sequence. When using a sequence comparison algorithm, the test sequence and the reference sequence are input into a computer, and subsequence coordinates are specified if necessary, and sequence algorithm program parameters are specified. Default program parameters can be used, or alternative parameters can be specified. Then, the sequence comparison algorithm calculates the sequence identity percentage of the test sequence relative to the reference sequence based on the program parameters.
[0431] As used herein, a "comparison window" includes reference to a segment of one of the number of contiguous positions selected from the group consisting of 20 to 600, typically about 50 to about 200, more typically about 100 to about 150, wherein a sequence can be compared to a reference sequence having the same number of contiguous positions after the two sequences are optimally aligned. Methods of sequence alignment for comparison are well known in the art. Optimal alignment of sequences for comparison can be performed, for example, by the local homology algorithm of Smith and Waterman, Adv. Appl. Math. 2:482c (1970), by the homology alignment algorithm of Needleman and Wunsch, J. Mol. Biol., 48:443 (1970), by the search for similarity method of Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85:2444 (1988), by computer implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection (see, e.g., Brent et al., Current Protocols in Current Protocols in Molecular Biology, 2003).
[0432] Two examples of algorithms suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., Nuc. Acids Res. 25:3389-3402, 1977; and Altschul et al., J. Mol. Biol. 215:403-410, 1990, respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information. The algorithm involves first identifying high-scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is called the neighborhood word score threshold (Altschul et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence as far as the cumulative alignment score can be increased. For nucleotide sequences, the cumulative score is calculated using the parameters M (reward score for a pair of matching residues; always >0) and N (penalty score for mismatched residues; always <0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction terminates when: the cumulative alignment score drops by the amount X from its maximum achieved value; the cumulative score goes to zero or lower due to the accumulation of one or more negatively scored residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses a word length (W) of 11, an expectation (E) of 10, M=5, N=-4, and a comparison of two chains as default values. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, an expectation (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Natl. Acad. Sci. USA 89:10915), alignments (B) 50, an expectation (E) of 10, M=5, N=-4, and a comparison of both strands.
[0433] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul, Proc. Natl. Acad. Sci. USA 90:5873-5787, 1993). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability that a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.
[0434] The percent identity between two amino acid sequences can also be determined using the algorithm of E. Meyers and W. Miller, Comput. Appl. Biosci., 4: 11-17 (1988), which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4. In addition, the percent identity between two amino acid sequences can be determined using the algorithm of Needleman and Wunsch, J. Mol, Biol., 48: 444-453, (1970), which has been incorporated into the GAP program in the GCG software package (available from www.gcg.com), using a BLOSUM62 matrix or a PAM250 matrix and a gap weight of 16, 14, 12, 10, 8, 6, or 4 and a length weight of 1, 2, 3, 4, 5, or 6.
[0435] In addition to the above-mentioned percentages of sequence identity, another indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross-reactive with antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, e.g., where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complementary sequences hybridize to each other under stringent conditions, as described below. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequence.
[0436] The term "nucleic acid" is used interchangeably with the term "polynucleotide" herein and refers to deoxyribonucleotides or ribonucleotides and polymers thereof in single-stranded or double-stranded form. The term encompasses nucleic acids containing backbone residues or connections of known nucleotide analogs or modifications that are synthetic, naturally occurring, and non-naturally occurring, have similar binding properties to reference nucleic acids, and are metabolized in a manner similar to reference nucleotides. Examples of such analogs include, but are not limited to, phosphorothioates, phosphoramidates, methylphosphonates, chiral-methylphosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs).
[0437] Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences as well as the explicitly indicated sequence. Specifically, as described in detail below, degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer et al., (1991) Nucleic Acid Res. 19:5081; Ohtsuka et al., (1985) J. Biol. Chem. 260:2605-2608; and Rossolini et al., (1994) Mol. Cell. Probes 8:91-98).
[0438] The term "operably linked" refers to the functional relationship between two or more polynucleotide (e.g., DNA) segments in the context of nucleic acids. Typically, it refers to the functional relationship between a transcriptional regulatory sequence and a transcribed sequence. For example, if a promoter or enhancer sequence stimulates or regulates the transcription of a coding sequence in an appropriate host cell or other expression system, the promoter or enhancer sequence is operably linked to the coding sequence. Typically, the promoter transcriptional regulatory sequence operably linked to the transcribed sequence is physically adjacent to the transcribed sequence, i.e., they are cis-acting. However, some transcriptional regulatory sequences, such as enhancers, do not need to be physically adjacent to or located very close to the position of the coding sequence that these transcriptional regulatory sequences enhance their transcription.
[0439] The terms "polypeptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The terms apply to amino acid polymers in which one or more amino acid residues is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers. Unless otherwise indicated, a particular polypeptide sequence also implicitly encompasses conservatively modified variants thereof.
[0440] As used herein, the term "antibody drug conjugate" or "immunoconjugate" refers to an antibody or its antigen-binding fragment connected to another agent such as a chemotherapeutic agent, a toxin, an immunotherapeutic agent, an imaging probe, etc. The connection can be a covalent bond or a non-covalent interaction, such as by electrostatic forces. A variety of linkers known in the art can be used to form antibody drug conjugates. In addition, the antibody drug conjugate can be provided in the form of a fusion protein that may be expressed from a polynucleotide encoding the immunoconjugate. As used herein, "fusion protein" refers to a protein produced by connecting two or more genes or gene fragments that originally encoded separate proteins (including peptides and polypeptides). Translation of the fusion gene produces a single protein with functional properties derived from each original protein.
[0441] The term "subject" includes humans and non-human animals. Non-human animals include all vertebrates, e.g., mammals and non-mammals such as non-human primates, sheep, dogs, cows, chickens, amphibians, and reptiles. Unless otherwise indicated, the terms "patient" or "subject" are used interchangeably herein.
[0442] As used herein, the term "cytotoxin" or "cytotoxic agent" refers to any agent that is detrimental to the growth and proliferation of cells and acts to reduce, inhibit or destroy cells or malignancies.
[0443] As used herein, the term "anti-cancer agent" refers to any agent that can be used to treat or prevent a cell proliferative disorder such as cancer, including but not limited to cytotoxic agents, chemotherapeutic agents, radiotherapy and radiotherapeutic agents, targeted anti-cancer agents, and immunotherapeutic agents.
[0444] As used herein, the term "drug moiety" or "load" refers to a chemical moiety conjugated to an antibody or antigen-binding fragment of the present disclosure, and can include any therapeutic or diagnostic agent, such as an anticancer agent, an anti-inflammatory agent, an anti-infective agent (e.g., an antifungal agent, an antibacterial agent, an antiparasitic agent, an antiviral agent), or an anesthetic. For example, the drug moiety can be an anticancer agent, such as a cytotoxin. In certain embodiments, the drug moiety is a targeted inhibitor compound. Additionally, the load can be a biophysical probe, a fluorophore, a spin label, an infrared probe, an affinity probe, a chelating agent, a spectroscopic probe, a radioactive probe, a lipid molecule, polyethylene glycol, a polymer, a spin label, DNA, RNA, a protein, a peptide, a surface, an antibody, an antibody fragment, a nanoparticle, a quantum dot, a liposome, a PLGA particle, a sugar, or a polysaccharide.
[0445] In some embodiments, the drug moiety or payload is a GNAQ inhibitor, a GNA11 inhibitor, or an inhibitor of GNAQ and GNA11 (GNAQ / GNA11 inhibitor). In some embodiments, a GNAQ / 11 inhibitor is a molecule that inhibits GNAQ / 11-mediated IP3 production and / or exhibits a dose-responsive antiproliferative effect in cells that rely on GNAQ / 11 signaling (i.e., GNAQ / 11 mutant uveal melanoma cells). In some embodiments, a GNAQ / 11 inhibitor is a compound that stabilizes GNAQ / 11 in an inactive GDP-bound state and prevents GDP release, or binds to an active GTP-bound state and prevents GNAQ / 11 from interacting with downstream effectors. In some embodiments, a GNAQ / 11 inhibitor acts by inhibiting mutant GNAQ and / or GNA11 (e.g., GNAQ and / or GNA11 comprising a Q209L / P mutation). Methods for attaching such drug moieties to linkers compatible with targeting moieties are provided herein, along with methods known in the art. See, eg, Singh et al., (2009) Therapeutic Antibodies: Methods and Protocols, Vol. 525, 445-457.
[0446] GNAQ (guanine nucleotide-binding protein G(q) subunit alpha, also known as CMC1, G-α-q, GAQ, SWS, and G protein subunit αq) and GNA11 (guanine nucleotide-binding protein subunit α-11, also known as FBH, FBH2, FHH2, GNA-11, HHC2, HYPOC2, and G protein subunit α11) are closely related GTPases that constitute the α subunits of heterotrimeric G proteins that act downstream of G protein-coupled receptors (GPCRs). The α subunits act as switches that activate G proteins by exchanging guanosine diphosphate (GDP) for guanosine triphosphate (GTP), thereby activating different downstream effectors. Activation is terminated by intrinsic GTPase activity when GTP is hydrolyzed to GDP (Van Raamsdonk et al., 2010, N Engl J Med.; 363(23):2191-9). Classical activation of the Gq protein cascade occurs via phospholipase C-β (PLC-β), which hydrolyzes the phospholipid phosphatidylinositol 4,5-bisphosphate to release two potent second messengers: D-inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). 2+The transient increase of IP3 rapidly converts to IP2, IP1 and inositol. On the other hand, DAG activates protein kinase C (PKC), leading to a series of RAF, MEK and ERK phosphorylations, and the PKC translocation to the nucleus regulates cell proliferation and survival (Krantz et al., 2017, Clin Ophthalmol. [Clinical Ophthalmology]; 11: 279-289).
[0447] Exemplary amino acid and nucleotide sequences of human GNAQ have been published in GenBank with accession numbers NP_002063 and NM_002072, respectively. Exemplary amino acid and nucleotide sequences of human GNAQ are also described in International Application Publication No. WO 2020 / 128612 as SEQ ID NOs: 268 and 269, respectively.
[0448] Exemplary amino acid and nucleotide sequences of human GNA11 have been published in GenBank with accession numbers NP_002058 and NM_002067, respectively. Exemplary amino acid and nucleotide sequences of human GNA11 are also described in International Application Publication No. WO 2020 / 128612 as SEQ ID NOs: 270 and 271, respectively.
[0449] "Tumor" refers to neoplastic cell growth and proliferation, whether malignant or benign, and all precancerous and cancerous cells and tissues.
[0450] The term "anti-tumor activity" refers to a decrease in the proliferation rate, viability, or metastatic activity of tumor cells. For example, anti-tumor activity can be demonstrated by a decrease in the growth rate of abnormal cells that occur during treatment, or by a stabilization or reduction in tumor size, or by a prolonged survival period due to treatment compared to an untreated control. This activity can be assessed using recognized in vitro or in vivo tumor models, including but not limited to xenograft models, allograft models, MMTV models, and other models known in the art for studying anti-tumor activity.
[0451] The term "malignancy" refers to a non-benign tumor or cancer. As used herein, the term "cancer" includes malignancies characterized by dysregulated or uncontrolled cell growth. Exemplary cancers include, but are not limited to, carcinomas (e.g., hepatocellular carcinoma), sarcomas, leukemias, lymphomas, eye cancers, eye tumors, and melanomas (e.g., uveal melanoma, non-uveal melanoma, malignant melanoma, ocular melanoma, subcutaneous melanoma, cutaneous melanoma, or mucosal melanoma).
[0452] The term "cancer" includes primary malignancies (e.g., those whose cells have not migrated to sites in the subject's body other than the site of the original tumor) and secondary malignancies (e.g., those arising from metastasis, the migration of tumor cells to secondary sites different from the site of the original tumor).
[0453] The term "PMEL17" (also known as premelanosomal protein (PMEL), D12S53E, ME20, ME20-M, ME20M, P1, P100, gp100, SI, SIL, and silver locus protein homolog (SILV)) refers to a single-pass type I transmembrane protein produced by melanocytes and involved in melanin synthesis. Exemplary amino acid and nucleotide sequences of human PMEL17 have been published in GenBank with accession numbers as follows: NP_008859, NP_001307050, NP_001307051, NP_001186982, NP_001186983 (amino acid sequences) and NM_006928, NM_001200053, NM_001200054, NM_001320121, NM_001320122 (nucleotide sequences). Exemplary amino acid and nucleotide sequences of human PMEL17 are also described in International Application Publication No. WO 2020 / 128612 as SEQ ID NOs: 272-276 (amino acid sequences) and SEQ ID NOs: 277-281 (nucleotide sequences). As used herein, the term "PMEL17" is used to collectively refer to all naturally occurring isoforms of PMEL17 protein, or variants thereof.
[0454] The term "variant" refers to a polypeptide having substantially the same amino acid sequence as a reference polypeptide, or encoded by substantially the same nucleotide sequence, and capable of having one or more activities of the reference polypeptide. For example, a variant can have about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more sequence identity to a reference polypeptide while retaining one or more activities of the reference polypeptide.
[0455] As used herein, the terms "treat," "treating," or "treatment" of any disease or disorder, in one embodiment, refers to ameliorating the disease or disorder (i.e., slowing, arresting, or reducing the development of the disease or at least one clinical symptom thereof). In another embodiment, "treating" refers to alleviating or alleviating at least one physical parameter, including those that cannot be discerned by the patient. In yet another embodiment, "treating" refers to modulating the disease or disorder physically (e.g., stabilization of discernible symptoms), physiologically (e.g., stabilization of physical parameters), or both.
[0456] As used herein, the term "prevention" of any disease or disorder refers to prophylactic treatment of the disease or disorder; or delaying the onset or progression of the disease or disorder.
[0457] The terms "therapeutically acceptable amount" or "therapeutically effective dose" interchangeably refer to an amount sufficient to achieve the desired result (i.e., reduction in tumor size, inhibition of tumor growth, prevention of metastasis, inhibition or prevention of viral, bacterial, fungal or parasitic infection). In some embodiments, a therapeutically acceptable amount does not induce or cause undesirable side effects. In some embodiments, a therapeutically acceptable amount induces or causes side effects, but only those that are acceptable to the patient's condition by the healthcare provider. A therapeutically acceptable amount can be determined by initially administering a low dose and then incrementally increasing the dose until the desired effect is achieved. A "prophylactically effective dose" and a "therapeutically effective dose" of the molecules of the present disclosure can prevent the onset of disease symptoms or cause a decrease in the severity of disease symptoms, respectively, including symptoms associated with cancer.
[0458] The term "co-administered" refers to the presence of two active agents in the blood of an individual. Co-administered active agents can be delivered concurrently or sequentially.
[0459] The terms "inhibit," "inhibitor," "binding antagonist," or "antagonist" encompass a decrease in some parameter (e.g., activity) of a given molecule. For example, the term encompasses inhibition of at least 5%, 10%, 20%, 30%, 40% or more of the activity of a given molecule. Thus, inhibition need not be 100%.
[0460] The term "activation," "activator," or "agonist" encompasses an increase in some parameter (e.g., activity) of a given molecule. For example, the term encompasses an increase in the activity of a given molecule by at least 5%, 10%, 25%, 50%, 75% or more.
[0461] Chromobacterium
[0462] Chromobacterium is a genus of Gram-negative, rod-shaped bacteria. Currently, there are 11 known species within this genus: C. alkanivorans, C. amazonense, C. aquaticum, C. haemolyticum, C. phragmitis, C. piscinae, C. pseudoviolaceum, C. rhizoryzae, C. subtsugae, C. vaccinii, and C. violaceum.
[0463] In some embodiments, the Chromobacterium genus is Chromobacterium vacciniae. Chromobacterium vacciniae was isolated from soil of cranberry trees (Soby et al. (2013) Int J Syst Evol Microbiol. [International Journal of Systematic and Evolutionary Microbiology]; 63(5):1840-6) and deposited in the DSMZ and ATCC strain collections (Chromobacterium vacciniae DSM 25150 = ATCC BAA-2314, = NRRL B-50840, = MWU205). The 16S rRNA gene sequence of this strain has a GenBank accession number of JN120869. The draft genome of Chromobacterium vacciniae DSM 25150 was obtained from et al. (2015) Genome Announc [Genome Annotation] 3, e00477-15 (GenBank accession number: NZ_JZJL00000000).
[0464] Chromobacterium vacciniae grows readily on nutrient agar and, after two days of incubation at 28°C, produces distinctive smooth, low-convex colonies with a deep purple metallic sheen due to the production of violacein. Chromobacterium vacciniae is unlikely to cause any illness in healthy adults and poses minimal potential hazards to laboratory personnel and the environment.
[0465] The microorganisms described herein include mutant forms of Chromobacterium vacciniae that naturally produce ester peptides (e.g., compound (A1)). In some embodiments, the Chromobacterium vacciniae mutant comprises a mutation that increases the titer of compound (A1). In some embodiments, the Chromobacterium vacciniae mutant comprises a mutation that increases the isolation yield of compound (A1). In some embodiments, the Chromobacterium vacciniae mutant comprises a mutation that increases the titer of compound (A1) and a mutation that increases the isolation yield of compound (A1). In some embodiments, the Chromobacterium vacciniae mutant comprises a promoter insertion mutation (e.g., a promoter insertion mutation described herein). In some embodiments, the Chromobacterium vacciniae mutant comprises a disruption mutation (e.g., a disruption mutation described herein). In some embodiments, the Chromobacterium vacciniae mutant comprises a plurality of disruption mutations (e.g., a plurality of disruption mutations described herein). In some embodiments, the Chromobacterium vacciniae mutant comprises a promoter insertion mutation (e.g., a promoter insertion mutation described herein) and a disruption mutation (e.g., a disruption mutation described herein). In some embodiments, the Chromobacterium vacciniae mutant comprises a promoter insertion mutation (e.g., a promoter insertion mutation described herein) and a disruption mutation (e.g., a disruption mutation described herein). In some embodiments, the Chromobacterium vacciniae mutant comprises a promoter insertion mutation (e.g., a promoter insertion mutation described herein) and a plurality of disruption mutations (e.g., a plurality of disruption mutations described herein).
[0466] Promoter insertion mutant
[0467] In some embodiments, the mutant of Chromobacterium vacciniae has an increased titer of compound (A1) when cultured under the same or similar conditions compared to a reference Chromobacterium vacciniae, such as wild-type Chromobacterium vacciniae. For example, the native promoter upstream of compound (A1)-BGC can be altered, for example, by replacing it with a non-native promoter, for example, a stronger non-native promoter. Without wishing to be bound by theory, it is believed that compound (A1)-BGC contains a single operon and its transcription may be driven by a single promoter.
[0468] The non-native promoter can be any promoter sequence that is not naturally operably linked to Compound (A1)-BGC and that, when so operably linked, increases the transcriptional activity of Compound (A1)-BGC.
[0469] In some embodiments, the non-native promoter is from Chromobacterium vacciniae, for example, a promoter that controls the expression of BGCs other than compound (A1)-BGC, for example, the vioP promoter. In other embodiments, the non-native promoter is not from Chromobacterium vacciniae. In some embodiments, the non-native promoter is from Escherichia coli.
[0470] In some embodiments, the non-primary promoter is a constitutive promoter. In some embodiments, the non-primary promoter is an inducible promoter. In some embodiments, the promoter, such as the vioP promoter, is induced by the production of homoserine lactone. In some embodiments, the non-primary promoter is the violacein promoter. In some embodiments, the non-primary promoter is a ribosomal promoter. In some embodiments, the non-primary promoter is located in a transposon.
[0471] In certain embodiments, the non-native promoter is a naturally occurring promoter. In other embodiments, the non-native promoter is a synthetic promoter. In other embodiments, the non-native promoter is a consensus promoter, e.g., comprising a consensus sequence of a group of related naturally occurring promoters.
[0472] In some embodiments, the non-native promoter is the vioP promoter. In some embodiments, the non-native promoter is the nptII promoter. In some embodiments, the non-native promoter is the rbs promoter.
[0473] Other non-native promoters include, but are not limited to, the J23119 promoter (e.g., as described in parts.igem.org), the pLpp promoter (e.g., as described in parts.igem.org), the PS12burk promoter (e.g., as described in Choi et al. (2008) App Environ Microbiol 74(4):1064-75), the Erme* promoter (e.g., as described in Bibb et al. (1994) Mol Microbiol 14(3):533-45), or the Pem7 promoter (e.g., as described in Zobel et al. (2015) ACS Synthetic Biology 4:1341-51).
[0474] In some embodiments, the non-native promoter is a promoter described in Table 1. In some embodiments, the heterologous promoter comprises a nucleotide sequence described in Table 1 or a functional fragment thereof. In some embodiments, the heterologous promoter comprises the nucleotide sequence of SEQ ID NO: 264, or a sequence having at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identity to the nucleotide sequence of SEQ ID NO: 264, or a functional fragment thereof. In some embodiments, the heterologous promoter comprises the nucleotide sequence of SEQ ID NO: 265, or a sequence having at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identity to the nucleotide sequence of SEQ ID NO: 265, or a functional fragment thereof. In some embodiments, the heterologous promoter comprises the nucleotide sequence of SEQ ID NO: 266, or a sequence having at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identity to the nucleotide sequence of SEQ ID NO: 266, or a functional fragment thereof. In some embodiments, the heterologous promoter comprises the nucleotide sequence of SEQ ID NO: 316, or a sequence having at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identity to the nucleotide sequence of SEQ ID NO: 316, or a functional fragment thereof. In some embodiments, the heterologous promoter comprises the nucleotide sequence of SEQ ID NO: 268, or a sequence having at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identity to the nucleotide sequence of SEQ ID NO: 268, or a functional fragment thereof. In some embodiments, the heterologous promoter comprises the nucleotide sequence of SEQ ID NO: 269, or a sequence having at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identity to the nucleotide sequence of SEQ ID NO: 269, or a functional fragment thereof.In some embodiments, the heterologous promoter comprises the nucleotide sequence of SEQ ID NO: 270, or a sequence having at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identity to the nucleotide sequence of SEQ ID NO: 270, or a functional fragment thereof. In some embodiments, the heterologous promoter comprises the nucleotide sequence of SEQ ID NO: 271, or a sequence having at least about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% identity to the nucleotide sequence of SEQ ID NO: 271, or a functional fragment thereof.
[0475] Table 1. Nucleotide sequences of exemplary promoters
[0476]
[0477]
[0478] For example, the strain Chromobacterium vacciniae vioP-frsA is a mutant generated from the strain Chromobacterium vacciniae DSM 25150 by inserting the promoter vioP in front of the compound (A1)-BGC to create a translational fusion. The promoter vioP was extracted from the violacein BGC inherent to this strain. The nucleotide sequence of the promoter vioP is shown in Table 1. The generation of this mutant is described in Example 1.
[0479] The vioP promoter from Chromobacterium vacciniae and the vioP promoter from Chromobacterium violaceum have essentially the same function and are approximately 82% identical in sequence. The vioP promoter from Chromobacterium violaceum is described, for example, in Morohoshi et al. (2010) Bioscie. Biotechnol. Biochem.; 74(10), 2116-2119 and Zhang et al. (2011) Appl Microbiol Biotechnol; 90: 1963-1971.
[0480] As another example, strain Chromobacterium vacciniae nptII-frsA is a mutant generated from strain Chromobacterium vacciniae DSM 25150 by inserting the promoter nptII in front of compound (A1)-BGC to create a translational fusion. Promoter nptII is a constitutive promoter. The nucleotide sequence of promoter nptII is shown in Table 1. The generation of this mutant is described in Example 1.
[0481] As yet another example, strain Chromobacterium vacciniae rbs-frsA is a mutant generated from strain Chromobacterium vacciniae DSM 25150 by inserting the promoter rbs in front of compound (A1)-BGC to create a translational fusion. The ribosomal promoter rbs is a constitutive promoter. The nucleotide sequence of the promoter rbs is shown in Table 1. The generation of this mutant is described in Example 1.
[0482] As another example, the promoters vioP, nptII or rbs can be replaced by promoters J23119, P S12 burk, Erme*, or pLpp. Promoter J23119 is a synthetic promoter. The nucleotide sequence of promoter J23119 is shown in Table 1. Promoter P S12 burk is a ribosomal promoter from Burkholderia thailandensis. S12 The nucleotide sequence of burk is shown in Table 1. Promoter P is also described in Choi et al. (2008) App Environ Microbiol 74(4):1064-75. S12 burk. P S12 Burk is also known as S12burk. The ErmE* promoter is a 23S rRNA methylase promoter from Saccharopolyspora erythraea. The nucleotide sequence of the ErmE* promoter is shown in Table 1. The ErmE* promoter is also described in Bibb et al. (1994) Mol Microbiol 14(3):533-45. The pLpp promoter is a synthetic promoter. The nucleotide sequence of the pLpp promoter is shown in Table 1. The pLpp promoter is also described at parts.igem.org. pLpp is also known as Plpp.
[0483] In some embodiments, the titer of compound (A1) of the Chromobacterium vaccinia promoter insertion mutant is increased by at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 fold compared to the titer of a reference Chromobacterium vaccinia (e.g., Chromobacterium vaccinia without a promoter insertion mutation in compound (A1)-BGC or wild-type Chromobacterium vaccinia) when cultured under the same conditions. In some embodiments, the titer of compound (A1) of the Chromobacterium vaccinia promoter insertion mutant is increased by at least about 3 fold, for example, at least about 3.5 fold, compared to the titer of compound (A1) of wild-type Chromobacterium vaccinia.
[0484] In some embodiments, the titer of compound (A1) of the Chromobacterium vacciniae promoter insertion mutant is increased by at least about 100 mg / L, about 200 mg / L, about 300 mg / L, about 400 mg / L, about 500 mg / L, about 600 mg / L, about 700 mg / L, about 800 mg / L, about 900 mg / L, or about 1000 mg / L compared to the titer of a reference Chromobacterium vacciniae (e.g., Chromobacterium vacciniae without a promoter insertion mutation in compound (A1)-BGC or wild-type Chromobacterium vacciniae) when cultured under the same conditions. In some embodiments, the titer of compound (A1) of the Chromobacterium vacciniae promoter insertion mutant is increased, for example, by no more than about 300 mg / L to at least about 600 mg / L or at least about 800 mg / L compared to the titer of compound (A1) of wild-type Chromobacterium vacciniae. In some embodiments, the titer of compound (A1) of the Chromobacterium vacciniae promoter insertion mutant is at least about 200 mg / L, about 250 mg / L, about 300 mg / L, about 350 mg / L, about 400 mg / L, about 450 mg / L, about 500 mg / L, about 550 mg / L, about 600 mg / L, about 650 mg / L, about 700 mg / L, about 750 mg / L, about 800 mg / L, about 850 mg / L, about 900 mg / L, about 950 mg / L, about 10 ... 800 mg / L, about 850 mg / L, about 900 mg / L, about 950 mg / L, about 1000 mg / L, about 1100 mg / L, about 1200 mg / L, about 1300 mg / L, about 1400 mg / L, about 1500 mg / L, about 1600 mg / L, about 1700 mg / L, about 1800 mg / L, about 1900 mg / L or about 2000 mg / L. In some embodiments, the titer of compound (A1) of the Chromobacterium vacciniae mutant is at least about 800 mg / L, for example, about 800 mg / L to about 850 mg / L. In some embodiments, the titer of compound (A1) of the Chromobacterium vacciniae promoter insertion mutant is at least about 600 mg / L, for example, about 600 mg / L to about 650 mg / L, for example, when cultured in a medium without animal components.
[0485] The Chromobacterium vacciniae promoter insertion mutants described herein can be used to produce compound (A1) on a small scale (e.g., research scale) or on a large scale (e.g., production scale). In some embodiments, compound (A1) is produced in a fermentor or bioreactor. In some embodiments, compound (A1) is produced in a fermentation volume of about 50 L to about 250 L, e.g., about 50 L to about 100 L, about 100 L to about 150 L, or about 150 L to about 250 L, e.g., about 50 L, about 100 L, about 150 L, about 200 L, or about 250 L. In some embodiments, compound (A1) is produced in a fermentation volume of about 1,000 L to about 20,000 L, e.g., about 1,000 L to about 10,000 L or about 10,000 L to about 20,000 L, e.g., about 1,000 L, about 2,000 L, about 5,000 L, about 7,500 L, about 10,000 L, about 15,000 L, or about 20,000 L.
[0486] Destroy mutants
[0487] Alternatively or in combination, in some embodiments, when cultured under the same conditions, the Chromobacterium vacciniae mutant has an increased isolation yield of compound (A1) compared to wild-type Chromobacterium vacciniae. For example, the level or activity of another natural product produced by Chromobacterium vacciniae can be reduced, for example, the BGC of such a natural product can be destroyed. Without wishing to be bound by theory, it is believed that in addition to compound (A1) and its analogs, Chromobacterium vacciniae produces at least two other natural product categories that interfere with the purification of compound (A1) to some extent. They belong to the purple bacteriocin class and the cyclic lipolipeptide class, of which compound J is the most abundant representative. In some embodiments, when the complexity of the by-products that interfere with the purification of compound (A1) is reduced, the isolation yield of compound (A1) can be increased.
[0488] In some embodiments, the BGC of violacein is altered, for example, one or more genes in the violacein-BGC are disrupted or knocked out. In some embodiments, the level or activity of violacein is reduced, for example, eliminated.
[0489] Violacin is a purple pigment with a bis-indole structure, which is common to most Chromobacterium species and is even the reason for the genus's name. The chemical structure of violacein is:
[0490]
[0491] Its biosynthesis has been elucidated and the respective BGCs described, for example, in August et al. (2000) J Mol Microbiol Biotechnol. [Journal of Molecular Microbiology and Biotechnology]; 2(4): 513-519. The presence of large amounts of violacein in the fermentation broth can be problematic during extraction due to precipitation during each evaporation step and the subsequent dissolution requiring time and effort. Therefore, size exclusion chromatography can be introduced as a first purification step to remove violacein and avoid further precipitation.
[0492] In some embodiments, the BGC of Compound J is altered, e.g., disrupted, or one or more genes in the Compound J-BGC are knocked out. For example, the production of one or more (e.g., two, three, four or more) compounds from the Compound J-BGC (e.g., any one, two, three, or all of Compound J, Compound F5, Compound F3, or Compound D) is reduced, e.g., eliminated. In some embodiments, the production of Compound J, Compound F5, Compound F3, and Compound D is reduced, e.g., eliminated.
[0493] In some embodiments, the level or activity of Compound J is reduced, e.g., eliminated. In some embodiments, the BGC of Compound J is altered, e.g., disrupted, or one or more genes in the Compound J-BGC are knocked out.
[0494] The chemical structure of compound J is:
[0495]
[0496] Reverse transcription biosynthesis analysis of compound J (cyclohexyl ester peptide biosynthesis sequence: N-Acyl-Ser-Val-His-Val-Leu-Val (SEQ ID NO: 318)) allowed the identification of its BGC from the sequenced genome of Chromobacterium vacciniae. In size exclusion chromatography, members of the compound J class co-eluted in fractions enriched with compound (A1) and resulted in very high viscosity (almost gel-like) when dissolved for further purification by preparative HPLC, hindering injection onto the column. Consequently, fractions often required further dilution, and the amount of compound that could be processed per run was limited.
[0497] In some embodiments, the level or activity of Compound F5 is reduced, eg, eliminated.
[0498] The chemical structure of compound F5 is:
[0499]
[0500] Compound F5 is a compound of the sequence N-(Z)-dec-3-enoyl- 1Ser- 2 Val- 3 His- 4 Val- 5 Leu- 6 Compared with compound J, 1 Ser hydroxyl group 6 The lactone between the C-terminal carboxyl groups of Val has been hydrolyzed.
[0501] In some embodiments, the level or activity of Compound F3 is reduced, eg, eliminated.
[0502] The chemical structure of compound F3 is:
[0503]
[0504] Compound F3 is a compound of the sequence N-octanoyl- 1 Ser- 2 Val- 3 His- 4 Val- 5 Leu- 6 Val (SEQ ID NO: 322). 1 Ser hydroxyl and 6 It is formed between the C-terminal carboxyl group of Val.
[0505] In some embodiments, the level or activity of Compound D is reduced, eg, eliminated.
[0506] The chemical structure of compound D is:
[0507]
[0508] Compound D is of the sequence N-octyl- 1 Ser- 2 Val- 3 His- 4 Val- 5 Leu- 6 Compared with compound F3, 1 Ser hydroxyl group 6 The lactone between the C-terminal carboxyl groups of Val has been hydrolyzed.
[0509] In some embodiments, the Chromobacterium vacciniae disruption mutant has two or more (e.g., three or four) disruption mutations. For example, both violacein-BGC and compound J-BGC can be altered, e.g., disrupted.
[0510] In some embodiments, the isolated yield of compound (A1) of the Chromobacterium vaccinia disruption mutant is increased by at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or about 90%, or at least about 1, about 2, about 3, about 4, or about 5 times, compared to the isolated yield of a reference Chromobacterium vaccinia (e.g., Chromobacterium vaccinia without the disruption mutation or wild-type Chromobacterium vaccinia) when cultured under the same conditions. In some embodiments, the isolated yield of compound (A1) of the Chromobacterium vaccinia disruption mutant is at least about 60%, for example, about 65% to about 70%. In some embodiments, the isolated yield of compound (A1) of wild-type Chromobacterium vaccinia is about 35% to about 45%, for example, about 40%.
[0511] In some embodiments, the titer of compound (A1) of the Chromobacterium vaccinia disruption mutant differs by no more than about 50%, about 40%, about 35%, about 30%, about 25%, 20%, about 15%, or about 10% compared to the titer of a reference Chromobacterium vaccinia (e.g., Chromobacterium vaccinia without the disruption mutation or wild-type Chromobacterium vaccinia) when cultured under the same conditions. In some embodiments, the titer of compound (A1) of the Chromobacterium vacciniae disruption mutant is at least about 200 mg / L, about 250 mg / L, about 300 mg / L, about 350 mg / L, about 400 mg / L, about 450 mg / L, about 500 mg / L, about 550 mg / L, about 600 mg / L, about 650 mg / L, about 700 mg / L, about 750 mg / L, about 800 mg / L, about 850 mg / L, about 900 mg / L, about 950 mg / L, about 1000 mg / L, about 1100 mg / L, about 1200 mg / L, about 1300 mg / L, about 1400 mg / L, about 1500 mg / L, about 1600 mg / L, about 1700 mg / L, about 1800 mg / L, about 1900 mg / L, or about 2000 mg / L. In some embodiments, the titer of compound (A1) of the Chromobacterium vacciniae disruption mutant is at least about 800 mg / L, such as about 800 mg / L to about 850 mg / L. In some embodiments, the titer of compound (A1) of the Chromobacterium vacciniae disruption mutant is at least about 600 mg / L, such as about 600 mg / L to about 650 mg / L, for example, when cultured in a medium free of animal components.
[0512] The Chromobacterium vacciniae disruption mutants described herein can be used to produce compound (A1) on a small scale (e.g., research scale) or on a large scale (e.g., production scale). In some embodiments, compound (A1) is produced in a fermentor or bioreactor. In some embodiments, compound (A1) is produced in a fermentation volume of about 50 L to about 250 L, e.g., about 50 L to about 100 L, about 100 L to about 150 L, or about 150 L to about 250 L, e.g., about 50 L, about 100 L, about 150 L, about 200 L, or about 250 L. In some embodiments, compound (A1) is produced in a fermentation volume of about 1,000 L to about 20,000 L, e.g., about 1,000 L to about 10,000 L or about 10,000 L to about 20,000 L, e.g., about 1,000 L, about 2,000 L, about 5,000 L, about 7,500 L, about 10,000 L, about 15,000 L, or about 20,000 L.
[0513] Biosynthesis of compound (A1)
[0514] The ester peptide compound (A1) was described in Fujioka et al. (1988) J. Org. Chem.; 53(12): 2820-2825. It was isolated from a methanol extract of the whole plant of Rhizoma Cinnamomi. About twenty years later, it was discovered that compound (A1) is actually produced by the strictly obligate bacterial endosymbiont Candidatus Burkholderia crenata of the plant Rhizoma Cinnamomi (Carlier et al. (2016) Environ Microbiol.; 18(8): 2507-22; GenBank accession number LGTG01000643.1 for the DNA sequence of the biosynthetic gene cluster (BGC) encoding the biosynthetic genes responsible for the biosynthesis of compound (A1). The biosynthesis of compound (A1) by heterologous expression in Escherichia coli is described, for example, in Crüsemann et al. (2018) Angew. Chem. Int. Ed.; 57, 836-840.
[0515] As described in Example 1 herein, the translated amino acid sequence of compound (A1)-BGC from Candida albicans was used as a query sequence in a genome mining effort against bacterial genomes from sequence databases and from sequencing efforts using PacBio sequencing technology. Clusters with very high homology in the translated amino acid sequence and identical protein function predictions were found in the sequenced genome of Chromobacterium vacciniae. Knowing that Chromobacterium vacciniae contains compound (A1)-BGC, frsC and frsH, but not the full-length genes frsA, frsD, frsE, frsF, frsG, were identified from their published draft genome ( et al. (2015) Genome Announc [Genome Annotation] 3, e00477-15) to search for significant BLAST hits. Hermes et al. (2021) used a similar approach to identify Chromobacterium vacciniae as the producer of A1. However, the cluster was distributed across six contigs, and extensive PCR-based gap closure was necessary to obtain the sequence of the entire compound (A1)-BGC (GenBank accession number: MT876545). The sequence generated in Example 1 herein demonstrates the advantage of PacBio sequencing for highly identical repetitive sequence segments. The entire compound (A1)-BGC could be identified, including upstream and downstream regions encoding additional large NRPSs and several transposable elements (GenBank accession number: BankIt2437961BSeq#1MW732719). The gene organization on the transposable element (76974 bp) containing the BGC of compound (A1) (frsA-H) and compound J (dis1-4) in Chromobacterium vacciniae is shown in Figure 1 The organization of the genomic regions containing Compound (A1)-BGC and NRPS A is further shown in Table 2-1.
[0516] The biosynthesis of compound (A1), including but not limited to the complete compound (A1)-BGC, is also disclosed in, for example, Pistorius et al. Genetic Engineering of Chromobacterium Vaccinii DSM 25150 for Improved Production of FR900359. ChemRxiv. Cambridge: Cambridge Open Engage; 2021, which is incorporated by reference in its entirety.
[0517] Cell culture and fermentation
[0518] The microorganisms described herein can be cultured under conditions that allow production of compound (A1). Generally speaking, the conditions that can be optimized include the type and amount of the carbon source, the type and amount of the nitrogen source, the carbon-nitrogen ratio, the oxygen level, the growth temperature, the pH, the length of the biomass production phase, the length of the target product accumulation phase, and the cell harvest time.
[0519] Substratum generally contains suitable carbon source.Carbon source can include but is not limited to monosaccharide (for example, glucose, fructose, wood sugar), disaccharide (for example, lactose, sucrose), oligosaccharide, polysaccharide (for example, starch, cellulose, hemicellulose, other lignocellulosic materials or its mixture), sugar alcohol (for example, glycerol) and renewable raw materials (for example, cheese whey permeate, corn steep liquor, beet molasses, barley malt).Carbon source can also be selected from one or more in following non-limiting examples: straight or branched alkane (for example, hexane), straight or branched alcohol (for example, hexanol), fatty acid (for example, about 10 carbons to about 22 carbons), fatty acid ester, monoglyceride, diglyceride, triglyceride, phosphatide and the fatty acid of various commercial sources, including vegetable oil (for example, soybean oil) and animal fat.Carbon source can include single carbon source (for example, carbon dioxide, methanol, formaldehyde, formate and carbon-containing amine), by its metabolizable conversion into key biochemical intermediate.It is expected that the carbon source utilized can cover a variety of carbon-containing sources and is only subject to the restriction of the selection of one or more engineered microorganisms. Non-limiting examples of acceptable growth media include Luria broth (LB) agar, King's broth B (KMB) agar, tryptic soy broth, yeast extract mannitol broth (YEM), yeast extract with glycerol (GYEA), yeast extract-peptone-glycerol (YPG), peptone yeast extract dextrose (PYG) MacConkey agar, or malt extract agar, or in flasks containing a suitable liquid medium (e.g., tryptic soy broth, LB broth, YEM broth, KMB broth, GYEA broth, YPG broth, PYG broth, etc.).
[0520] Nitrogen can be provided by inorganic sources (e.g., (NH4)2SO4) or organic sources (urea or glutamate). In addition to appropriate carbon and nitrogen sources, the culture medium may also contain appropriate minerals, salts, cofactors, buffers, vitamins, metal ions (e.g., Mn 2+ 、Co 2+ 、Zn 2+ Mg 2+) and other components suitable for microbial culture. Other chemicals can be added to the culture as needed. Non-limiting examples of such chemicals include tryptone, calcium carbonate, propionic acid, sodium propionate, L-isoleucine, L-valine, L-phenylalanine, L-phenylbutyric acid, L-phenyllactic acid, sodium chloride, glycerol, bacterial soytone, Bacto peptone, Bacto soy peptone, Bacto yeast extract, soy peptone F, soy peptone papain digest, vegetable peptone, vegetable yeast extract, broad bean peptone, casein peptone, HEPES, ammonium sulfate, magnesium sulfate, soyamine, Soy protein, salt-free yeast extract, Potato starch, L-phenyllactic acid and L-phenylpyruvic acid.
[0521] Microorganisms are sometimes cultured in complex media (e.g., yeast extract-peptone-dextrose broth (YPD)). In some embodiments, the culture medium is a common commercially prepared culture medium, e.g., LB broth. Other defined or synthetic growth media are known in the art and may also be used.
[0522] Microorganisms can be cultured on or in solid, semi-solid or liquid culture media. In certain embodiments, culture media is discharged from cells adhering to flat plates. In certain embodiments, as known in the art, the liquid-cell mixture is centrifuged at a speed sufficient to precipitate cells but not to destroy cells and to allow extraction of culture media. The cells can then be resuspended in fresh culture media. The target product can be purified from the culture media according to methods known in the art. In certain embodiments, the target product is extracted from the cultivated microorganisms. The microbial cells can be concentrated by centrifugation at a speed sufficient to shear the cell membrane. In certain embodiments, the cells can be physically destroyed (e.g., shearing force, ultrasonic treatment) or chemically destroyed (e.g., contacted with detergents or other lysing agents). Each phase can be separated by centrifugation or other methods known in the art, and the target product can be separated according to known methods.
[0523] Fermentation conditions can comprise any culture condition that is suitable for maintaining microorganism (for example, being in static or proliferation state).For example, fermentation conditions can comprise some parameters, include but not limited to temperature, oxygen content, nutrient content (for example, glucose content), pH, stirring level (for example, revolutions per minute), air flow rate (for example, air, oxygen, nitrogen), redox potential, cell density (for example, optical density), cell viability etc.The change of fermentation conditions (for example, switching fermentation conditions) is the change, modification or conversion of one or more fermentation parameters.For example, can by increasing or reducing temperature, increasing or reducing pH (for example, adding or removing acid, alkali or carbon dioxide), increasing or reducing oxygen content (for example, introducing air, oxygen, carbon dioxide, nitrogen), increasing or reducing air pressure (for example, by introducing air, oxygen, carbon dioxide, nitrogen), increasing or reducing stirring and / or adding or removing nutrients (for example, one or more sugars or sugar sources, biomass, vitamins etc.), increasing or reducing the ratio of culture and flask volume or aforesaid combination change fermentation conditions.The example of fermentation conditions is described herein. Aerobic conditions typically comprise greater than about 50% dissolved oxygen (e.g., about 52%, about 54%, about 56%, about 58%, about 60%, about 62%, about 64%, about 66%, about 68%, about 70%, about 72%, about 74%, about 76%, about 78%, about 80%, about 82%, about 84%, about 86%, about 88%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, or about 99%, or greater than any of the foregoing). Anaerobic conditions typically comprise less than about 50% dissolved oxygen (e.g., about 1%, about 2%, about 4%, about 6%, about 8%, about 10%, about 12%, about 14%, about 16%, about 18%, about 20%, about 22%, about 24%, about 26%, about 28%, about 30%, about 32%, about 34%, about 36%, about 38%, about 40%, about 42%, about 44%, about 46%, about 48%, or less than any of the foregoing).
[0524] A variety of fermentation processes can be employed to produce the product of interest. In some embodiments, production of the product of interest from a recombinant microbial host is performed using, for example, a batch, fed-batch, or continuous fermentation process.
[0525] Batch fermentation process is normally a closed system, and wherein culture medium composition is fixed when process starts, and except maintaining pH and oxygen level required in process, does not further add.When culturing process begins, with required organism inoculation culture medium, and allow growth or metabolic activity, and do not add other source (for example, carbon source and nitrogen source) to culture medium.In batch process, the metabolite and the biomass composition of system constantly change, until cultivation terminates.In typical batch process, cell enters high growth logarithmic phase through static lag phase, finally enters stationary phase, and wherein growth rate reduces or stops.If not handled in time, the cell in stationary phase finally can die.
[0526] A variant of the standard batch process is the fed-batch process, in which a carbon source is continuously added to the fermentor tank during the fermentation process. The fed-batch process is useful when catabolite repression tends to inhibit the metabolism of the cell or when it is necessary to have a limited amount of carbon source in the culture medium at any time. The measurement of carbon source concentration in the fed-batch system can be estimated based on the change of measurable factors such as pH, dissolved oxygen, and waste gas partial pressure (e.g., CO ). Batch and fed-batch culture methods are known in the art. Examples of such methods can be found in: Thomas D. Brock, in Biotechnology: A Textbook of Industrial Microbiology [biotechnology: industrial microbiology textbook], Supplement 2, (1989) Sinauer Associates Sunderland [Sunderland Snow Associates], Massachusetts and Deshpande, Mukund V., Appl. Biochem. Biotechnol. [applied biochemistry and biotechnology], 36: 227 (1992).
[0527] In a continuous fermentation process, a defined culture medium is usually added continuously to a bioreactor while an equal amount of culture volume is removed to recycle the product. Continuous culture is typically maintained at a constant cell density in the logarithmic growth phase. Continuous or semi-continuous culture methods allow for the regulation of a factor or any number of factors that affect cell growth or end product concentration. For example, a method may limit the carbon source and allow all other parameters to regulate metabolism. In some systems, many factors affecting growth may constantly change, while the cell concentration measured by culture medium turbidity remains constant. Continuous systems typically maintain steady-state growth, and therefore cell growth rate is typically balanced with the cell loss caused by extracting the culture medium from the culture. Regulating the nutrients and growth factor methods of continuous culture processes and the technology of maximizing product formation rate are known, and Brock (ibid.) describes various methods in detail.
[0528] The target product can be provided in the microorganism of the culture containing the target product, and the microorganism of culture can be freshly provided or frozen or dried in liquid culture medium.Fresh or freezing microorganism can be contained in suitable moisture-proof container, and also can control temperature if necessary.The target product is sometimes provided in the culture medium of acellular basically.In certain embodiments, the target product provides (for example, 50% pure or higher, 60% pure or higher, 70% pure or higher, 80% pure or higher, 90% pure or higher, 95% pure or higher, 99% pure or higher or 99.5% pure or higher) with the form of pure basically.In certain embodiments, the target product can be modified into any one of multiple downstream products.
[0529] Drug part (D)
[0530] In some embodiments, the drug moiety (D) of the antibody drug conjugates of the present disclosure is a GNAQ inhibitor, a GNA11 inhibitor, or an inhibitor of GNAQ and GNA11 (GNAQ / GNA11 inhibitor). In some embodiments, the drug moiety (D) of the antibody drug conjugates of the present disclosure is a GNAQ inhibitor. In some embodiments, the drug moiety (D) of the antibody drug conjugates of the present disclosure is a GNA11 inhibitor. In some embodiments, the drug moiety (D) of the antibody drug conjugates of the present disclosure is an inhibitor of GNAQ and GNA11 (GNAQ / GNA11 inhibitor).
[0531] In some embodiments, the drug moiety (D) of the antibody drug conjugates of the present disclosure is a compound having the structure of formula (A)
[0532]
[0533] wherein Ro is methyl or ethyl, Ri is methyl or isopropyl, and R2 is methyl or ethyl.
[0534] In some embodiments, the drug moiety (D) of the antibody drug conjugates of the present disclosure is a compound (A1) having the following structure,
[0535]
[0536] The synthesis of compound (A1) is also described in Example 3 of International Application Publication No. WO 2020 / 128612, which is incorporated by reference in its entirety.
[0537] The metabolic stability and PK properties of compound (A1) are also described in Examples 8 and 9, respectively, of International Application Publication No. WO 2020 / 128612, which is incorporated by reference in its entirety.
[0538] In some embodiments, the drug portion (D) of the antibody drug conjugates of the present disclosure is a compound having the structure of formula (Ab):
[0539]
[0540] where R o is methyl or ethyl, R i 、R s and R t are each independently methyl, isopropyl or methylthiomethyl, and R 2 It is methyl or ethyl.
[0541] In some embodiments, the drug moiety (D) of the antibody drug conjugates of the present disclosure is a compound (Ab1) having the following structure,
[0542]
[0543] In some embodiments, the drug moiety (D) of the antibody drug conjugates of the present disclosure is a compound (Ab2) having the following structure,
[0544]
[0545] In some embodiments, the drug moiety (D) of the antibody drug conjugates of the present disclosure is a compound (Ab3) having the following structure,
[0546]
[0547] In some embodiments, the drug moiety (D) of the antibody drug conjugates of the present disclosure is a compound having the structure of formula (Ac)
[0548]
[0549] Among them, R 1 is methyl or isopropyl, and R 2 It is methyl or ethyl.
[0550] In some embodiments, the drug moiety (D) of the antibody drug conjugates of the present disclosure is a compound (Ac1) having the following structure,
[0551]
[0552] In some embodiments, the drug moiety (D) of the antibody drug conjugates of the present disclosure is a compound (Ac2) having the following structure,
[0553]
[0554] In some embodiments, the drug moiety (D) of the antibody drug conjugates of the present disclosure is a compound (Ac3) having the following structure,
[0555]
[0556] In some embodiments, the drug moiety (D) of the antibody drug conjugates of the present disclosure is a compound (Ac4) having the following structure,
[0557]
[0558] wherein R1 is methyl or =CH2, R2 is methyl or ethyl, R3 is methyl, ethyl or isopropyl, and R4 is H, N-Ac-Hle or N-Pr-Hle.
[0559] In some embodiments, the drug moiety (D) of the antibody drug conjugates of the present disclosure is any one of compounds (A1) and 2-15, for example, as disclosed in Example 3.
[0560] Linker-Drug Moiety (L A -(D) n )
[0561] In some embodiments, the linker-drug moiety (L A -(D) n ))) Includes connector (L A ) covalently attached to one or more drug moieties, wherein the one or more drug moieties are each independently selected from a GNAQ inhibitor, a GNA11 inhibitor, or an inhibitor of GNAQ and GNA11 (GNAQ / GNA11 inhibitor).
[0562] In some embodiments, the linker-drug moiety (L A -(D) n ))) Includes connector (L A ) covalently attached to one or more drug moieties, wherein the one or more drug moieties are each independently selected from GNAQ inhibitors.
[0563] In some embodiments, the linker-drug moiety (L A -(D) n ))) Includes connector (L A ) attached, wherein the one or more drug moieties are each independently selected from GNA11 inhibitors.
[0564] In some embodiments, the linker-drug moiety (L A -(D)n ))) Includes connector (L A ) covalently attached to one or more drug moieties, wherein the one or more drug moieties are each independently selected from inhibitors of GNAQ and GNA11 (GNAQ / GNA11 inhibitors).
[0565] In some embodiments, the linker-drug moiety (L A -(D) n ))) Includes connector (L A ) covalently attached to one or more drug moieties, wherein the linker (L A ) is a cleavable linker and the one or more drug moieties are each independently selected from a GNAQ inhibitor, a GNA11 inhibitor, or an inhibitor of GNAQ and GNA11 (GNAQ / GNA11 inhibitor).
[0566] In some embodiments, the linker-drug moiety (L A -(D) n ))) Includes connector (L A ) covalently attached to one or more drug moieties, wherein the linker (L A ) is a cleavable linker and the one or more drug moieties are each independently selected from a GNAQ inhibitor.
[0567] In some embodiments, the linker-drug moiety (L A -(D) n ))) Includes connector (L A ) covalently attached to one or more drug moieties, wherein the linker (L A ) is a cleavable linker and the one or more drug moieties are each independently selected from GNA11 inhibitors.
[0568] In some embodiments, the linker-drug moiety (L A -(D) n ))) Includes connector (L A ) covalently attached to one or more drug moieties, wherein the linker (L A ) is a cleavable linker and the one or more drug moieties are each independently selected from inhibitors of GNAQ and GNA11 (GNAQ / GNA11 inhibitors).
[0569] In some embodiments, the linker-drug moiety (L A -(D) n ))) Includes connector (L A) covalently attached to one or more drug moieties, wherein the linker (L A ) is a non-cleavable linker and the one or more drug moieties are each independently selected from a GNAQ inhibitor, a GNA11 inhibitor, or an inhibitor of GNAQ and GNA11 (GNAQ / GNA11 inhibitor).
[0570] In some embodiments, the linker-drug moiety (L A -(D) n ))) Includes connector (L A ) covalently attached to one or more drug moieties, wherein the linker (L A ) is a non-cleavable linker and the one or more drug moieties are each independently selected from a GNAQ inhibitor.
[0571] In some embodiments, the linker-drug moiety (L A -(D) n ))) Includes connector (L A ) covalently attached to one or more drug moieties, wherein the linker (L A ) is a non-cleavable linker and the one or more drug moieties are each independently selected from GNA11 inhibitors.
[0572] In some embodiments, the linker-drug moiety (L A -(D) n ))) Includes connector (L A ) covalently attached to one or more drug moieties, wherein the linker (L A ) is a non-cleavable linker and the one or more drug moieties are each independently selected from inhibitors of GNAQ and GNA11 (GNAQ / GNA11 inhibitors).
[0573] In some embodiments, the linker-drug moiety (L A -(D) n )))'s connector (L A ) has the following formula:
[0574]
[0575] in:
[0576] X1 is a divalent coupling group;
[0577] X2 is a suicide spacer;
[0578] Y1 is Where * of Y1 indicates the attachment point to X2 and ** of Y1 indicates other attachment points;
[0579] L1 is a divalent peptide linker, and
[0580] L2 is a key or linker.
[0581] In some embodiments, the linker-drug moiety (L A -(D) n ))) has the following formula:
[0582]
[0583] in:
[0584] D is a GNAQ inhibitor, a GNA11 inhibitor, or an inhibitor of GNAQ and GNA11;
[0585] X1 is a divalent coupling group;
[0586] X2 is a suicide spacer;
[0587] Y1 is Where * of Y1 indicates the point of attachment to X2 and ** of Y1 indicates the point of attachment to D;
[0588] L1 is a divalent peptide linker, and
[0589] L2 is a key or linker.
[0590] Linker-Drug Compound (L B -(D) n )
[0591] In some embodiments, the linker-drug of the present disclosure is a compound having a structure of Formula (B), or a stereoisomer or pharmaceutically acceptable salt thereof,
[0592] R 8 -L B -(D) n (B)
[0593] in:
[0594] D is a GNAQ inhibitor, a GNA11 inhibitor, or an inhibitor of GNAQ and GNA11;
[0595] R 8 It is a reactive group;
[0596] L B is a cleavable linker or a non-cleavable linker, and
[0597] n is 1, 2, 3, or 4.
[0598] In some embodiments, the linker-drug disclosed herein has a compound having a structure of formula (B), or a stereoisomer or pharmaceutically acceptable salt thereof, wherein
[0599] D is a GNAQ inhibitor, a GNA11 inhibitor, or an inhibitor of GNAQ and GNA11;
[0600] R 8 It is a reactive group;
[0601] L B is a cleavable linker comprising one or more linker components selected from the group consisting of a suicide spacer, a phosphate group, a carbonate group, and a divalent peptide linker, and
[0602] n is 1, 2, 3, or 4.
[0603] In some embodiments, the linker-drug of the present disclosure is a compound having a structure of formula (B-1), or a stereoisomer or pharmaceutically acceptable salt thereof,
[0604]
[0605] in:
[0606] D is a GNAQ inhibitor, a GNA11 inhibitor, or an inhibitor of GNAQ and GNA11;
[0607] R 8 It is a reactive group;
[0608] X2 is a suicide spacer;
[0609] Y1 is Where * of Y1 indicates the point of attachment to X2 and ** of Y1 indicates the point of attachment to D;
[0610] L1 is a divalent peptide linker, and
[0611] L2 is a key or linker.
[0612] Certain embodiments and examples of the linker-drug compounds of the present disclosure are provided in the following list of additional enumerated embodiments. It will be appreciated that the features specified in each embodiment can be combined with other specified features to provide further embodiments of the present disclosure.
[0613] Example 1. A compound of formula (B) or formula (B-1), or a stereoisomer or pharmaceutically acceptable salt thereof, wherein D is a GNAQ inhibitor.
[0614] Example 2. A compound of formula (B) or formula (B-1), or a stereoisomer or pharmaceutically acceptable salt thereof, wherein D is a GNA11 inhibitor.
[0615] Example 3. A compound of formula (B) or formula (B-1), or a stereoisomer or pharmaceutically acceptable salt thereof, wherein D is an inhibitor of GNAQ and GNA11.
[0616] Example 4. A compound of formula (B) or formula (B-1), or a stereoisomer or pharmaceutically acceptable salt thereof, wherein D is
[0617]
[0618] where R 0 is methyl or ethyl, R 1 is methyl or isopropyl, R 2 is methyl or ethyl, and *** indicates that it is the same as L B Or the attachment point of Y1.
[0619] Example 4a. A compound of formula (Bb) or formula (Bb-1), or a stereoisomer or pharmaceutically acceptable salt thereof, wherein D is
[0620]
[0621] where R 0 is methyl or ethyl, R 1 、R s 、R t are each independently methyl, isopropyl or methylthiomethyl, R 2 is methyl or ethyl, and *** indicates that it is the same as L B Or the attachment point of Y1.
[0622] Example 4b. A compound of formula (Bc) or formula (Bc-1), or a stereoisomer or pharmaceutically acceptable salt thereof, wherein D is
[0623]
[0624] where R 0 is methyl or ethyl, R 1 is methyl or isopropyl, R 2 is methyl or ethyl, and *** indicates that it is the same as L B Or the attachment point of Y1.
[0625] Example 5. A compound of formula (B) or formula (B-1), or a stereoisomer or pharmaceutically acceptable salt thereof, wherein D is
[0626]
[0627] Where *** indicates L B Or the attachment point of Y1.
[0628] Example 6. A compound of formula (B) or formula (B-1), or a stereoisomer or pharmaceutically acceptable salt thereof, having a structure of formula (B-2), or a pharmaceutically acceptable salt thereof:
[0629]
[0630] in:
[0631] R 0 is methyl or ethyl;
[0632] R 1 is methyl or isopropyl;
[0633] R 2 is methyl or ethyl, and
[0634] X2, L1, L2, and R 8 The formula is as defined in the compound having the above formula (B-1).
[0635] Example 6a. A compound of formula (Bb) or formula (Bb-1), or a stereoisomer or pharmaceutically acceptable salt thereof, having a structure of formula (Bb-2), or a pharmaceutically acceptable salt thereof:
[0636]
[0637] in:
[0638] R 0 is methyl or ethyl;
[0639] R 1 、R s and R t are each independently methyl, methylthiomethyl or isopropyl;
[0640] R 2 is methyl or ethyl, and
[0641] X2, L1, L2, and R 8 As defined above for the compound of formula (Bb-1).
[0642] Example 6b. A compound of formula (Bc) or formula (Bc-1), or a stereoisomer or pharmaceutically acceptable salt thereof, having a structure of formula (Bc-2), or a pharmaceutically acceptable salt thereof:
[0643]
[0644] in:
[0645] R 0 is methyl or ethyl;
[0646] R 1 is methyl or isopropyl;
[0647] R 2 is methyl or ethyl, and
[0648] X2, L1, L2, and R 8 As defined above for the compound of formula (Bc-1).
[0649] Example 7. A compound of formula (B), formula (B-1) or formula (B-2), or a stereoisomer or pharmaceutically acceptable salt thereof, having a structure of formula (B-2a), or a pharmaceutically acceptable salt thereof:
[0650]
[0651] in:
[0652] X2, L1, L2, and R 8 The formula is as defined in the compound having the above formula (B-1).
[0653] Example 8. A compound of formula (B) or formula (B-1), or a stereoisomer or pharmaceutically acceptable salt thereof, having a structure of formula (B-3), or a pharmaceutically acceptable salt thereof:
[0654]
[0655] in:
[0656] R 0 is methyl or ethyl;
[0657] R 1 is methyl or isopropyl;
[0658] R 2 is methyl or ethyl, and
[0659] X2, L1, L2, and R 8 The formula is as defined in the compound having the above formula (B-1).
[0660] Example 8a. A compound of formula (Bb) or formula (Bb-1), or a stereoisomer or pharmaceutically acceptable salt thereof, having a structure of formula (Bb-3), or a pharmaceutically acceptable salt thereof:
[0661]
[0662] in:
[0663] R 0 is methyl or ethyl;
[0664] R 1 、R s and R t are each independently methyl, methylthiomethyl or isopropyl;
[0665] R 2 is methyl or ethyl, and
[0666] X2, L1, L2, and R 8 As defined above for the compound of formula (Bb-1).
[0667] Example 8b. A compound of formula (Bc) or formula (Bc-1), or a stereoisomer or pharmaceutically acceptable salt thereof, having a structure of formula (Bc-3), or a pharmaceutically acceptable salt thereof:
[0668]
[0669] in:
[0670] R 0 is methyl or ethyl;
[0671] R 1 is methyl or isopropyl;
[0672] R 2 is methyl or ethyl, and
[0673] X2, L1, L2, and R 8 As defined above for the compound of formula (Bc-1).
[0674] Example 9. A compound of formula (B), formula (B-1) or formula (B-3), or a stereoisomer or pharmaceutically acceptable salt thereof, having a structure of formula (B-3a), or a pharmaceutically acceptable salt thereof:
[0675]
[0676] in:
[0677] X2, L1, L2, and R 8 The formula is as defined in the compound having the above formula (B-1).
[0678] Example 10. The compound of formula (B-2) as described in Example 6, the compound of formula (B-3) as described in Example 8, or a pharmaceutically acceptable salt thereof:
[0679] in:
[0680] R 0 is methyl or ethyl;
[0681] R 1 is methyl or isopropyl;
[0682] R 2 is methyl or ethyl;
[0683] X2 is a suicide spacer selected from the group consisting of: Where * of X2 indicates the attachment point with L1 and ** of X2 indicates the The point of attachment of the group or the point of attachment of the group;
[0684] L1 is a bivalent peptide linker consisting of 2 to 4 amino acid residues;
[0685] L2 is the connector,
[0686] R 8 Selected from -N3, -ONH2, -NR 4 C(=O)CH=CH2, SH, -SSR 13 、-S(=O)2(CH=CH2)、-NR 4 S(=O)2(CH=CH2), -NR 4 C(=O)CH2Br, -NR 4 C(=O)CH2I, -NHC(=O)CH2Br, -NHC(=O)CH2I, -C(=O)NHNH2, -CO2H, -NH2, in:
[0687] Each R 4 Independently selected from H and C1-C6 alkyl;
[0688] Each R 5 Independently selected from H, C1-C6 alkyl, F, Cl and -OH;
[0689] Each R 6 independently selected from H, C1-C6 alkyl, F, Cl, -NH2, -OCH3, -OCH2CH3, -N(CH3)2, -CN, -NO2 and -OH,
[0690] as well as
[0691] Each R 7 Independently selected from H, C 1-6Alkyl, fluorine, benzyloxy substituted with -C(=O)OH, benzyl substituted with -C(=O)OH, C 1-4 Alkoxy and C substituted by -C(=O)OH 1-4 alkyl.
[0692] Embodiment 11. A compound as described in any one of embodiments 1 to 10, wherein X2 is selected from Suicide spacers wherein * of X2 indicates the point of attachment to L1, and ** of X2 indicates the point of attachment to Y1, The point of attachment of the group or The point of attachment of the group.
[0693] Embodiment 12. A compound as described in any one of embodiments 1 to 11, wherein X2 is Where * of X2 indicates the attachment point to L1, and ** of X2 indicates the attachment point to Y1, The point of attachment of the group or The point of attachment of the group.
[0694] Embodiment 13. The compound of any one of embodiments 1 to 12, wherein L1 is a bivalent peptide linker comprising 2 to 4 amino acid residues.
[0695] Embodiment 14. The compound of any one of embodiments 1 to 12, wherein L1 is a bivalent peptide linker comprising an amino acid residue selected from valine, citrulline, lysine, isoleucine, phenylalanine, methionine, asparagine, proline, alanine, leucine, tryptophan, and tyrosine.
[0696] Embodiment 15. The compound of any one of embodiments 1 to 12, wherein L1 is a bivalent peptide linker comprising at least one valine (Val) or citrulline (Cit) residue.
[0697] Embodiment 16. The compound of any one of embodiments 1 to 12, wherein L1 is a divalent dipeptide linker selected from ValCit, PheLys, ValAla, and ValLys.
[0698] Embodiment 17. A compound as described in any one of embodiments 1 to 12, wherein L1 is selected from wherein * of L1 indicates the point of attachment to L2 and ** of L1 indicates the point of attachment to X2.
[0699] Embodiment 18. The compound of any one of embodiments 1 to 12, wherein L1 is ValCit.
[0700] Embodiment 19. The compound of any one of embodiments 1 to 12, wherein
[0701] L1 is Where * of L1 indicates the attachment point with L2 and ** of L1 indicates the attachment point with X2.
[0702] Embodiment 20. The compound of any one of embodiments 1 to 19, wherein L2 is a linker.
[0703] Embodiment 21. A compound as described in any one of embodiments 1 to 19, wherein L2 is a linker selected from:
[0704] -*C(=O)((CH2) m O) p (CH2) m **-、-*C(=O)(CH2) m **-、-*C(=O)(CH2) n NHC(=O)(CH2) m **-、-*C(=O)(CH2) m NHC(=O)((CH2) m O) p (CH2) m **-、-*((CH2) m O) p (CH2) m **-、-*((CH2) m O) p (CH2) m **-、-(CH2) m -、-*(CH2) m NHC(=O)(CH2) m **-、-*(CH2) m NHC(=O)(CH2) m C(=O)NH(CH2) m **-、-*((CH2) m O) p (CH2) m NHC(=O)(CH2) m **-、-**((CH2) m O) p CH2) m C(=O)NH(CH2) m **-、-*(CH2) m C(R3)2**-, and -*(CH2) m C(R3)2SS(CH2) m NHC(=O)(CH2)m **-, where * of L2 indicates the attachment point to L1, and ** of L2 indicates the attachment point to R8;
[0705] And among them:
[0706] Each R3 is independently selected from H and C1-C6 alkyl;
[0707] Each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and
[0708] Each p is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14.
[0709] Embodiment 22. The compound of any one of embodiments 1 to 19, wherein L2 is -*C(=O)((CH2) m O) p (CH2) m **-or-*C(=O)(CH2) m **-, where * of L2 indicates the attachment point to L1, and ** of L2 indicates the attachment point to R8,
[0710] and wherein each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 and p is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14.
[0711] Embodiment 23. A compound as described in any one of embodiments 1 to 19, wherein L2 is Where * of L2 indicates the attachment point with L1, and ** of L2 indicates the attachment point with R8.
[0712] Embodiment 24. A compound as described in any one of embodiments 1 to 23, wherein R 8 yes -N3, -ONH2, -NR 4 C(=O)CH=CH2, SH, -SSR 13 、-S(=O)2(CH=CH2)、-NR 4 S(=O)2(CH=CH2), -NR 4 C(=O)CH2Br, -NR 4 C(=O)CH2I, -NHC(=O)CH2Br, -NHC(=O)CH2I, -C(=O)NHNH2, -CO2H, -NH2, in:
[0713] Each R 4Independently selected from H and C1-C6 alkyl;
[0714] Each R 5 Independently selected from H, C1-C6 alkyl, F, Cl and -OH;
[0715] Each R 6 independently selected from H, C1-C6 alkyl, F, Cl, -NH2, -OCH3, -OCH2CH3, -N(CH3)2, -CN, -NO2 and -OH,
[0716] as well as
[0717] Each R 7 Independently selected from H, C 1-6 Alkyl, fluorine, benzyloxy substituted with -C(=O)OH, benzyl substituted with -C(=O)OH, C 1-4 Alkoxy and C substituted by -C(=O)OH 1-4 alkyl.
[0718] Embodiment 25. A compound as described in any one of embodiments 1 to 23, wherein R 8 yes -ONH2,
[0719] Embodiment 26. A compound as described in any one of embodiments 1 to 23, wherein R 8 yes
[0720] Example 27. The compound of formula (B-2) or a pharmaceutically acceptable salt thereof as described in Example 6:
[0721] in:
[0722] R 0 is methyl or ethyl;
[0723] R 1 is methyl or isopropyl;
[0724] R 2 is methyl or ethyl;
[0725] X2 is Where * of X2 indicates the attachment point with L1 and ** of X2 indicates the the point of attachment of the group;
[0726] L1 is Where * of L1 indicates the attachment point with L2 and ** of L1 indicates the attachment point with X2;
[0727] L2 is Where * of L2 indicates the attachment point with L1 and ** of L2 indicates the attachment point with R8,
[0728] as well as
[0729] R 8 yes
[0730] Example 28. The compound of formula (B-3) or a pharmaceutically acceptable salt thereof as described in Example 8:
[0731] in:
[0732] R 0 is methyl or ethyl;
[0733] R 1 is methyl or isopropyl;
[0734] R 2 is methyl or ethyl;
[0735] X2 is Where * of X2 indicates the attachment point with L1 and ** of X2 indicates the the point of attachment of the group;
[0736] L1 is Where * of L1 indicates the attachment point with L2 and ** of L1 indicates the attachment point with X2;
[0737] L2 is Where * of L2 indicates the attachment point with L1 and ** of L2 indicates the attachment point with R8,
[0738] as well as
[0739] R 8 yes
[0740] Embodiment 29. A compound of formula (B), formula (B-1) or formula (B-2), wherein the compound is
[0741]
[0742] Embodiment 30. A compound of formula (B), formula (B-1) or formula (B-2), wherein the compound is
[0743]
[0744] Embodiment 31. A compound of formula (B), formula (B-1) or formula (B-3), wherein the compound is
[0745]
[0746] Embodiment 32. A compound of formula (B), formula (B-1) or formula (B-3), wherein the compound is
[0747]
[0748] The synthesis of exemplary linker-drug compounds is also described in Example 1 of International Application Publication No. WO 2020 / 128612, which is incorporated by reference in its entirety.
[0749] Antibody-drug conjugates
[0750] In some embodiments, the antibody drug conjugates of the present disclosure are conjugates of formula (C):
[0751] Ab-(L A -(D) n ) y (C)
[0752] in:
[0753] D is the drug part;
[0754] Ab is an antibody or antigen-binding fragment thereof that binds to human PMEL17 protein;
[0755] L A It is a joint;
[0756] n is 1, 2, 3, or 4, and
[0757] y is 1, 2, 3, or 4,
[0758] wherein the linker-drug moiety (L A -(D) n ) is covalently attached to the antibody or antigen-binding fragment thereof.
[0759] In some embodiments, the antibody drug conjugates of the present disclosure have the structure of Formula (C), wherein:
[0760] D is a GNAQ inhibitor, a GNA11 inhibitor, or an inhibitor of GNAQ and GNA11;
[0761] Ab is an antibody or antigen-binding fragment thereof that binds to human PMEL17 protein;
[0762] L A is a cleavable linker comprising one or more linker components selected from the group consisting of a suicide spacer, a phosphate group, a carbonate group, and a divalent peptide linker;
[0763] n is 1, 2, 3, or 4, and
[0764] y is 1, 2, 3, or 4,
[0765] wherein the linker-drug moiety (L A -(D) n ) is covalently attached to the antibody or antigen-binding fragment thereof.
[0766] In some embodiments, the antibody drug conjugate of formula (C) is a conjugate of formula (C-1):
[0767]
[0768] in:
[0769] D is a GNAQ inhibitor, a GNA11 inhibitor, or an inhibitor of GNAQ and GNA11;
[0770] Ab is an antibody or antigen-binding fragment thereof that binds to human PMEL17 protein;
[0771] X1 is a divalent coupling group;
[0772] X2 is a suicide spacer;
[0773] Y1 is Where * of Y1 indicates the point of attachment to X2 and ** of Y1 indicates the point of attachment to D;
[0774] L1 is a divalent peptide linker;
[0775] L2 is a key or linker, and
[0776] y is 1, 2, 3, or 4.
[0777] In the conjugate having formula (C), one or more linker-drug moieties (L B -(D) n ) can be covalently attached to an antibody or antigen-binding fragment thereof Ab, thereby linking A One or more drug moieties D are covalently attached to the antibody or antigen-binding fragment thereof Ab. A is any chemical moiety capable of linking the antibody or antigen-binding fragment thereof Ab to one or more drug moieties D. The conjugate of formula (C) (wherein one or more drug moieties D are covalently linked to the antibody or antigen-binding fragment thereof Ab) can be formed using a bifunctional or multifunctional linker reagent having one or more identical or different reactive functional groups. One of the reactive functional groups of the bifunctional or multifunctional linker reagent is used to react with a group (e.g., a thiol or amine (e.g., cysteine, N-terminus, or an amino acid side chain such as lysine)) on the antibody or antigen-binding fragment thereof Ab to react with the linker L. ASuch reactive functional groups of bifunctional or multifunctional linker reagents include, but are not limited to, maleimide, thiol, and NHS ester. One or more other reactive functional groups of bifunctional or multifunctional linker reagents are used to covalently attach one or more drug moieties D to linker L. A .
[0778] In some embodiments, L A is a cleavable linker. In some embodiments, L A is a non-cleavable linker. In some embodiments, L A is an acid-labile linker, a photolabile linker, a peptidase-cleavable linker, an esterase-cleavable linker, a glycosidase-cleavable linker, a phosphodiesterase-cleavable linker, a disulfide-reducible linker, a hydrophilic linker, or a dicarboxylic acid-based linker.
[0779] In some embodiments, L A is a cleavable linker comprising one or more linker components selected from the group consisting of a suicide spacer, a phosphate group, a carbonate group, and a bivalent peptide linker.
[0780] In some embodiments, L A is a cleavable linker comprising one or more linker components selected from the group consisting of a suicide spacer, a phosphate group, a carbonate group, a divalent peptide linker, and a divalent coupling group.
[0781] In some embodiments, L A is a cleavable linker comprising one or more linker components selected from the group consisting of a suicide spacer, a phosphate group, and a bivalent peptide linker.
[0782] In some embodiments, L A is a cleavable linker comprising one or more linker components selected from the group consisting of a suicide spacer, a phosphate group divalent peptide linker, and a divalent coupling group.
[0783] In some embodiments, the linker (L A ) has the following formula:
[0784]
[0785] in:
[0786] X1 is a divalent coupling group;
[0787] X2 is a suicide spacer;
[0788] Y1 is Where * of Y1 indicates the attachment point to X2 and ** of Y1 indicates other attachment points;
[0789] L1 is a divalent peptide linker, and
[0790] L2 is a key or linker.
[0791] In some embodiments, the linker (L A ) has the following formula:
[0792]
[0793] in:
[0794] X1 is a divalent coupling group;
[0795] X2 is a suicide spacer;
[0796] Y1 is The * of Y1 indicates the attachment point with X2;
[0797] L1 is a divalent peptide linker, and
[0798] L2 is a key or linker.
[0799] In some embodiments, the linker (L A ) has the following formula:
[0800]
[0801] in:
[0802] X1 is a divalent coupling group;
[0803] X2 is a suicide spacer;
[0804] Y1 is The * of Y1 indicates the attachment point with X2;
[0805] L1 is a divalent peptide linker, and
[0806] L2 is a key or linker.
[0807] While the drug-to-antibody ratio has an exact integer value for a particular conjugate molecule (e.g., the product of n and y in Formula (C)), it will be understood that when used to describe a sample containing many molecules, this value is typically an average value due to some degree of heterogeneity typically associated with the conjugation step. The average loading of a conjugate sample is referred to herein as the drug-to-antibody ratio or "DAR." In some embodiments, the DAR is between about 1 and about 5, and is typically about 1, 2, 3, or 4. In some embodiments, at least 50% of the sample by weight is a compound having an average DAR plus or minus 2, and preferably at least 50% of the sample is a conjugate containing an average DAR plus or minus 1. Other embodiments include conjugates wherein the DAR is about 2. In some embodiments, a DAR of "about y" refers to a measured value of the DAR that is within 20% of the product of n and y in Formula (I). In some embodiments, a DAR of "about n" refers to a measured value of the DAR that is within 20% of n in Formula (II).
[0808] In some embodiments, the average molar ratio of drug to antibody in the conjugate of Formula (C) (i.e., the average of the product of n and y, also referred to as the drug to antibody ratio (DAR)) is from about 1 to about 10, from about 1 to about 6 (e.g., 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.10, 3.20, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.11, 4.12, 4.13, 4.14, 4.15, 4.16, 4.17, 4.18, 4.19, 5. 8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, or 6.0), about 1 to about 5, about 1.5 to about 4.5, or about 2 to about 4.
[0809] In some embodiments provided herein, the conjugates have very high purity and have one or more of the following characteristics: (a) greater than about 90% (e.g., greater than or equal to about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or about 100%), preferably greater than about 95%, of the conjugated material is monomeric, (b) the level of unconjugated linker in the conjugate preparation is less than about 10% (e.g., less than or equal to about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, about 2%, about 1%, or about 0%) (relative to total linker), (c) less than 10% of the conjugate is cross-linked (e.g., less than or equal to about 10%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 1%, about 0%, about 1%, or about 0%). or about 0%), and (d) the level of free drug (ADP-induced platelet aggregation inhibitor, such as a GNAQ inhibitor, a GNA11 inhibitor, or a GNAQ and GNA11 inhibitor) in the conjugate formulation is less than about 2% (e.g., less than or equal to about 1.5%, about 1.4%, about 1.3%, about 1.2%, about 1.1%, about 1.0%, about 0.9%, about 0.8%, about 0.7%, about 0.6%, about 0.5%, about 0.4%, about 0.3%, about 0.2%, about 0.1%, or about 0%) (mol / mol relative to total drug).
[0810] Certain embodiments and examples of the antibody drug conjugates of the present disclosure are provided in the following list of additional enumerated embodiments. It will be appreciated that the features specified in each embodiment can be combined with other specified features to provide further embodiments of the present disclosure.
[0811] Example 33. The conjugate of formula (C) or formula (C-1), wherein D is a GNAQ inhibitor.
[0812] Example 34. The conjugate of formula (C) or formula (C-1), wherein D is a GNA11 inhibitor.
[0813] Example 35. The conjugate of formula (C) or formula (C-1), wherein D is an inhibitor of GNAQ and GNA11.
[0814] Example 36. Conjugates of formula (C) or (C-1), wherein D is
[0815]
[0816] where R 0 is methyl or ethyl, R1 is methyl or isopropyl, R2 is methyl or ethyl, and *** indicates that L A Or the attachment point of Y1.
[0817] Example 36a. A conjugate of formula (Cb) or formula (Cb-1), wherein D is
[0818]
[0819] where R 0 is methyl or ethyl, R 1 、R s and R t are each independently methyl, methylthiomethyl or isopropyl, R2 is methyl or ethyl, and *** represents the same as L A Or the attachment point of Y1.
[0820] Example 36b. A conjugate of formula (Cc) or formula (Cc-1), wherein D is
[0821]
[0822] where R 0 is methyl or ethyl, R1 is methyl or isopropyl, R2 is methyl or ethyl, and *** indicates that L A Or the attachment point of Y1.
[0823] Example 37. Conjugates of formula (C) or (C-1), wherein D is
[0824]
[0825] Where *** indicates L A Or the attachment point of Y1.
[0826] Example 38. A conjugate of formula (C) or formula (C-1) having a structure of formula (C-2):
[0827]
[0828] in:
[0829] R 0 is methyl or ethyl;
[0830] R 1 is methyl or isopropyl;
[0831] R 2 is methyl or ethyl;
[0832] Ab is an antibody or antigen-binding fragment thereof that binds to human PMEL17 protein;
[0833] X1 is a divalent coupling group;
[0834] X2 is a suicide spacer;
[0835] L1 is a divalent peptide linker;
[0836] L2 is a key or linker, and
[0837] y is 1, 2, 3, or 4.
[0838] Example 38a. A conjugate of formula (Cb) or formula (Cb-1) having a structure of formula (Cb-2):
[0839]
[0840] in:
[0841] R 0 is methyl or ethyl;
[0842] R 1 、R s and R t are each independently methyl, methylthiomethyl or isopropyl;
[0843] R 2 is methyl or ethyl;
[0844] Ab is an antibody or antigen-binding fragment thereof that binds to human PMEL17 protein;
[0845] X1 is a divalent coupling group;
[0846] X2 is a suicide spacer;
[0847] L1 is a divalent peptide linker;
[0848] L2 is a key or linker, and
[0849] y is 1, 2, 3, or 4.
[0850] Example 38b. A conjugate of formula (Cc) or formula (Cc-1) having a structure of formula (Cc-2):
[0851]
[0852] in:
[0853] R 0 is methyl or ethyl;
[0854] R 1 is methyl or isopropyl;
[0855] R 2 is methyl or ethyl;
[0856] Ab is an antibody or antigen-binding fragment thereof that binds to human PMEL17 protein;
[0857] X1 is a divalent coupling group;
[0858] X2 is a suicide spacer;
[0859] L1 is a divalent peptide linker;
[0860] L2 is a key or linker, and
[0861] y is 1, 2, 3, or 4.
[0862] Example 39. A conjugate of formula (C) or formula (C-1) having a structure of formula (C-2a):
[0863]
[0864] in:
[0865] Ab is an antibody or antigen-binding fragment thereof that binds to human PMEL17 protein;
[0866] X1 is a divalent coupling group;
[0867] X2 is a suicide spacer;
[0868] L1 is a divalent peptide linker;
[0869] L2 is a key or linker, and
[0870] y is 1, 2, 3, or 4.
[0871] Example 40. A conjugate of formula (C) or formula (C-1) having a structure of formula (C-3):
[0872]
[0873] in:
[0874] R 0 is methyl or ethyl;
[0875] R 1 is methyl or isopropyl;
[0876] R 2 is methyl or ethyl;
[0877] Ab is an antibody or antigen-binding fragment thereof that binds to human PMEL17 protein;
[0878] X1 is a divalent coupling group;
[0879] X2 is a suicide spacer;
[0880] L1 is a divalent peptide linker;
[0881] L2 is a key or linker, and
[0882] y is 1, 2, 3, or 4.
[0883] Example 40a. A conjugate of formula (Cb) or formula (Cb-1) having a structure of formula (Cb-3):
[0884]
[0885] in:
[0886] R 0 is methyl or ethyl;
[0887] R 1 、R s and R t are each independently methyl, methylthiomethyl or isopropyl;
[0888] R 2 is methyl or ethyl;
[0889] Ab is an antibody or antigen-binding fragment thereof that binds to human PMEL17 protein;
[0890] X1 is a divalent coupling group;
[0891] X2 is a suicide spacer;
[0892] L1 is a divalent peptide linker;
[0893] L2 is a key or linker, and
[0894] y is 1, 2, 3, or 4.
[0895] Example 40b. A conjugate of formula (Cc) or formula (Cc-1) having a structure of formula (Cc-3):
[0896]
[0897] in:
[0898] R 0 is methyl or ethyl;
[0899] R 1 is methyl or isopropyl;
[0900] R 2 is methyl or ethyl;
[0901] Ab is an antibody or antigen-binding fragment thereof that binds to human PMEL17 protein;
[0902] X1 is a divalent coupling group;
[0903] X2 is a suicide spacer;
[0904] L1 is a divalent peptide linker;
[0905] L2 is a key or linker, and
[0906] y is 1, 2, 3, or 4.
[0907] Example 41. A conjugate of formula (C) or formula (C-1) having a structure of formula (C-3a):
[0908]
[0909] in:
[0910] Ab is an antibody or antigen-binding fragment thereof that binds to human PMEL17 protein;
[0911] X1 is a divalent coupling group;
[0912] X2 is a suicide spacer;
[0913] L1 is a divalent peptide linker;
[0914] L2 is a key or linker, and
[0915] y is 1, 2, 3, or 4.
[0916] Example 42. The conjugate of formula (C-2) as described in Example 54 or the conjugate of formula (C-3) as described in Example 58:
[0917] in:
[0918] R 0 is methyl or ethyl;
[0919] R 1 is methyl or isopropyl;
[0920] R 2 is methyl or ethyl;
[0921] Ab is an antibody or antigen-binding fragment thereof that binds to human PMEL17 protein;
[0922] X2 is a suicide spacer selected from the group consisting of: Where * of X2 indicates the attachment point with L1 and ** of X2 indicates the The point of attachment of the group or the point of attachment of the group;
[0923] L1 is a bivalent peptide linker consisting of 2 to 4 amino acid residues;
[0924] L2 is the connector;
[0925] X1 is a divalent coupling group selected from the following: -*NR 4 C(=O)CH2**-, -*NHC(=O)CH2**-, -*S(=O)2CH2CH2**-, -*(CH2)2S(=O)2CH2CH2**-, -*NR 4 S(=O)2CH2CH2**-、-*NR 4 C(=O)CH2CH2**-, -NH-, -C(=O)-, -*NHC(=O)**-, -*CH2NHCH2CH2**-, -*NHCH2CH2**-, -S-, where * of X1 indicates the attachment point to L2, and ** of X1 indicates the attachment point to Ab;
[0926] And among them:
[0927] Each R 4 Independently selected from H and C1-C6 alkyl;
[0928] Each R 5 Independently selected from H, C1-C6 alkyl, F, Cl and -OH;
[0929] Each R 6 independently selected from H, C1-C6 alkyl, F, Cl, -NH2, -OCH3, -OCH2CH3, -N(CH3)2, -CN, -NO2 and -OH,
[0930] as well as
[0931] Each R 7 Independently selected from H, C 1-6 Alkyl, fluorine, benzyloxy substituted with -C(=O)OH, benzyl substituted with -C(=O)OH, C 1-4 Alkoxy and C substituted by -C(=O)OH 1-4 alkyl,
[0932] as well as
[0933] y is 1, 2, 3, or 4.
[0934] Embodiment 43. The conjugate of any one of embodiments 38 to 42, wherein X2 is selected from Suicide spacers wherein * of X2 indicates the point of attachment to L1, and ** of X2 indicates the point of attachment to Y1, or The point of attachment of the group or The point of attachment of the group.
[0935] Embodiment 44. The conjugate of any one of embodiments 38 to 43, wherein X2 is Where * of X2 indicates the attachment point to L1, and ** of X2 indicates the attachment point to Y1, or The point of attachment of the group or The point of attachment of the group.
[0936] Embodiment 45. The conjugate of any one of embodiments 38 to 44, wherein L1 is a bivalent peptide linker comprising 2 to 4 amino acid residues.
[0937] Embodiment 46. The conjugate of any one of embodiments 38 to 45, wherein L1 is a bivalent peptide linker comprising an amino acid residue selected from valine, citrulline, lysine, isoleucine, phenylalanine, methionine, asparagine, proline, alanine, leucine, tryptophan, and tyrosine.
[0938] Embodiment 47. The conjugate of any one of embodiments 38-44, wherein L1 is a bivalent peptide linker comprising at least one valine (Val) or citrulline (Cit) residue.
[0939] Embodiment 48. The conjugate of any one of embodiments 38 to 44, wherein L1 is a divalent dipeptide linker selected from ValCit, PheLys, ValAla, and ValLys.
[0940] Embodiment 49. The conjugate of any one of embodiments 38 to 44, wherein L1 is selected from wherein * of L1 indicates the point of attachment to L2 and ** of L1 indicates the point of attachment to X2.
[0941] Embodiment 50. The conjugate of any one of embodiments 38 to 44, wherein L1 is ValCit.
[0942] Embodiment 51. The conjugate of any one of embodiments 38 to 44, wherein
[0943] L1 is Where * of L1 indicates the attachment point with L2 and ** of L1 indicates the attachment point with X2.
[0944] Embodiment 52. The conjugate of any one of embodiments 38 to 51, wherein L2 is a linker.
[0945] Embodiment 53. The conjugate of any one of embodiments 38 to 51, wherein L2 is a linker selected from:
[0946] -*C(=O)((CH2) m O)p (CH2) m **-、-*C(=O)(CH2) m **-、-*C(=O)(CH2) n NHC(=O)(CH2) m **-、-*C(=O)(CH2) m NHC(=O)((CH2) m O) p (CH2) m **-、-*((CH2) m O) p (CH2) m **-、-*((CH2) m O) p (CH2) m **-、-(CH2) m -、-*(CH2) m NHC(=O)(CH2) m **-、-*(CH2) m NHC(=O)(CH2) m C(=O)NH(CH2) m **-、-*((CH2) m O) p (CH2) m NHC(=O)(CH2) m **-、-**((CH2) m O) p CH2) m C(=O)NH(CH2) m **-、-*(CH2) m C(R3)2**-, and -*(CH2) m C(R3)2SS(CH2) m NHC(=O)(CH2) m **-, where * of L2 indicates the attachment point to L1, and ** of L2 indicates the attachment point to X1;
[0947] And among them:
[0948] Each R3 is independently selected from H and C1-C6 alkyl;
[0949] Each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10, and
[0950] Each p is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 and 14.
[0951] Embodiment 54. The conjugate of any one of embodiments 38 to 51, wherein L2 is -*C(=O)((CH2) m O) p (CH2) m **-or-*C(=O)(CH2) m **-, where * of L2 indicates the attachment point with L1, and ** of L2 indicates the attachment point with X1,
[0952] and wherein each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 and p is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14.
[0953] Embodiment 55. The conjugate of any one of embodiments 38 to 51, wherein L2 is Where * of L2 indicates the attachment point with L1, and ** of L2 indicates the attachment point with X1.
[0954] Embodiment 56. The conjugate of any one of embodiments 38 to 55,
[0955] wherein X1 is a divalent coupling group selected from the following: -*NR 4 C(=O)CH2**-, -*NHC(=O)CH2**-, -*S(=O)2CH2CH2**-, -*(CH2)2S(=O)2CH2CH2**-, -*NR 4 S(=O)2CH2CH2**-、-*NR 4 C(=O)CH2CH2**-, -NH-, -C(=O)-, -*NHC(=O)**-, -*CH2NHCH2CH2**-, -*NHCH2CH2**-, -S-, **-, where * of X1 indicates the point of attachment to L2, and ** of X1 indicates the point of attachment to Ab;
[0956] And among them:
[0957] Each R 4 Independently selected from H and C1-C6 alkyl;
[0958] Each R 5 Independently selected from H, C1-C6 alkyl, F, Cl and -OH;
[0959] Each R 6independently selected from H, C1-C6 alkyl, F, Cl, -NH2, -OCH3, -OCH2CH3, -N(CH3)2, -CN, -NO2 and -OH,
[0960] as well as
[0961] Each R 7 Independently selected from H, C 1-6 Alkyl, fluorine, benzyloxy substituted with -C(=O)OH, benzyl substituted with -C(=O)OH, C 1-4 Alkoxy and C substituted by -C(=O)OH 1-4 alkyl.
[0962] Embodiment 57. The conjugate of any one of embodiments 38 to 55,
[0963] Where X1 is selected from wherein the * of X1 represents the point of attachment to L2, and the ** of X1 represents the point of attachment to Ab.
[0964] Embodiment 58. The conjugate of any one of embodiments 38 to 55,
[0965] Where X1 is selected from wherein the * of X1 represents the point of attachment to L2, and the ** of X1 represents the point of attachment to Ab.
[0966] Embodiment 59. The conjugate of formula (C-2) as described in embodiment 38, wherein:
[0967] Ab is an antibody or antigen-binding fragment thereof that binds to human PMEL17 protein;
[0968] R 0 is methyl or ethyl;
[0969] R 1 is methyl or isopropyl;
[0970] R 2 is methyl or ethyl;
[0971] X1 is selected from A divalent coupling group wherein * of X1 represents the attachment point to L2 and ** of X1 represents the attachment point to Ab
[0972] X2 is Where * of X2 indicates the attachment point with L1 and ** of X2 indicates the the point of attachment of the group;
[0973] L1 is Where * of L1 indicates the attachment point with L2 and ** of L1 indicates the attachment point with X2;
[0974] L2 is Where * of L2 indicates the attachment point with L1 and ** of L2 indicates the attachment point with R8,
[0975] as well as
[0976] y is 1, 2, 3, or 4.
[0977] Embodiment 60. The conjugate of formula (C-3) as described in embodiment 40, wherein:
[0978] Ab is an antibody or antigen-binding fragment thereof that binds to human PMEL17 protein;
[0979] R 0 is methyl or ethyl;
[0980] R 1 is methyl or isopropyl;
[0981] R 2 is methyl or ethyl;
[0982] X1 is selected from A divalent coupling group wherein * of X1 represents the attachment point to L2 and ** of X1 represents the attachment point to Ab
[0983] X2 is Where * of X2 indicates the attachment point with L1 and ** of X2 indicates the the point of attachment of the group;
[0984] L1 is Where * of L1 indicates the attachment point with L2 and ** of L1 indicates the attachment point with X2;
[0985] L2 is Where * of L2 indicates the attachment point with L1 and ** of L2 indicates the attachment point with R8,
[0986] as well as
[0987] y is 1, 2, 3, or 4.
[0988] Example 61. A conjugate of Formula (C), Formula (C-1), or Formula (C-2) having the following structure:
[0989]
[0990] in:
[0991] y is 2 or 4 and
[0992] Ab is an antibody or an antigen-binding fragment thereof that binds to human PMEL17 protein.
[0993] Example 62. A conjugate of Formula (C), Formula (C-1), or Formula (C-2) having the following structure:
[0994]
[0995] in:
[0996] y is 2 or 4 and
[0997] Ab is an antibody or an antigen-binding fragment thereof that binds to human PMEL17 protein.
[0998] Example 63. A conjugate of formula (C), formula (C-1), or formula (C-3) having the following structure:
[0999]
[1000] in:
[1001] y is 2 or 4 and
[1002] Ab is an antibody or an antigen-binding fragment thereof that binds to human PMEL17 protein.
[1003] Example 64. A conjugate of formula (C), formula (C-1), or formula (C-3) having the following structure:
[1004]
[1005] in:
[1006] y is 2 or 4 and
[1007] Ab is an antibody or an antigen-binding fragment thereof that binds to human PMEL17 protein.
[1008] Example 65. Conjugate of compound (E) having the following structure:
[1009]
[1010] in:
[1011] y is 2; and
[1012] Ab is an antibody or an antigen-binding fragment thereof that binds to human PMEL17 protein.
[1013] In addition, the antibodies, antibody fragments (e.g., antigen binding fragments) or functional equivalents of the present disclosure can be conjugated to a drug portion that modulates a given biological response. The drug portion should not be construed as being limited to classical chemotherapeutic agents. For example, the drug portion can be a protein, peptide, or polypeptide having a desired biological activity. Such proteins can include, for example, toxins such as abrin, ricin A, Pseudomonas exotoxin, cholera toxin, or diphtheria toxin; proteins such as tumor necrosis factor, α-interferon, β-interferon, nerve growth factor, platelet-derived growth factor, tissue plasminogen activator, cytokines, apoptotic agents, anti-angiogenic agents; or biological response modifiers such as lymphokines.
[1014] In one embodiment, the antibodies, antibody fragments (e.g., antigen binding fragments) or functional equivalents of the present disclosure are conjugated to a drug moiety, such as a cytotoxin, a drug (e.g., an immunosuppressant) or a radiotoxin. Examples of cytotoxins include, but are not limited to, taxanes (see, e.g., International (PCT) Patent Application Nos. WO 01 / 38318 and PCT / US 03 / 02675), DNA-alkylating agents (e.g., CC-1065 analogs), anthracyclines, tubulysin analogs, duocarmycin analogs, auristatin E, auristatin F, maytansine alkaloids, pyrrolobenzodiazepines, (PBD) and cytotoxic agents comprising a reactive polyethylene glycol moiety (see, e.g., Sasse et al., J. Antibiot. (Tokyo), 53, 879-85 (2000); Suzawa et al., Bioorg. Med. Chem., 8, 2175-84 (2000); Ichimura et al., J. Antibiot. (Tokyo), 44, 1045- 53 (1991); Francisco et al., Blood (2003) (electronic publication ahead of print); U.S. Patent Nos. 5,475,092, 6,340,701, 6,372,738, and 6,436,931, U.S. Patent Application Publication No. 2001 / 0036923A1, pending U.S. Patent Application Serial Nos. 10 / 024,290 and 10 / 116,053, and International (PCT) Patent Application No. WO 01 / 49698), taxon, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxyanthracenedione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol and puromycin and their analogs or homologs. Therapeutic agents also include, for example, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), ablative agents (e.g., mechlorethamine, thiotepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin and anthramycin (AMC)), and antimitotic agents (e.g., vincristine and vinblastine). (See, e.g., Seattle Genetics US20090304721).
[1015] Other examples of cytotoxins that can be conjugated to the antibodies, antibody fragments (antigen-binding fragments) or functional equivalents of the disclosure include duocarmycin, calicheamicin, maytansine and auristatin and their derivatives.
[1016] Various cytotoxin types, linkers, and methods for conjugating therapeutic agents to antibodies are known in the art, see, for example, Saito et al., (2003) Adv. Drug Deliv. Rev. 55:199-215; Trail et al., (2003) Cancer Immunol. Immunother. 52:328-337; Payne, (2003) Cancer Cell 3:207-212; Allen, (2002) Nat. Rev. Cancer 2:750-763; Pastan and Kreitman, (2002) Curr. Opin. Investig. Drugs 3:1089-1091; Senter and Springer, (2001) Adv. Drug Deliv. Rev. [Advanced Drug Delivery Reviews] 53:247–264.
[1017] The antibodies, antibody fragments (e.g., antigen binding fragments) or functional equivalents disclosed herein can also be conjugated to radioactive isotopes to produce cytotoxic radiopharmaceuticals, referred to as radioimmunoconjugates. Examples of radioisotopes that can be conjugated to antibodies for diagnostic or therapeutic use include, but are not limited to, iodine-131, indium-111, yttrium-90, and lutetium-177. Methods for preparing radioimmunoconjugates are established in the art. Examples of radioimmunoconjugates are commercially available and include Zevalin, TM (DEC Pharmaceuticals) and Bexxar TM (Corixa Pharmaceuticals), and similar methods can be used to prepare radioimmunoconjugates using the antibodies of the present disclosure. In certain embodiments, the macrocyclic chelator is 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA), which can be attached to the antibody via a linker molecule. Such linker molecules are well known in the art and are described in Denardo et al., (1998) Clin Cancer Res. 4(10):2483-90; Peterson et al., (1999) Bioconjug. Chem. 10(4):553-7; and Zimmerman et al., (1999) Nucl. Med. Biol. 26(8):943-50, each of which is incorporated by reference in its entirety.
[1018] The antibodies, antibody fragments (e.g., antigen binding fragments) or functional equivalents of the present disclosure can also be conjugated to heterologous proteins or polypeptides (or fragments thereof, preferably polypeptides of at least about 10, at least about 20, at least about 30, at least about 40, at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, or at least about 100 amino acids) to produce fusion proteins. In particular, the present disclosure provides fusion proteins comprising antibody fragments (e.g., antigen binding fragments) described herein (e.g., Fab fragments, Fd fragments, Fv fragments, F(ab)2 fragments, VH domains, VH CDRs, VL domains, or VL CDRs) and heterologous proteins, polypeptides, or peptides.
[1019] Additional fusion proteins can be generated by the techniques of gene shuffling, motif shuffling, exon shuffling, and / or codon shuffling (collectively referred to as "DNA shuffling"). DNA shuffling can be employed to alter the activity of an antibody or fragment thereof of the disclosure (e.g., an antibody or fragment thereof with higher affinity and lower off-rate). See generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458; Patten et al., (1997) Curr. Opinion Biotechnol. 8:724-33; Harayama, (1998) Trends Biotechnol. 16(2):76-82; Hansson et al., (1999) J. Mol. Biol. 287:265-76; and Lorenzo and Blasco, (1998) Biotechniques 24(2):308-313 (each of these patents and publications is hereby incorporated by reference in its entirety). Antibodies or fragments thereof, or encoded antibodies or fragments thereof, can be altered by random mutagenesis by error-prone PCR, random nucleotide insertion, or other methods prior to recombination. Polynucleotides encoding antibodies or fragments thereof that specifically bind to an antigen can be recombined with one or more components, motifs, segments, parts, domains, fragments, etc., of one or more heterologous molecules.
[1020] In addition, the antibodies, antibody fragments (e.g., antigen binding fragments) or functional equivalents disclosed herein can be conjugated to marker sequences such as peptides to facilitate purification. In a preferred embodiment, the marker amino acid sequence is a hexahistidine peptide (SEQ ID NO: 267), such as the tag provided in the pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), many of which are commercially available. As described in Gentz et al., (1989) Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States] 86: 821-824, for example, hexahistidine (SEQ ID NO: 267) facilitates purification of the fusion protein. Other peptide tags that can be used for purification include, but are not limited to, the hemagglutinin ("HA") tag corresponding to an epitope derived from the influenza hemagglutinin protein (Wilson et al., (1984) Cell 37:767) and the "FLAG" tag (A. Einhauer et al., J. Biochem. Biophys. Methods 49:455-465, 2001). According to the present disclosure, antibodies or antigen-binding fragments can also be conjugated to tumor-penetrating peptides to improve their efficacy.
[1021] In other embodiments, the antibodies, antibody fragments (e.g., antigen binding fragments) or functional equivalents of the present disclosure are conjugated to a diagnostic or detectable agent. Such immunoconjugates can be used to monitor or prognose the onset, development, progression and / or severity of a disease or disorder as part of a clinical trial program (e.g., to determine the efficacy of a particular therapy). Such diagnosis and detection can be achieved by coupling the antibody to a detectable substance, which includes but is not limited to various enzymes, such as but not limited to horseradish peroxidase, alkaline phosphatase, β-galactosidase or acetylcholinesterase; prosthetic groups, such as but not limited to streptavidin / biotin and avidin / biotin; fluorescent materials, such as but not limited to Alexa Fluor 350, Alexa Fluor 405, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 500, Alexa Fluor 514, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 555, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 610, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor 660, Alexa Fluor 680, Alexa Fluor 700, Alexa Fluor 800, Alexa Fluor 810, Alexa Fluor 820, Alexa Fluor 830, Alexa Fluor 841, Alexa Fluor 850, Alexa Fluor 861, Alexa Fluor 870, Alexa Fluor 880, Alexa Fluor 890, Alexa Fluor 901, Alexa Fluor 911, Alexa Fluor 921, Alexa Fluor 932, Alexa Fluor 941, Alexa Fluor 950, Alexa Fluor 961, Alexa Fluor 970, Alexa Fluor 980, Alexa Fluor 990, Alexa Fluor 1000, Alexa Fluor 1011 750, umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; luminescent materials such as but not limited to luminol; bioluminescent materials such as but not limited to luciferase, luciferin and aequorin; radioactive materials such as but not limited to iodine ( 131 I. 125 I. 123 I and 121 I), carbon ( 14 C), sulfur ( 35 S), tritium ( 3 H), indium ( 115 In, 113 In, 112 In and 111 In), technetium ( 99 Tc), thallium ( 201 Ti), gallium ( 68 Ga, 67 Ga), Palladium ( 103 Pd), molybdenum ( 99 Mo), xenon ( 133 Xe), fluorine ( 18 F), 153 Sm, 177 Lu, 159 Gd, 149 Pm,140 La, 175 Yb, 166 Ho, 90 Y. 47 Sc, 186 Re、 188 Re、 142 Pr, 105 Rh, 97 Such as 68 Ge, 57 Co、 65 Zn, 85 Sr. 32 P. 153 Gd, 169 Yb, 51 Cr, 54 Mn, 75 Se, 64 Cu, 113 Sn and 117 Sn; and positron-emitting metals and non-radioactive paramagnetic metal ions using various positron emission tomography methods.
[1022] The antibodies, antibody fragments (e.g., antigen binding fragments) or functional equivalents of the present disclosure can also be attached to a solid support particularly useful for immunoassays or purification of the target antigen. Such solid supports include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.
[1023] Conjugation and preparation of ADC
[1024] Methods for preparing antibody drug conjugates of formula (C), formula (C-1) and formula (C-2)
[1025] The general reaction method to form the conjugate of formula (C) is shown below in Scheme 1:
[1026] Solution 1
[1027]
[1028] wherein: RG1 is a reactive group (by way of example only, a thiol, amine, or ketone) on the antibody or antigen-binding fragment thereof Ab that is compatible with a reactive group R attached to the linker-drug compound 8 The antibody or antigen-binding fragment thereof Ab is covalently attached to one or more linker-drug moieties. 8 A non-limiting example of such a reaction of a group is maleimide (R 8 ) reacts with thiol (RG1) to give a succinimide ring, or hydroxylamine (R 8 ) reacts with ketone (RG1) to give oxime.
[1029] In one embodiment, D is a GNAQ inhibitor, a GNA11 inhibitor, or an inhibitor of GNAQ and GNA11 (GNAQ / GNA11 inhibitor), and L a is a joint (which further comprises when RG1 and R 8 wherein n is 1, 2, 3 or 4, and y is 1, 2, 3 or 4.
[1030] The general reaction method to form the conjugate of formula (C-1) is shown in Scheme 2 below:
[1031] Option 2
[1032]
[1033] wherein: RG1 is a reactive group (by way of example only, a thiol, amine, or ketone) on the antibody or antigen-binding fragment thereof Ab that is compatible with a reactive group R attached to the linker-drug moiety 8 The antibody or antigen-binding fragment thereof Ab is covalently attached to one or more linker-drug moieties. 8 A non-limiting example of such a reaction of a group is maleimide (R 8 ) reacts with thiol (RG1) to give a succinimide ring, or hydroxylamine (R 8 ) reacts with ketone (RG1) to give oxime.
[1034] In one embodiment, D is a GNAQ inhibitor, a GNA11 inhibitor, or an inhibitor of GNAQ and GNA11 (GNAQ / GNA11 inhibitor), and X1 is 8 A divalent coupling group (e.g., a succinimide ring or oxime) is formed upon reaction, Y1 is a phosphate group, X2 is a suicide spacer, L1 is a divalent peptide linker, L2 is a bond or linker, and y is 1, 2, 3, or 4.
[1035] The general reaction method to form the conjugate of formula (C-2) is shown below in Scheme 3:
[1036] Option 3
[1037]
[1038] wherein: RG1 is a reactive group (by way of example only, a thiol, amine, or ketone) on the antibody or antigen-binding fragment thereof Ab that is compatible with a reactive group R attached to the linker-drug moiety 8 The antibody or antigen-binding fragment thereof Ab is covalently attached to one or more linker-drug moieties. 8 A non-limiting example of such a reaction of a group is maleimide (R8 ) reacts with thiol (RG1) to give a succinimide ring, or hydroxylamine (R 8 ) reacts with ketone (RG1) to give oxime.
[1039] where R 0 is methyl, R 1 is isopropyl, R 2 For ethyl, X1 is when RG1 and R 8 A divalent coupling group (eg, a succinimide ring or an oxime) is formed upon reaction, X2 is a suicide spacer, L1 is a divalent peptide linker, L2 is a bond or linker, and y is 1, 2, 3, or 4.
[1040] The general reaction method to form the conjugate of formula (C-2) is shown below in Scheme 4:
[1041] Option 4
[1042]
[1043] wherein: RG1 is a reactive group (by way of example only, a thiol, amine, or ketone) on the antibody or antigen-binding fragment thereof Ab that is compatible with a reactive group R attached to the linker-drug moiety 8 The antibody or antigen-binding fragment thereof Ab is covalently attached to one or more linker-drug moieties. 8 A non-limiting example of such a reaction of a group is maleimide (R 8 ) reacts with thiol (RG1) to give a succinimide ring, or hydroxylamine (R 8 ) reacts with ketone (RG1) to give oxime.
[1044] where R 0 is methyl, R 1 is isopropyl, R 2 For ethyl, X1 is when RG1 and R 8 A divalent coupling group (eg, a succinimide ring or an oxime) is formed upon reaction, X2 is a suicide spacer, L1 is a divalent peptide linker, L2 is a bond or linker, and y is 1, 2, 3, or 4.
[1045] Methods for conjugation to engineered cysteine antibody residues
[1046] The conjugates of the present disclosure can be prepared using cysteine residues engineered into antibodies by, for example, site-directed mutagenesis. Such site-specific conjugates are homogeneous and have improved properties (Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, Gorrell J, Katta V, Kim A, McDorman K, Flagella K, Venook R, Ross S, Spencer SD, Lee Wong W, Lowman HB, Vandlen R, Sliwkowski MX, Scheller RH, Polakis P, Mallet W. (2008) Nature Biotechnology 26:925-932).
[1047] Because engineered cysteines in antibodies expressed in mammalian cells are modified by adducts (disulfides) such as glutathione (GSH) and / or cysteine during their biosynthesis (Chen et al. 2009), the engineered cysteine residues in the initially expressed product are unresponsive to thiol-reactive reagents (such as maleimido or bromoacetamide or iodoacetamide groups). In order to conjugate a payload to the engineered cysteine after expression, it is necessary to remove the glutathione or cysteine adducts by reducing these disulfide adducts, which generally also requires reducing the native disulfides in the expressed protein. Deprotection of the adducted engineered cysteine can be accomplished by first exposing the antibody to a reducing agent, such as dithiothreitol (DTT), TCEP, or reduced cysteine, followed by a procedure that allows reoxidation of all native disulfide bonds of the antibody to restore and / or stabilize the functional antibody structure.
[1048] Several methods can be used to reduce and reoxidize antibodies with engineered cysteine residues for the preparation of antibody drug conjugates. An attempt was made to use high concentrations of CuSO4 to follow the reoxidation protocol previously described in the literature to cause protein precipitation (Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M, Tsai SP, Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, Gorrell J, Katta V, Kim A, McDorman K, Flagella K, Venook R, Ross S, Spencer SD, Lee Wong W, Lowman HB, Vandlen R, Sliwkowski MX, Scheller RH, Polakis P, Mallet W. (2008) Nature Biotechnology 26:925). We have successfully prepared and obtained antibody-drug conjugates using several different reduction and antibody reoxidation methods.
[1049] The following is a method for reducing and reoxidizing antibodies with engineered cysteine residues for the preparation of antibody drug conjugates: Freshly prepared DTT is added to the purified Cys mutant antibody to a final concentration of 10 mM. After incubation with DTT at room temperature for 1 hour, the mixture is dialyzed with PBS at 4 ° C for 3 days, changing the buffer every day to remove DTT and reoxidize the native disulfide bonds of the antibody. An alternative method is to remove the reducing agent by a desalting column such as Sephadex G-25 balanced with PBS. Once the protein is fully reduced, 1 mM oxidized ascorbate (dehydro-ascorbic acid) is optionally added to the desalted sample and reoxidized for 20-24 hours.
[1050] In another exemplary method, deprotection of engineered Cys residues is accomplished by adding a 20 mM concentration of fully reduced cysteine to an antibody bound to a protein A-agarose resin. Reduction of the Cys adduct is achieved by incubating at room temperature for approximately 30-60 minutes, followed by rapid removal of the reducing agent by washing the resin with 50 beds of PBS. Reoxidation of the reduced antibody is achieved by incubating the washed slurry at room temperature with or without the addition of 50-2000 nM CuCl2 as an accelerator. The examples herein use each of the protocols described herein with similar results, except for the use of copper sulfate. Reoxidation restores intrachain disulfides, while dialysis, desalting, or protein A chromatography removes the reducing agent as well as the cysteine and glutathione originally attached to one or more engineered cysteines of the antibody. HPLC reverse phase chromatography is typically used to monitor the reoxidation process: the antibody is loaded onto a PLRP-S column ( The ELISA was performed on a 50 mm x 2.1 mm, Agilent plate and eluted at 1.5 mL / min using a linear gradient of 30% to 45% CH 3 CN in water containing 0.1% TFA with peak detection at 215, 254, and 280 nm.
[1051] After reoxidation, the antibody is conjugated to a linker-drug compound (see Schemes 1-4) of, for example, a compound of Formula (B), (B-1), (B-2), or (B-3). For example, a compound of Formula (B), (B-1), (B-2), or (B-3) is added to the reoxidized Cys mutant antibody in an amount of 5-10 molar equivalents relative to the antibody in PBS buffer (pH 7.2). The incubation is performed for 1-2 hours. The conjugation process is monitored by reverse phase HPLC, which is capable of separating the conjugated antibody from the non-conjugated antibody. The conjugated reaction mixture is heated to 80° C. on a PRLP-S column ( The protein was analyzed on a 50 mm x 2.1 mm column (Agilent) and eluted by a linear gradient of 30% to 60% acetonitrile in water containing 0.1% TFA at a flow rate of 1.5 ml / min. The elution of protein from the column was monitored at 280 nm, 254 nm, and 215 nm.
[1052] Alternatively, for antibodies bound to protein A resin, once the antibody is reoxidized, the resin is washed with 10 column volumes of PBS, then the resin is resuspended in an equal volume of PBS and an 8-fold excess of a compound of formula (B), (B-1), (B-2), or (B-3) (in DMSO) is added and incubated at room temperature for 2 hours. The resin is then washed with 50 column volumes of PBS, the resulting antibody drug conjugate is eluted from the protein A resin, neutralized with 1 / 10 volume of 1 M Tris pH 9.0, and the buffer is exchanged for an appropriate buffer for preparative size exclusion chromatography (if necessary).
[1053] The feature of immunoconjugate is also the average loading of drug moiety and antibody binding portion, commonly referred to as drug to antibody ratio (DAR). For example, DAR value is extrapolated from LC-MS data of reduction and deglycosylation samples. LC / MS allows the average number of load (drug moiety) molecules attached to antibody in quantitative ADC. HPLC separates antibody into light chain and heavy chain, and also separates heavy chain (HC) and light chain (LC) according to the number of joint-load groups of each chain. Mass spectral data can identify the component species in the mixture, such as LC, LC+1, LC+2, HC, HC+1, HC+2, etc. By the average loading on LC and HC chains, the average DAR of ADC can be calculated. The DAR of a given immunoconjugate sample represents the average number of drug (load) molecules attached to a tetrameric antibody containing two light chains and two heavy chains.
[1054] Throughout this application, if there is a discrepancy between the text of the specification and the sequence listing, the text of the specification controls.
[1055] Table 2. Examples of anti-PMEL17 antibodies
[1056]
[1057]
[1058]
[1059]
[1060]
[1061]
[1062]
[1063]
[1064]
[1065]
[1066]
[1067]
[1068]
[1069]
[1070]
[1071]
[1072]
[1073]
[1074]
[1075]
[1076]
[1077]
[1078]
[1079]
[1080]
[1081]
[1082]
[1083]
[1084]
[1085]
[1086]
[1087]
[1088]
[1089]
[1090]
[1091]
[1092]
[1093]
[1094]
[1095]
[1096]
[1097]
[1098]
[1099]
[1100]
[1101]
[1102]
[1103]
[1104]
[1105]
[1106]
[1107]
[1108]
[1109]
[1110]
[1111]
[1112]
[1113]
[1114]
[1115]
[1116]
[1117]
[1118]
[1119]
[1120]
[1121]
[1122]
[1123] The generation of anti-PMEL17 antibodies is also described in Example 2 of International Application Publication No. WO 2020 / 128612, which is incorporated by reference in its entirety.
[1124] Other antibodies of the disclosure include those in which amino acids or nucleic acids encoding amino acids have been mutated; but have at least about 60%, about 70%, about 80%, about 90%, or about 95% identity to the sequences set forth in Table 2. In some embodiments, about 1, about 2, about 3, about 4, or about 5 amino acids in the variable region have been mutated when compared to the variable region depicted in the sequences set forth in Table 2, while retaining substantially the same therapeutic activity as the antibodies listed in Table 2.
[1125] In some embodiments, the present invention relates to the invention and the invention relates to the invention. In some embodiments, the present invention relates to the invention and the invention relates to the invention. In some embodiments, the present invention relates to the invention and the invention relates to the invention. In some embodiments, the present invention relates to the invention and the invention relates to the invention. In some embodiments, the present invention relates to the invention and the invention relates to the invention. In some embodiments, the present invention relates to the invention and the invention relates to the invention. In some embodiments, the present invention relates to the invention and the invention relates to the invention. In some embodiments, the present invention relates to the invention and the invention relates to the invention. In some embodiments, the present invention relates to the invention and the invention relates to the invention. Therefore, in some embodiments, the present disclosure provides an isolated monoclonal antibody or its antigen-binding region, which monoclonal antibody or its antigen-binding region has: a heavy chain variable region, wherein the heavy chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 10, 42, 64, 88, 112, 132, 149, 165, 184, 196, 215, 227, 239 or 254; and a light chain variable region, wherein the light chain variable region comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 21, 25, 29, 53, 75, 99, 119, 143, 159, 171, 190, 202, 221, 233, 248 or 260; wherein the antibody specifically binds PMEL17.
[1126] In some embodiments, the disclosure provides (i) an isolated monoclonal antibody having: a full-length heavy chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 12, 44, 66, 90, 114, 134, 151, 167, 186, 198, 217, 229, 241, 256, or 315, which has been optimized for expression in a cell of a mammalian expression system; and a full-length light chain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 23, 27, 31, 55, 77, 101, 121, 145, 161, 173, 192, 204, 223, 235, 250, or 262, which has been optimized for expression in a mammalian cell; or (ii) a functional protein comprising an antigen binding portion thereof.
[1127] In some embodiments, the present disclosure provides PMEL17-binding antibodies comprising heavy and light chain CDR1s, CDR2s, and CDR3s, or combinations thereof, as described in Table 2. The amino acid sequences of the VH CDR1s of the antibodies are shown, e.g., in SEQ ID NOs: 1, 4, 5, 7, 33, 36, 37, 39, 57, 60, 79, 82, 83, 85, 103, 106, 107, 109, 123, 126, 127, 129, 175, 178, 179, 181, 206, 209, 210, and 212. The amino acid sequence of the VH CDR2 of the antibody is shown, for example, in SEQ ID NO: 2, 6, 8, 34, 38, 40, 58, 61, 62, 80, 84, 86, 104, 108, 110, 124, 128, 130, 176, 180, 182, 207, 211, and 213. The amino acid sequence of the VH CDR3 of the antibody is shown, for example, in SEQ ID NO: 3, 9, 35, 41, 59, 63, 81, 87, 105, 111, 125, 131, 147, 148, 163, 164, 177, 183, 194, 195, 208, 214, 225, 226, 237, 238, 252, and 253. The amino acid sequence of the VL CDR1 of the antibody is shown, for example, in SEQ ID NO: 14, 17, 20, 46, 49, 52, 68, 71, 74, 92, 95, 98, 116, 136, 139, 142, 153, 156, 158, 243, 245, and 247. The amino acid sequence of the VLCDR2 of the antibody is shown, for example, in SEQ ID NO: 15, 18, 47, 50, 69, 72, 93, 96, 137, 140, and 154. The amino acid sequence of the VL CDR3 of the antibody is shown, for example, in SEQ ID NO: 16, 19, 48, 51, 70, 73, 94, 97, 117, 118, 138, 141, 155, 157, 169, 170188, 189, 200, 201, 219, 220, 231, 232, 244, 246, 258, and 259.
[1128] In view of the fact that each in these antibodies can be in conjunction with PMEL17 and antigen binding specificity is mainly provided by CDR1, 2 and 3 districts, VH CDR1, CDR2 and CDR3 sequences and VL CDR1, CDR2 and CDR3 sequences can be " mixed and matched " (that is, CDR from different antibodies can be mixed and matched). Such " mixed and matched " PMEL17 binding antibodies can be tested using those binding assays described in binding assays known in the art and examples (e.g., ELISA). When mixing and matching VH CDR sequences, CDR1, CDR2 and / or CDR3 sequences from specific VH sequences should be replaced by one or more structurally similar CDR sequences. Similarly, when mixing and matching VL CDR sequences, CDR1, CDR2 and / or CDR3 sequences from specific VL sequences should be replaced by one or more structurally similar CDR sequences. It will be readily apparent to those of ordinary skill that new VH and VL sequences can be generated by substituting one or more VH and / or VL CDR region sequences with structurally similar sequences from the CDR sequences presented herein for the monoclonal antibodies of the disclosure.
[1129] Thus, in some embodiments, the present disclosure provides an isolated monoclonal antibody or antigen-binding region thereof comprising: a heavy chain CDR1 comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 1, 4, 5, 7, 33, 36, 37, 39, 57, 60, 79, 82, 83, 85, 103, 106, 107, 109, 123, 126, 127, 129, 175, 178, 179, 181, 206, 209, 210, and 212; and a heavy chain CDR2 comprising an amino acid sequence selected from the group consisting of: SEQ ID NO: 1, 4, 5, 7, 33, 36, 37, 39, 57, 60, 79, 82, 83, 85, 103, 106, 107, 109, 123, 126, 127, 129, 175, 178, 179, 181, 206, 209, 210, and 212. NO: 2, 6, 8, 34, 38, 40, 58, 61, 62, 80, 84, 86, 104, 108, 110, 124, 128, 130, 176, 180, 182, 207, 211, and 213; a heavy chain CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 3, 9, 35, 41, 59, 63, 81, 87, 105, 111, 125, 131, 147, 148, 163, 164, 177, 183, 194, 195, 208, 214, 225, 226, 237, 238, 252, and 253; a light chain CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 3 NO: 14, 17, 20, 46, 49, 52, 68, 71, 74, 92, 95, 98, 116, 136, 139, 142, 153, 156, 158, 243, 245, and 247; a light chain CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 15, 18, 47, 50, 69, 72, 93, 96, 137, 140, and 154; and a light chain CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 NO: 16, 19, 48, 51, 70, 73, 94, 97, 117, 118, 138, 141, 155, 157, 169, 170, 188, 189, 200, 201, 219, 220, 231, 232, 244, 246, 258, and 259; wherein the antibody specifically binds PMEL17.
[1130] In specific embodiments, the antibody or antibody fragment (e.g., antigen-binding fragment) that specifically binds to PMEL17 comprises a heavy chain CDR1 of SEQ ID NO: 1, 4, 5 or 7, a heavy chain CDR2 of SEQ ID NO: 2, 6 or 8; a heavy chain CDR3 of SEQ ID NO: 3 or 9; a light chain CDR1 of SEQ ID NO: 14, 17 or 20; a light chain CDR2 of SEQ ID NO: 15 or 18; and a light chain CDR3 of SEQ ID NO: 16 or 19.
[1131] In specific embodiments, the antibody or antibody fragment (e.g., antigen-binding fragment) that specifically binds to PMEL17 comprises a heavy chain CDR1 of SEQ ID NO: 33, 36, 37 or 39, a heavy chain CDR2 of SEQ ID NO: 34, 38 or 40; a heavy chain CDR3 of SEQ ID NO: 35 or 41; a light chain CDR1 of SEQ ID NO: 46, 49 or 52; a light chain CDR2 of SEQ ID NO: 47 or 50; and a light chain CDR3 of SEQ ID NO: 48 or 51.
[1132] In certain embodiments, an antibody or antibody fragment (e.g., an antigen-binding fragment) that specifically binds to PMEL17 comprises a heavy chain CDR1 of SEQ ID NO: 5, 7, 57, or 60, a heavy chain CDR2 of SEQ ID NO: 58, 61, or 62; a heavy chain CDR3 of SEQ ID NO: 59 or 63; a light chain CDR1 of SEQ ID NO: 68, 71, or 74; a light chain CDR2 of SEQ ID NO: 69 or 72; and a light chain CDR3 of SEQ ID NO: 70 or 73.
[1133] In certain embodiments, an antibody or antibody fragment (e.g., an antigen-binding fragment) that specifically binds to PMEL17 comprises a heavy chain CDR1 of SEQ ID NO: 79, 82, 83, or 85, a heavy chain CDR2 of SEQ ID NO: 80, 84, or 86; a heavy chain CDR3 of SEQ ID NO: 81 or 87; a light chain CDR1 of SEQ ID NO: 92, 95, or 98; a light chain CDR2 of SEQ ID NO: 93, or 96; and a light chain CDR3 of SEQ ID NO: 94, or 97.
[1134] In specific embodiments, the antibody or antibody fragment (e.g., antigen-binding fragment) that specifically binds to PMEL17 comprises a heavy chain CDR1 of SEQ ID NO: 103, 106, 107 or 109, a heavy chain CDR2 of SEQ ID NO: 104, 108 or 110; a heavy chain CDR3 of SEQ ID NO: 105 or 111; a light chain CDR1 of SEQ ID NO: 49, 52 or 116; a light chain CDR2 of SEQ ID NO: 47 or 50; and a light chain CDR3 of SEQ ID NO: 117 or 118.
[1135] In specific embodiments, the antibody or antibody fragment (e.g., antigen-binding fragment) that specifically binds to PMEL17 comprises a heavy chain CDR1 of SEQ ID NO: 123, 126, 127 or 129, a heavy chain CDR2 of SEQ ID NO: 124, 128 or 130; a heavy chain CDR3 of SEQ ID NO: 125 or 131; a light chain CDR1 of SEQ ID NO: 136, 139 or 142; a light chain CDR2 of SEQ ID NO: 137 or 140; and a light chain CDR3 of SEQ ID NO: 138 or 141.
[1136] In specific embodiments, the antibody or antibody fragment (e.g., antigen-binding fragment) that specifically binds to PMEL17 comprises a heavy chain CDR1 of SEQ ID NO: 123, 126, 127 or 129, a heavy chain CDR2 of SEQ ID NO: 124, 128 or 130; a heavy chain CDR3 of SEQ ID NO: 147 or 148; a light chain CDR1 of SEQ ID NO: 153, 156 or 158; a light chain CDR2 of SEQ ID NO: 50 or 154; and a light chain CDR3 of SEQ ID NO: 155 or 157.
[1137] In specific embodiments, the antibody or antibody fragment (e.g., antigen-binding fragment) that specifically binds to PMEL17 comprises a heavy chain CDR1 of SEQ ID NO: 103, 106, 107 or 109, a heavy chain CDR2 of SEQ ID NO: 104, 108 or 110; a heavy chain CDR3 of SEQ ID NO: 163 or 164; a light chain CDR1 of SEQ ID NO: 49, 52 or 116; a light chain CDR2 of SEQ ID NO: 47 or 50; and a light chain CDR3 of SEQ ID NO: 169 or 170.
[1138] In certain embodiments, an antibody or antibody fragment (e.g., an antigen-binding fragment) that specifically binds to PMEL17 comprises a heavy chain CDR1 of SEQ ID NO: 175, 178, 179, or 181, a heavy chain CDR2 of SEQ ID NO: 176, 180, or 182; a heavy chain CDR3 of SEQ ID NO: 177 or 183; a light chain CDR1 of SEQ ID NO: 49, 52, or 116; a light chain CDR2 of SEQ ID NO: 47 or 50; and a light chain CDR3 of SEQ ID NO: 188 or 189.
[1139] In specific embodiments, the antibody or antibody fragment (e.g., antigen-binding fragment) that specifically binds to PMEL17 comprises a heavy chain CDR1 of SEQ ID NO: 103, 106, 107 or 109, a heavy chain CDR2 of SEQ ID NO: 104, 108 or 110; a heavy chain CDR3 of SEQ ID NO: 194 or 195; a light chain CDR1 of SEQ ID NO: 49, 52 or 116; a light chain CDR2 of SEQ ID NO: 47 or 50; and a light chain CDR3 of SEQ ID NO: 200 or 201.
[1140] In certain embodiments, an antibody or antibody fragment (e.g., an antigen-binding fragment) that specifically binds to PMEL17 comprises a heavy chain CDR1 of SEQ ID NO: 206, 209, 210, or 212, a heavy chain CDR2 of SEQ ID NO: 207, 211, or 213; a heavy chain CDR3 of SEQ ID NO: 208 or 214; a light chain CDR1 of SEQ ID NO: 153, 156, or 158; a light chain CDR2 of SEQ ID NO: 50 or 154; and a light chain CDR3 of SEQ ID NO: 219 or 220.
[1141] In certain embodiments, an antibody or antibody fragment (e.g., an antigen-binding fragment) that specifically binds to PMEL17 comprises a heavy chain CDR1 of SEQ ID NO: 206, 209, 210, or 212, a heavy chain CDR2 of SEQ ID NO: 207, 211, or 213; a heavy chain CDR3 of SEQ ID NO: 225 or 226; a light chain CDR1 of SEQ ID NO: 136, 139, or 142; a light chain CDR2 of SEQ ID NO: 137 or 140; and a light chain CDR3 of SEQ ID NO: 231 or 232.
[1142] In specific embodiments, an antibody or antibody fragment (e.g., an antigen-binding fragment) that specifically binds to PMEL17 comprises a heavy chain variable region comprising HCDR1 of SEQ ID NO: 206, 209, 210 or 212, HCDR2 of SEQ ID NO: 207, 211, 213, and HCDR3 of SEQ ID NO: 237 or 238; and a light chain variable region comprising LCDR1 of SEQ ID NO: 243, 245 or 247, LCDR2 of SEQ ID NO: 47 or 50, and LCDR3 of SEQ ID NO: 244 or 246.
[1143] In certain embodiments, an antibody or antibody fragment (e.g., an antigen-binding fragment) that specifically binds to PMEL17 comprises a heavy chain variable region comprising HCDR1 of SEQ ID NO: 206, 209, 210, or 212, HCDR2 of SEQ ID NO: 207, 211, or 213, and HCDR3 of SEQ ID NO: 252 or 253; and a light chain variable region comprising LCDR1 of SEQ ID NO: 153, 156, or 158, LCDR2 of SEQ ID NO: 50 or 154, and LCDR3 of SEQ ID NO: 258 or 259.
[1144] In specific embodiments, an antibody or antibody fragment (eg, antigen-binding fragment) that specifically binds to PMEL17 comprises a CDR sequence selected from the group consisting of:
[1145] The heavy chain CDR1 of SEQ ID NO: 1, the heavy chain CDR2 of SEQ ID NO: 2, the heavy chain CDR3 of SEQ ID NO: 3, the light chain CDR1 of SEQ ID NO: 14, the light chain CDR2 of SEQ ID NO: 15, and the light chain CDR3 of SEQ ID NO: 16;
[1146] The heavy chain CDR1 of SEQ ID NO:4, the heavy chain CDR2 of SEQ ID NO:2, the heavy chain CDR3 of SEQ ID NO:3, the light chain CDR1 of SEQ ID NO:14, the light chain CDR2 of SEQ ID NO:15, and the light chain CDR3 of SEQ ID NO:16;
[1147] The heavy chain CDR1 of SEQ ID NO:5, the heavy chain CDR2 of SEQ ID NO:6, the heavy chain CDR3 of SEQ ID NO:3, the light chain CDR1 of SEQ ID NO:17, the light chain CDR2 of SEQ ID NO:18, and the light chain CDR3 of SEQ ID NO:19; or
[1148] The heavy chain CDR1 of SEQ ID NO:7, the heavy chain CDR2 of SEQ ID NO:8, the heavy chain CDR3 of SEQ ID NO:9, the light chain CDR1 of SEQ ID NO:20, the light chain CDR2 of SEQ ID NO:18, and the light chain CDR3 of SEQ ID NO:16.
[1149] In specific embodiments, an antibody or antibody fragment (eg, antigen-binding fragment) that specifically binds to PMEL17 comprises a CDR sequence selected from the group consisting of:
[1150] The heavy chain CDR1 of SEQ ID NO:33, the heavy chain CDR2 of SEQ ID NO:34, the heavy chain CDR3 of SEQ ID NO:35, the light chain CDR1 of SEQ ID NO:46, the light chain CDR2 of SEQ ID NO:47, and the light chain CDR3 of SEQ ID NO:48;
[1151] The heavy chain CDR1 of SEQ ID NO:36, the heavy chain CDR2 of SEQ ID NO:34, the heavy chain CDR3 of SEQ ID NO:35, the light chain CDR1 of SEQ ID NO:46, the light chain CDR2 of SEQ ID NO:47, and the light chain CDR3 of SEQ ID NO:48;
[1152] The heavy chain CDR1 of SEQ ID NO:37, the heavy chain CDR2 of SEQ ID NO:38, the heavy chain CDR3 of SEQ ID NO:35, the light chain CDR1 of SEQ ID NO:49, the light chain CDR2 of SEQ ID NO:50, and the light chain CDR3 of SEQ ID NO:51; or
[1153] The heavy chain CDR1 of SEQ ID NO:39, the heavy chain CDR2 of SEQ ID NO:40, the heavy chain CDR3 of SEQ ID NO:41, the light chain CDR1 of SEQ ID NO:52, the light chain CDR2 of SEQ ID NO:50, and the light chain CDR3 of SEQ ID NO:48.
[1154] In specific embodiments, an antibody or antibody fragment (eg, antigen-binding fragment) that specifically binds to PMEL17 comprises a CDR sequence selected from the group consisting of:
[1155] a) the heavy chain CDR1 of SEQ ID NO:57, the heavy chain CDR2 of SEQ ID NO:58, the heavy chain CDR3 of SEQ ID NO:59, the light chain CDR1 of SEQ ID NO:68, the light chain CDR2 of SEQ ID NO:69, and the light chain CDR3 of SEQ ID NO:70;
[1156] b) the heavy chain CDR1 of SEQ ID NO:60, the heavy chain CDR2 of SEQ ID NO:58, the heavy chain CDR3 of SEQ ID NO:59, the light chain CDR1 of SEQ ID NO:68, the light chain CDR2 of SEQ ID NO:69, and the light chain CDR3 of SEQ ID NO:70;
[1157] c) the heavy chain CDR1 of SEQ ID NO: 5, the heavy chain CDR2 of SEQ ID NO: 61, the heavy chain CDR3 of SEQ ID NO: 59, the light chain CDR1 of SEQ ID NO: 71, the light chain CDR2 of SEQ ID NO: 72, and the light chain CDR3 of SEQ ID NO: 73; or
[1158] d) the heavy chain CDR1 of SEQ ID NO: 7, the heavy chain CDR2 of SEQ ID NO: 62, the heavy chain CDR3 of SEQ ID NO: 63, the light chain CDR1 of SEQ ID NO: 74, the light chain CDR2 of SEQ ID NO: 72, and the light chain CDR3 of SEQ ID NO: 70.
[1159] In specific embodiments, an antibody or antibody fragment (eg, antigen-binding fragment) that specifically binds to PMEL17 comprises a CDR sequence selected from the group consisting of:
[1160] The heavy chain CDR1 of SEQ ID NO:79, the heavy chain CDR2 of SEQ ID NO:80, the heavy chain CDR3 of SEQ ID NO:81, the light chain CDR1 of SEQ ID NO:92, the light chain CDR2 of SEQ ID NO:93, and the light chain CDR3 of SEQ ID NO:94;
[1161] The heavy chain CDR1 of SEQ ID NO:82, the heavy chain CDR2 of SEQ ID NO:80, the heavy chain CDR3 of SEQ ID NO:81, the light chain CDR1 of SEQ ID NO:92, the light chain CDR2 of SEQ ID NO:93, and the light chain CDR3 of SEQ ID NO:94;
[1162] The heavy chain CDR1 of SEQ ID NO:83, the heavy chain CDR2 of SEQ ID NO:84, the heavy chain CDR3 of SEQ ID NO:81, the light chain CDR1 of SEQ ID NO:95, the light chain CDR2 of SEQ ID NO:96, and the light chain CDR3 of SEQ ID NO:97; or
[1163] The heavy chain CDR1 of SEQ ID NO:85, the heavy chain CDR2 of SEQ ID NO:86, the heavy chain CDR3 of SEQ ID NO:87, the light chain CDR1 of SEQ ID NO:98, the light chain CDR2 of SEQ ID NO:96, and the light chain CDR3 of SEQ ID NO:94.
[1164] In specific embodiments, an antibody or antibody fragment (eg, antigen-binding fragment) that specifically binds to PMEL17 comprises a CDR sequence selected from the group consisting of:
[1165] The heavy chain CDR1 of SEQ ID NO: 103, the heavy chain CDR2 of SEQ ID NO: 104, the heavy chain CDR3 of SEQ ID NO: 105, the light chain CDR1 of SEQ ID NO: 116, the light chain CDR2 of SEQ ID NO: 47, and the light chain CDR3 of SEQ ID NO: 117;
[1166] The heavy chain CDR1 of SEQ ID NO: 106, the heavy chain CDR2 of SEQ ID NO: 104, the heavy chain CDR3 of SEQ ID NO: 105, the light chain CDR1 of SEQ ID NO: 116, the light chain CDR2 of SEQ ID NO: 47, and the light chain CDR3 of SEQ ID NO: 117;
[1167] The heavy chain CDR1 of SEQ ID NO: 107, the heavy chain CDR2 of SEQ ID NO: 108, the heavy chain CDR3 of SEQ ID NO: 105, the light chain CDR1 of SEQ ID NO: 49, the light chain CDR2 of SEQ ID NO: 50, and the light chain CDR3 of SEQ ID NO: 118; or
[1168] The heavy chain CDR1 of SEQ ID NO: 109, the heavy chain CDR2 of SEQ ID NO: 110, the heavy chain CDR3 of SEQ ID NO: 111, the light chain CDR1 of SEQ ID NO: 52, the light chain CDR2 of SEQ ID NO: 50, and the light chain CDR3 of SEQ ID NO: 117.
[1169] In specific embodiments, an antibody or antibody fragment (eg, antigen-binding fragment) that specifically binds to PMEL17 comprises a CDR sequence selected from the group consisting of:
[1170] The heavy chain CDR1 of SEQ ID NO: 123, the heavy chain CDR2 of SEQ ID NO: 124, the heavy chain CDR3 of SEQ ID NO: 125, the light chain CDR1 of SEQ ID NO: 136, the light chain CDR2 of SEQ ID NO: 137, and the light chain CDR3 of SEQ ID NO: 138;
[1171] The heavy chain CDR1 of SEQ ID NO: 126, the heavy chain CDR2 of SEQ ID NO: 124, the heavy chain CDR3 of SEQ ID NO: 125, the light chain CDR1 of SEQ ID NO: 136, the light chain CDR2 of SEQ ID NO: 137, and the light chain CDR3 of SEQ ID NO: 138;
[1172] The heavy chain CDR1 of SEQ ID NO: 127, the heavy chain CDR2 of SEQ ID NO: 128, the heavy chain CDR3 of SEQ ID NO: 125, the light chain CDR1 of SEQ ID NO: 139, the light chain CDR2 of SEQ ID NO: 140, and the light chain CDR3 of SEQ ID NO: 141; or
[1173] The heavy chain CDR1 of SEQ ID NO: 129, the heavy chain CDR2 of SEQ ID NO: 130, the heavy chain CDR3 of SEQ ID NO: 131, the light chain CDR1 of SEQ ID NO: 142, the light chain CDR2 of SEQ ID NO: 140, and the light chain CDR3 of SEQ ID NO: 138.
[1174] In specific embodiments, an antibody or antibody fragment (eg, antigen-binding fragment) that specifically binds to PMEL17 comprises a CDR sequence selected from the group consisting of:
[1175] The heavy chain CDR1 of SEQ ID NO: 123, the heavy chain CDR2 of SEQ ID NO: 124, the heavy chain CDR3 of SEQ ID NO: 147, th...
Claims
1. A method for producing a partially reoxidized antibody or antigen-binding fragment thereof, the method comprising: Providing an antibody or antigen-binding fragment thereof comprising one or more capped cysteine residues; reducing the one or more capped cysteine residues, thereby providing an antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues; as well as storing the antibody or antigen-binding fragment thereof comprising one or more decapped cysteine residues under oxidative conditions that allow re-capping of one or more off-target cysteine residues, Thereby producing the partially reoxidized antibody or antigen-binding fragment thereof.
2. The method of claim 1, wherein the one or more capping cysteine residues are located in the heavy chain constant domain of the antibody or antigen-binding fragment thereof.
3. The method of any one of claims 1 or 2, wherein the antibody or antigen-binding fragment thereof comprises two or four capping cysteine residues.
4. The method of any one of claims 1 to 3, wherein the antibody or antigen-binding fragment thereof comprises a capping cysteine residue located in the CH1 region of the antibody or antigen-binding fragment thereof, Optionally, wherein the antibody or antigen-binding fragment thereof comprises a capping cysteine residue located in each CH1 region of the antibody or antigen-binding fragment thereof.
5. The method of any one of claims 1-4, wherein the one or more capping cysteine residues are one or more engineered surface-exposed cysteine residues.
6. The method of any one of claims 1-5, wherein the antibody or antigen-binding fragment thereof comprises a capping cysteine residue located at residue 152 (EU numbering) in the CH1 region of the antibody or antigen-binding fragment thereof.
7. The method of any one of claims 1-6, wherein the one or more capped cysteine residues are capped with cysteine or glutathione.
8. The method of any one of claims 1-7, wherein the one or more uncapping cysteine residues are located in the heavy chain constant domain of the antibody or antigen-binding fragment thereof.
9. The method of any one of claims 1-8, wherein the antibody or antigen-binding fragment thereof comprises two or four uncapping cysteine residues.
10. The method of any one of claims 1 to 9, wherein the antibody or antigen-binding fragment thereof comprises an uncapped cysteine residue located in the CH1 region of the antibody or antigen-binding fragment thereof, Optionally, wherein the antibody or antigen-binding fragment thereof comprises an uncapping cysteine residue located in each CH1 region of the antibody or antigen-binding fragment thereof.
11. The method of any one of claims 1-10, wherein the one or more uncapping cysteine residues are one or more engineered surface-exposed cysteine residues.
12. The method of any one of claims 1-11, wherein the antibody or antigen-binding fragment thereof comprises an uncapping cysteine residue located at residue 152 (EU numbering) in the CH1 region of the antibody or antigen-binding fragment thereof.
13. The method of any one of claims 1-12, wherein the method comprises reducing the one or more capped cysteine residues by contacting the antibody or antigen-binding fragment thereof comprising one or more capped cysteine residues with a reducing wash buffer, thereby providing the antibody or antigen-binding fragment comprising one or more uncapped cysteine residues.
14. The method of any one of claims 1-13, wherein the reducing wash buffer comprises 5 mM to 50 mM cysteine, optionally wherein the reducing wash buffer comprises 10 mM to 40 mM, 20 mM to 30 mM, 5 mM to 15 mM, 5 mM to 25 mM, 5 mM to 35 mM, 5 mM to 45 mM, 40 mM to 50 mM, 30 mM to 50 mM, 20 mM to 50 mM, 10 mM to 50 mM, 10 mM to 20 mM, 15 mM to 25 mM, 25 mM to 35 mM, 30 mM to 40 mM, or 35 mM to 45 mM cysteine, optionally wherein the reducing wash buffer comprises 10 mM, 12 mM, 14 mM, 16 mM, 20 mM, 25 mM, or 30 mM cysteine.
15. The method of any one of claims 1-14, wherein the reducing wash buffer has a pH of 6.0 to 7.5, optionally wherein the pH is 6.5 to 7.2 or 6.8 to 7.0, optionally the pH is 6.
9.
16. The method of any one of claims 1-15, wherein contacting the antibody or antigen-binding fragment thereof comprising one or more capped cysteine residues with the reducing wash buffer is performed on a column, optionally the column is a cation exchange chromatography column.
17. The method of any one of claims 1-16, wherein the method further comprises collecting the antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues in the eluate after contacting with the reducing wash buffer.
18. The method of any one of claims 1-17, wherein the eluate has a pH of 5.5 to 6.0, optionally the pH is 5.
8.
19. The method of any one of claims 1 to 18, wherein the concentration of the antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues in the eluate is 5 g / L to 25 g / L, optionally wherein the concentration of the antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues in the eluate is 8 g / L to 20 g / L, 10 g / L to 18 g / L, 12 g / L to 15 g / L, 5 g / L to 20 g / L, 5 g / L to 15 g / L, 5 g / L to 10 g / L, 20 g / L to 25 g / L, 15 g / L to 25 g / L, 10 g / L to 5 g / L, 14 g / L, 15 g / L, 16 g / L, 17 g / L, 18 g / L, 19 g / L, 20 g / L, 21 g / L, 22 g / L, 23 g / L, 24 g / L or 25 g / L.
20. The method of any one of claims 1-19, wherein the antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues is stored in the eluate under agitation.
21. The method of any one of claims 1-19, wherein the antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues is stored in the eluate without agitation.
22. The method of any one of claims 1-21, wherein the antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues is stored in a container filled to a maximum of 50% to 70% or 60% volume, optionally wherein the container is filled to a maximum of 60% volume.
23. The method of any one of claims 1-22, wherein the antibody or antigen-binding fragment thereof comprising one or more decapping cysteine residues is stored for 12 hours to 96 hours, optionally the antibody or antigen-binding fragment thereof comprising one or more decapping cysteine residues is stored for 12 hours to 84 hours, 24 hours to 84 hours, 36 hours to 72 hours, 48 hours to 60 hours, 24 hours to 72 hours, 24 hours to 60 hours, 24 hours to 48 hours, 24 hours to 36 hours, 72 hours to 84 hours, 60 hours to 84 hours, 48 hours to 84 hours, 36 hours to 84 hours, 12 hours to 36 hours, 24 hours to 48 hours, 36 hours to 60 hours, 48 hours to 72 hours, or 72 hours to 96 hours, optionally wherein the antibody or antigen-binding fragment thereof comprising one or more decapping cysteine residues is stored for 12 hours, 24 hours, 36 hours, 48 hours, 60 hours, 72 hours, 84 hours or 96 hours.
24. The method of any one of claims 1-25, wherein the antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues is stored at room temperature, or at 2°C to 8°C or at 4°C.
25. The method of any one of claims 1-24, wherein the antibody or antigen-binding fragment thereof comprising one or more uncapped cysteine residues is stored under air coverage.
26. The method of any one of claims 1-25, wherein the method further comprises purifying the partially reoxidized antibody or antigen-binding fragment thereof.
27. The method of any one of claims 1-26, wherein the antibody or antigen-binding fragment comprises a substitution of one or more amino acids with cysteine on its constant region at a position selected from the group consisting of positions 117, 119, 121, 124, 139, 152, 153, 155, 157, 164, 169, 171, 174, 189, 191, 195, 197, 205, 207, 246, 258, 269, 274, 286, 288, 290, 292, 293, 320, 322, 326, 333, 334, 335, 337, 344, 355, 360, 375, 382, 390, 392, 398, 400, and 422 of the heavy chain of the antibody or antigen-binding fragment thereof, and wherein positions are numbered according to the EU system.
28. The method of any one of claims 1-27, wherein the antibody or antigen-binding fragment comprises a substitution of one or more amino acids with cysteine on its constant region at a position selected from the group consisting of positions 107, 108, 109, 114, 129, 142, 143, 145, 152, 154, 156, 159, 161, 165, 168, 169, 170, 182, 183, 197, 199, and 203 of the light chain of the antibody or antibody fragment, wherein the positions are numbered according to the EU system, and wherein the light chain is a human kappa light chain.
29. The method of any one of claims 1-28, wherein the antibody or antigen-binding fragment comprises a substitution of an amino acid with cysteine on its constant region at position 152, position 375, or both positions 152 and 375 of the heavy chain of the antibody or antigen-binding fragment thereof, wherein the positions are numbered according to the EU system.
30. A method for producing an antibody drug conjugate, wherein the method comprises conjugating a linker-drug moiety to a partially reoxidized antibody or antigen-binding fragment thereof produced by the method of any one of claims 1 to 29, thereby producing the antibody drug conjugate.
31. The method of claim 30, wherein the method further comprises purifying the antibody drug conjugate.
32. The method of claim 30 or 31, wherein the method results in at least 75%, optionally at least 80%, 85%, 90% or 95%, site-coupled, or one linker-drug moiety ("HC1") per heavy chain.
33. The method of any one of claims 30-32, wherein the method produces less than 25%, optionally at least 20%, 15%, 10% or 5%, non-site conjugation, or one linker-drug moiety per light chain ("LC1") and / or two linkers-drug moieties per heavy chain ("HC2").
34. The method of any one of claims 1-33, wherein the method results in at least 70% purity, optionally at least 75%, 80%, 85%, 90% or 95% purity, optionally wherein the purity is determined by non-reducing CE-SDS.
